1
Status: Approved ,  Date: 12 June 2019Janssen Research & Development *
Clinical Protocol
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs 
Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple 
Myeloma who are Ineligible for High Dose Therapy
Protocol 54767414MMY3008; Phase 3
AMENDMENT 6
JNJ-54767414 Daratumumab
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen-C ilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen 
Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout 
the protocol to represent these various legal entities; the sponsor is identified on the Contact Information 
page that accompanies the protocol.
EudraCT NUMBER: 2014 -002273 -11
Status: Approved
Date: 12 June 2019
Prepared by: Janssen Research & Development, LLC   
EDMS number: EDMS- ERI-85965381; 9.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidenti al and 
may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed
by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
2
Approved , Date: 12 June 2019TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF A TTACHMENTS ............................................................................................................................ 5
LIST OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 32
TIME AND EVENTS SCHE DULE OVERVIEW .......................................................................................... 37
TIME AND EVENTS SCHE DULE, DOSE A DMINISTRA TION .................................................................. 41
ABBREVIA TIONS ...................................................................................................................................... 43
1. INTRODUCTION ................................................................................................................................ 45
1.1. Background .................................................................................................................................... 45
1.1.1. Multiple Myeloma ........................................................................................................................ 45
1.1.2. Treatment Options for Multiple Myeloma .................................................................................... 45
1.1.3. Transplant -ineligible Population ................................................................................................ .46
1.2. Daratumumab ................................................................................................................................ 46
1.2.1. Nonclinical Studies ..................................................................................................................... 46
1.2.2. Clinical Studies ........................................................................................................................... 47
1.2.2.1. Single -Agent Daratumumab Studies (GEN501 and MMY2002) ............................................. 47
1.2.2.2. Combination Daratumumab Studies ....................................................................................... 48
1.3. Lenalidomide .................................................................................................................................. 49
1.4. Lenalidomide and Daratumumab ................................................................................................... 50
1.5. Overall Rationale for the Study ...................................................................................................... 51
2. OBJECTIVES A ND HYPOT HESIS ................................................................................................... 52
2.1. Objectives ...................................................................................................................................... 52
2.2. Hypothesis ..................................................................................................................................... 53
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .53
3.1. Overview of Study Design .............................................................................................................. 53
3.2. Study Design Rationale .................................................................................................................. 56
4. SUBJECT POPUL ATION.................................................................................................................. 58
4.1. Inclusion Criteria ............................................................................................................................ 58
4.2. Exclusion Criteria ........................................................................................................................... 60
4.3. Prohibitions and Restrictions ......................................................................................................... 63
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 64
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 64
6.1. Daratumumab (Arm B Only) .......................................................................................................... 65
6.1.1. Daratumumab Preparation ......................................................................................................... 65
6.1.2. Daratumumab Administration ..................................................................................................... 65
6.1.3. Prevention of Infusion Reactions ................................................................................................ 66
6.1.3.1. Preinfusion Medication ............................................................................................................ 66
6.1.3.2. Postinfusion Medication ........................................................................................................... 66
6.1.4. Management of Infusion -related Reactions ................................................................................ 67
6.1.4.1. Infusion -Related Events of Grade 1 or Grade 2 ...................................................................... 67
6.1.4.2. Infusion -Related Reactions of Grade 3 or Higher ................................................................... 68
6.2. Lenalidomide (Arm A and Arm B) .................................................................................................. 68
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
3
Approved , Date: 12 June 20196.3. Dexamethasone (Arm A and Arm B) ............................................................................................. 68
6.4. Dose Delay s and Dose Modifica tion.............................................................................................. 69
6.4.1. Daratumumab Dose Modification ............................................................................................... 69
6.4.1.1. Daratumumab -Related Toxicity Management ......................................................................... 69
6.4.1.2. Daratumumab Interruption or Missed Dose s........................................................................... 70
6.4.2. Lenalidomide Dose Reductions .................................................................................................. 70
6.4.2.1. Thrombocy topenia ................................................................................................................... 70
6.4.2.2. Neutropenia ............................................................................................................................. 71
6.4.2.3. Renal Impairment .................................................................................................................... 71
6.4.2.4. Other Adverse Events ............................................................................................................. 71
6.4.3. Dexamethasone Dose Modifications .......................................................................................... 72
7. TREA TMENT COMPLIA NCE ............................................................................................................ 72
8. CONCOMIT ANT THERA PY.............................................................................................................. 72
8.1. Recommended Therapies .............................................................................................................. 73
8.1.1. Prevention of Deep Vein Thrombosis and Pulmonary Embolism ............................................... 73
8.1.2. Bisphosphonate Therapy ............................................................................................................ 73
8.1.3. Therapy for Tumor Ly sis Syndrome ........................................................................................... 74
8.1.4. Prophylaxis for Pneum ocystis carinii .......................................................................................... 74
8.1.5. Prophylaxis for Herpes Zoster Reactivation ............................................................................... 74
8.1.6. Prevention of Steroid Induced Gastritis ...................................................................................... 74
8.1.7. Management of Hepatitis B Virus Reactivation .......................................................................... 74
8.2. Permitted Therapies ....................................................................................................................... 74
8.3. Prohibited Therapies ...................................................................................................................... 75
8.4. Subsequent Therapies ................................................................................................................... 75
9. STUDY EVA LUATIONS .................................................................................................................... 76
9.1. Study Procedures ........................................................................................................................... 76
9.1.1. Overview ..................................................................................................................................... 76
9.1.2. Screening Phase ........................................................................................................................ 76
9.1.3. Treatment Phase ........................................................................................................................ 77
9.1.4. Follow -up Phase ......................................................................................................................... 78
9.1.5. Assessments Following the Positive Second Interim Analysis of PFS ...................................... 78
9.1.6. Assessments Following the Interim OS Analysis ....................................................................... 79
9.2. Efficacy ........................................................................................................................................... 79
9.2.1. Evaluations ................................................................................................................................ .79
9.2.1.1. Response Categories .............................................................................................................. 80
9.2.1.2. Myeloma Protein Measurements in Serum and Urine ............................................................ 81
9.2.1.3. Serum Calcium Corrected for Albumin .................................................................................... 82
9.2.1.4. β2-microglobulin and Albumin .................................................................................................. 83
9.2.1.5. Bone Marrow Examination ...................................................................................................... 83
9.2.1.6. Minimal Residual Disease Assessment .................................................................................. 84
9.2.1.7. Assessment of Lytic Disease ................................................................................................... 84
9.2.1.8. Documentation of Extramedullar y Plasm acytomas ................................................................ .84
9.2.2. Endpoints .................................................................................................................................... 85
9.3. Pharmacokinetics and Immunogenicity ......................................................................................... 87
9.3.1. Evaluations ................................................................................................................................ .87
9.3.2. Analytical Procedures ................................................................................................................. 87
9.3.3. Pharmacokinetic Parameters ..................................................................................................... 87
9.3.4. Immunogenicity Assessments (Antibodies to daratumumab) .................................................... 88
9.4. Pharmacokinetic/Pharmacodynamic Evaluations .......................................................................... 88
9.5. Biom arkers ..................................................................................................................................... 88
9.6. Medical Resource Utilization .......................................................................................................... 89
9.7. Patient Reported Outcomes ........................................................................................................... 89
9.8. Safety Evaluations ......................................................................................................................... 90
9.9. Sample Collection and Handling .................................................................................................... 93
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
4
Approved , Date: 12 June 201910. SUBJECT COMPLETION/W ITHDRA WAL....................................................................................... 94
10.1. Completion ..................................................................................................................................... 94
10.2. Discontinuation of Study Treatment ............................................................................................... 94
10.3. Withdrawal From the Study ............................................................................................................ 95
11. STATISTICA L METHODS ................................................................................................................. 95
11.1. Subject Information ........................................................................................................................ 95
11.2. Sample Size Determination ........................................................................................................... 96
11.3. Efficacy  Analyses ........................................................................................................................... 96
11.4. Pharmacokinetic Analy ses............................................................................................................. 97
11.5. Immunogenicity Analyses .............................................................................................................. 97
11.6. Pharmacokinetic/Pharmacodynamic Analyses .............................................................................. 97
11.7. Biom arker Analyses ....................................................................................................................... 97
11.8. Patient Reported Outcomes ........................................................................................................... 98
11.9. Safety Analyses ............................................................................................................................. 98
11.10. Interim Analysis .............................................................................................................................. 99
11.11. Data Monitoring Committee ......................................................................................................... 100
12. ADVERSE EVENT REPORT ING.................................................................................................... 100
12.1. Definitions .................................................................................................................................... 100
12.1.1. Adverse Event Definitions and Classifications ......................................................................... 100
12.1.2. Attribution Definitions ................................................................................................................ 101
12.1.3. Severity Criteria ........................................................................................................................ 102
12.2. Special Reporting Situations ........................................................................................................ 103
12.3. Procedures ................................................................................................................................... 103
12.3.1. All Adverse Events .................................................................................................................... 103
12.3.2. Serious Adverse Events ........................................................................................................... 104
12.3.3. Suspected Unexpected Serious Adverse Reactions ................................................................ 105
12.3.4. Pregnancy ................................................................................................................................ .105
12.4. Contacting Sponsor Regarding Safety ......................................................................................... 106
13. PRODUCT QUA LITY COMP LAINT HA NDLING ............................................................................ 106
13.1. Procedures ................................................................................................................................... 106
13.2. Contacting Sponsor Regarding Product Quality .......................................................................... 106
14. STUDY DRUG INFORM ATION....................................................................................................... 107
14.1. Physical Description of Study Dr ug.............................................................................................. 107
14.2. Packaging .................................................................................................................................... 107
14.3. Labeling ........................................................................................................................................ 107
14.4. Preparation, Handling, and Storage ............................................................................................. 107
14.5. Drug Accountability ...................................................................................................................... 107
15. STUDY -SPECIFIC M ATERIA LS..................................................................................................... 108
16. ETHICA L ASPECTS ....................................................................................................................... 108
16.1. Study-Specific Design Considerations ......................................................................................... 108
16.2. Regulatory Ethics Compliance ..................................................................................................... 109
16.2.1. Investigator Responsibilities ..................................................................................................... 109
16.2.2. Independent Ethics Committee or Institutional Review Board ................................................. 109
16.2.3. Informed Consent ..................................................................................................................... 110
16.2.4. Privac y of Personal Data .......................................................................................................... 111
16.2.5. Long- Term Retention of Samples for Additional Future Research .......................................... 112
16.2.6. Countr y Selection ..................................................................................................................... 112
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 112
17.1. Protocol Amendments .................................................................................................................. 112
17.2. Regulatory Documentation .......................................................................................................... 113
17.2.1. Regulatory Approval/Notification .............................................................................................. 113
17.2.2. Required Prestudy Documentation ........................................................................................... 113
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
5
Approved , Date: 12 June 201917.3. Subject Identification, Enrollment, and Screening Logs .............................................................. 114
17.4. Source Documentation ................................................................................................................. 114
17.5. Case Report Form Completion .................................................................................................... 115
17.6. Data Quality Assurance/Quality Control ...................................................................................... 116
17.7. Record Retention ......................................................................................................................... 116
17.8. Monitoring .................................................................................................................................... 117
17.9. Study Com pletion/Termination ..................................................................................................... 117
17.9.1. Study Com pletion ..................................................................................................................... 117
17.9.2. Study Termination ..................................................................................................................... 117
17.10. On-Site Audits .............................................................................................................................. 118
17.11. Use of Information and Publication .............................................................................................. 118
REFERENCES .......................................................................................................................................... 120
INVESTIGA TOR A GREEME NT....................................................... ERROR! BOOKMARK NOT DEFINED.
LIST OF A TTACHMENTS
Attachment 1: Modified IM WG Diagnostic Criteria for Multiple Myeloma ........................................ 123
Attachment 2: ECOG Performance Status Scale ............................................................................ 124
Attachment 3: Calculated and Measured Creatinine Clearance ..................................................... 125
Attachment 4: Serum Calcium Corrected for Albumin ..................................................................... 126
Attachment 5: Lenalidomide Global Pregnancy Prevention Plan .................................................... 127
Attachment 6: Conversion Table for Glucocorticosteroid Dose ....................................................... 136
Attachment 7: Asthma Guidelines ................................................................................................... 137
Attachment 8: International Staging system .................................................................................... 140
Attachment 9: The Family of antihistamine medications ................................................................ .141
Attachment 10 : Anticipated Adverse Events ...................................................................................... 142
LIST OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Daratumumab Single -Agent Studies GEN501 and MMY2002 ................................................. 47
Table 2: Daratumumab Combination Studies GEN503 and MMY1001 ................................................. 48
Table 3: Daratumumab -Related Toxicity Ma nagement .......................................................................... 69
Table 4: Lenalidomide Dose Adjustment for Thrombocy topenia ............................................................ 71
Table 5: Lenalidomide Dose Adjustment for Neutropenia ...................................................................... 71
Table 6: Lenalidomide Dose Adjustment for Re nal Im pairment ............................................................. 71
Table 7: Recommended Dose Reduction for Dexamethasone .............................................................. 72
Table 8: International Uniform Response Criteria Consensus Recommendations ................................ 80
Table 9: Bone Marrow Testing ................................................................................................................ 83
FIGURES
Figure 1: Improvement of Daratumumab -induced Antibody -dependent Cell -mediated 
Cytotoxicity by Lenalidomide in Bone Marrow Mononuclear Cells from Patients with 
Multiple Myeloma ...................................................................................................................... 51
Figure 2: Schematic Overview of the Study ............................................................................................. 54
Figure 3: Daratumumab Maxi mal Target Suppression ............................................................................ 57
Figure 4: Schematic Overview Study Treatment Administration ............................................................. 65
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
6
Approved , Date: 12 June 2019PROTOCOL A MENDMENTS
Protocol Version Issue Date
Original Protocol 14 July 2014
Amendment INT-1 29 October 2014
Amendment INT -2 26 August 2015
Amendment INT -3 2 November 2016
Amendment INT -4 22May 2017
Amendment 5 15 January 2019
Amendment 6 12June 2019
Amendments below are listed beginning with the most recent amendment.
Amendment 6(12June 2019 )
The overall reason for the amendment: The overall reason for the amendment is in response to identification of 
a new important risk (hepatitis B virus [HBV] reactivation).
Applicable Section(s) Description of Change(s)
Rationale: The text for identification of HBV reactivation, testing, and management of subjects with the 
potential for HBV reactivation was added or modified in response to identification of a new important risk (HBV 
reactivation).
Time and Events Schedule –
Overvie wAdded HBV DNA assessment at e very 3 months during treatment ± 1 month 
until 6 months after last dose of daratumumab with the note ‘Arm B subjects 
with known history of hepatitis B infection or positive hepatitis B serologies 
(HBsAg, Anti-HBc and/or Anti-HBs with exception of serologic findings 
suggestive of HBVvaccination [Anti-HBs positivity as the only serologic 
marker ]and a known history of prior HBV vaccination )’.
8.1.7 Management of Hepatitis B 
Virus ReactivationAdded a new section for information for the management of HBV 
reactivation.
9.8Safety Evaluations Added information detailing the conduct of HBV serology and updated 
DNA tests
Rationale: To clarify the mode of subject monitoring post end-of-treatment (EOT).
Time and Events Schedule –
Overvie w(Disease Evaluations)The follow ing details clarifying subject monitoring post EOT were added –
‘After EOT, subjects in both treatment arms prior to disease progression 
(PD) will continue to return for disease evaluations. After PD is 
documented, subjects will be follow ed for s urvival, time from randomization 
to progression on the next line of therapy or death, whichever comes first 
(PFS2), second primary malignancies, and subsequent anti-myeloma 
therapy. After the primary clinical cut-off date (24 Septem ber 2018), subject 
monitoring will be conducted as per Section 9.1.5 .After the second interim 
OS analysis has occurred and the mPFS for DRd group has been confirmed , 
subject monitoring will be conducted according to Section 9.1.6 ’
Rationale: To provide a window  forthe 6-monthly collection ofEastern Cooperat ive Oncology Group (ECOG)
and patient -reported outcome (PRO ) assessments.
Time and Events Schedule –
Overvie w; 9.1.5: Assessments 
Follow ing the Positive Second 
Interim Analysis of PFSAdded ‘±14 days’ to the 6-monthly collection of ECOG and PRO 
assessments after completing the first year for these procedures.
Rationale: To clarify the guidance for delay in treatment .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
7
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
6.4.1.2 Daratumumab 
Interruption or Missed DosesText in bold added:
A daratumumab dose that is held for more than the permitted time (Table 3) 
from the per -protocol administration date for any reason other than toxicities 
suspected to be related to daratumumab should be brought to the attention of 
the Sponsor at the earliest possible time. Subjects whose dose was delayed 
for more than 4 weeks (Cycle 1 to Cycle 6) or more than 6weeks (Cycle 7 
and beyond) should have study treatment discontinued, unless, upon 
consultation with thesponsor and the revie w of safety and efficacy, 
continuation is agreed upon. Infusion -related reactions may occur upon 
re-initiation of daratumumab after a prolonged delay in treatm ent.
Rationale: To provide additional details regarding the provision of daratumamb by the sponsor for subjects 
randomized to Arm A (Rd) who are receiving any subsequent line of therapy .
8.4. Subsequent Therapies Added the sentence ‘For these subjects, daratumumab should not be added to 
an ongoing subsequent therapy regim en until the subject has progressed on 
that regim en’ and mentioned that safety management for and during the 
administration of daratumumab must be in accordance with local prescribing 
information and local regulations . Also clarified that second primary 
malignancy reporting should continue to end of study.
Rationale: To clarify the timing when disease evaluation will switch to local lab oratorie s.
9.1.6 Assessments Following the 
Interim OS AnalysisText in strikethrough has been deleted, text in bold has been added:
Once the interim overall survival (OS)analysis has occurred and when 
the median progression free survival (PFS)is reached in the DRd arm, 
the sponsor will notify the investigators that from  that point onward, 
disease evaluations are to For subjects without disease progression at the 
time of the interim OS analysis, disease assessments will continue but will 
be performed locally per the site’s standard of care.
Rationale: Minor errors w ere noted
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
Amendment 5 (15 January 2019 )
The overall reason for the amendment: Following review of data from the second i nterim analysis by the 
Independent Data Monitoring Committee (IDMC) , the study is being amended to allow  subjects in Arm A 
(lenalidomide and dexamethasone [Rd]alone) access to daratumumab after sponsor confirmation of disease 
progression (PD) per International Myeloma Working Group (IMWG) criteria.
Applicable Section(s) Description of Change(s)
Rationale: Subjects randomized to Arm A ( Rd) who have sponsor -confirmed disease progression may have the
optiontoreceive daratumumab provided by the sponsor (in any subsequent line of therapy) in the Follow- up phase ,
if recommended by the inve stigator . Eligibility for and administration of daratumumab must be in accordance w ith 
local prescribing information and local regulations. 
8.4. Subsequent 
TherapiesA new section has been added.
Rationale: To update the protocol follow ing positive second interim analysis results .
Synopsis, Overview of 
Study Design;
Synopsis, Statistical 
Methods;Details of IDMC reviews andplanned interim analyses have been revised .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
8
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
3.1. Overview  of 
Study Design;
11.10 .Interim 
Analysis
Synopsis, Overview of 
Study Design;
Synopsis, Statistical 
Methods;
3.1. Overview  of 
Study Design;
9.2.2. Endpoints ;
11.10 .Interim 
AnalysisIt is explained that the interim PFS analysis will function as the primary PFS analysis of 
this endpoint, as the superiority of daratumumab plu s Rd (DRd) over Rd alone was
established at the second interim analysis.
Synopsis, Overview of 
Study Design;
Time and Events 
Schedule , Overview ;
3.1. Overview  of 
Study DesignRemoved text which referred to reduced data collection as described in Section 9.1.4. 
Where appropriate, added references to subject monitoring as described in the ne w 
Sections 9.1.5 (follow ing positive second interim analysis of PFS) and 9.1.6 (following 
interim overall survival [OS] analysis).
Synopsis, Overview of 
Study Design;
3.1. Overview  of 
Study Design; 
11.10. Interim 
AnalysisDescribed that the second interim OS will now occur when approximately 260 deaths have 
occurred which will be about the same time the primary PFS analysis would have taken 
place .
9.1.4. Follow -up 
PhaseRemoved the following text:
A clinical cut -off will be established after the primary PFS analysis (390 PFS events). 
Follow ing the clinical cut -off d ate, disease assessments will no longer be required and 
data collection w ill be limited to the following:
•For subjects still receiving study treatment: study treatment administration, adverse 
events , SAEs, laboratory data associated with SAEs
•For all s ubjects: all subsequent anticancer treatment, PFS2 ( based on investigator 
judgment), second primary malignancies, and survival follow -up
9.1.5. Assessments 
Follow ing the Positive 
Second Interim 
Analysis of PFSA new section has been added.
9.1.6. Assessments 
Follow ing the Interim 
OS AnalysisA new section has been added.
11.3. Efficacy 
AnalysesDescribed that the analysis of OS may be confounded by subjects from Arm A receiving 
daratumumab after disease progression . Exploratory analysis may be performed to adjust 
for the effect daratumumab exposure may have on OS for the subjects who w ere 
randomized to Arm A (Rd).
11.3. Efficacy 
AnalysesText describing secondary endpoints was revised to align with the secondary endpoints 
which were planned to be sequentially tested at the second interim analysis.
Rationale: To clarify/emphasize the requirement to wait until confirmed PDprior to starting subsequent 
anti-myeloma therapy.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
9
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
Synopsis, Overview of 
Study Design;
3.1. Overview  of 
Study DesignIt is emphasized that for both Arm A ( Rd) and Arm B (DRd ), subjects entering the 
Follow -up Phase should not be started on subsequent anti -myeloma therapy ‘until
confirmed disease progression’.
8.3. Prohibited 
TherapiesClarified that the prohibition on concomitant administration of any other antineoplastic 
therapy for the intention of treating multiple myeloma applies prior to confirmation of 
disease progression.
Text in strikethrough has been deleted, text in bold has been added: 
and other cancers not defined in the study protocol is prohibited
For m anagement of second primary m alignancies please see Section 10.2.
Synopsis, Overview of 
Study Design;
3.1. Overview  of 
Study Design;
9.1.4. Follow -up 
Phase;
9.2.1.1. Response 
CategoriesCross -references t o the new Section 8.4 Subsequent Therapies have been added.
Rationale: Clarification of the IDMC’s role in data review following the interim PFS analy sis.
Synopsis, Overview of 
Study Design;
Synopsis, Statistical 
Methods;
3.1. Overview  of 
Study Design;
11.11. Data 
Monitoring 
CommitteeIt is noted that the IDMC will no longer revie w study data after the interim PFS analysis 
has been completed .
Rationale: To clarify the daratumumab pharmacokinetics (PK) and immunogenicity assessments specific to Arm B 
(DRd).
Synopsis, 
Pharm acokinetic and 
Immunogenicity 
Evaluations;
9.3.1. Evaluations;
9.3.4. Immunogenicity 
Assessments 
(Antibodies to 
daratumumab)Added text stating that in the Follow -up Phase, for all subjects in Arm B (DRd ), samples 
for PK and immunogenicity assessments are to be collected 8 w eeks after the last dose of 
daratumumab, regardless of whether there has been confirmed disease progression.
Time and Events 
Schedule , OverviewWithin the rows describing daratumumab PK and immunogenicity assessments, text has 
been added to emphasize that these assessments apply only to subjects in Arm B.
Rationale: Clarification of visit time points to e nsure consistent timing of assessments for both ECOG and ePRO
and align with other daratumumab protocol s.
Time and Events 
Schedule , OverviewText in strikethrough has been deleted, text in bold has been added:
Within the ECOG and PRO rows:
‘D1 of Cycle 3, 6, 9, 12 for year 1; every 6th month cycle thereafter until EOT ( PD)’
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
10
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
Rationale: Additional timepoints for MRD monitoring added to allow  for MRD durability assessment.
Time and Events 
Schedule , OverviewText in strikethrough has been deleted, text in bold has been added :
Within the b one marrow  aspirate/biopsy row:
‘To confirm CR/sCR, assess MRD, and evaluate PD (if feasible). Samples are requested at 
time of suspected CR/sCR and at 12, 18, 24,and30, 36, 48, and 60months post C1D1 
(+/-1 month).’
9.2.1.5. Bone Marrow  
Examination , Table 9Text has been revised in the Bone Marrow  Testing Table:
During Treatment
1.Central Testing: A portion of bone marrow  aspirates collected at time of suspected 
CR/sCR, and 12, 18, 24,and30, 36, 48, and 60(+/-1) months post C1D1, w ill be 
analyzed for MRD* .
Footnote: **Immunohistochemistry or immunofluorescence (both require kappa/lambda 
ratio from analysis of >100 plasm acells) or 2-to 4-color flow cytom etry are acceptable 
methods to evaluate plasma cell clonality .
Rationale: To clarify visit time points for quantitative immunoglobulin (Ig) assessments.
Time and Events 
Schedule , OverviewText in strikethrough has been deleted, text in bold has been added: 
Within the quantitative Ig row, for‘Day 1 of each cycle (28 -day cycles):
every 16 weeks 3 months
9.2.1.2. Myeloma 
Protein Measurements 
in Serum and Urine Serum quantitative immunoglobulins (QIgs)
 All subjects will be evaluated for IgG, IgA, IgM, IgE, and IgD at Screening. 
Every 16 week s3 months during treatment and at the EOT visit, subjects with 
IgD or IgE disease will be evaluated for IgG, IgA, IgM, IgE, and IgD and 
subjects with IgG, IgA, or IgM disease will be evaluated for IgG, IgA, and IgM.
Rationale: Widening of window  for collection of visit time points for hematology and clinical chemistry 
assessments.
Time and Events 
Schedule , Dose 
AdministrationText in strikethrough has been deleted, text in bold has been added:
Within the hematology and clinical chemistry rows:
‘For Cycle 1 Day 1, no need to repeat tests if they have been performed within the past 5 
days. Testing may be performed up to 32days before other infusion days. ’
Rationale: Additional text added to include Arm A cycle delays.
6.Dosage a nd 
AdministrationText in bold has been added:
Subjects whose study treatment is delayed for m ore than 4 weeks (Cycle 1 to Cycle 6) 
or m ore than 6 weeks (Cycle 7 and beyond) should have study treatm ent 
discontinued, unless, upon consultation with the sponsor and the review of safety and 
efficacy, continuation is agreed upon .
Rationale: Clarification that lenalidomide and dexamethasone doses can be re -escalated at the investigator’s 
discretion.
6.4.2. Lenalidomide 
Dose ReductionsText in bold has been added:
In the event of a dose adjustment, lenalidomide doses maybe re- escalated at the 
investigator’s discretion.
6.4.3. Dexamethasone 
Dose ModificationsIn the event of a dose adjustment, dexamethasone doses maybe re -escalated at the 
investigator’s discretion.
Rationale: To clarify that Eastern Cooperative Oncology Group (ECOG) and patient -reported outcomes (PRO) 
assessments that occur at Week 8 and Week 16 post -PD should be scheduled relative to the date of laboratory 
confirm eddisease progression.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
11
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
9.1.4. Fol low-up 
PhaseText in bold has been added:
‘Every 16 -week follow -up contacts , as well as Week 8 and Week 16 post -PD ECOG 
and ePRO assessments, should be scheduled from the date of confirmed progression (ie, 
the date of the confirm atory laboratory assessment , not the date of confirm ation by 
the sponsor) .’
Rationale: Remo ved text that was not pertinent to subject swho achieved a partial response (PR) or disease 
progression (PD).
9.2.1.1. Response
Categories , Table 8Text has been deleted from the International Uniform Response Criteria Consensus 
Recommendations Table:
Partial response (PR)
If serum and urine M -protein are not measurable, and serum free light assay is also 
not measurable, ≥50% reduction in bone marrow PCs is required in place of 
M-protein, provided baseline bone marrow  plasma cell percentage was ≥30%
Progressive disease (PD)†
Only in subjects without measurable serum and urine M -protein levels and without 
measurable disease by FLC levels, bone marrow  PC percentage (absolute percenta ge 
must be ≥10%)
Bone marrow  plasma cell percentage: the absolute percentage must be >10%
Abbreviations EBMT has been deleted from the list of abbreviations
Rationale: Replaced time qualifier of ‘1 -3 weeks later’ because in urgent situations, a repeat investigation may be 
needed sooner. ‘At least 1 day later’ is used to make clear that the confirmatory test cannot happen on the same day 
as the initial test.
9.2.1.2. Myeloma 
Protein Measurements 
in Serum and UrineText in strikethrough has been deleted, text in bold has been added :
‘Disease progression based on 1 of the laboratory tests alone must be confirmed by at least 
1repeat investigation performed at least 1 day 1 to 3 w eeks later’.
Rationale: To clarify definitions for study end.
10.1. Completion Text added that the study end is defined as when 330 deaths have occurred or 7years after 
the last subject is randomized, whichever comes first .
Rationale: Alignment of text with recent protocol template changes.
Title page Added ‘Janssen Pharmaceutica NV’ to the list of legal entities.
12.3.1. All Adverse 
EventsRevised the text for expected disease progression not being recorded as an adverse event 
or a serious adverse event term. Noted that ‘ if determined by the investigator to be more 
likely related to the study treatment than the underlying disease, the clinical signs or 
symptoms of progression and the possibility that the study treatment is enhancing disease 
progression, should be reported per the usual reporting requirements see Sect ion 12.1’.
17.3. Subject 
Identification ,
Enrollment, and 
Screening LogsText in strikethrough has been deleted, text in bold has been added :
All reports and communications relating to the study will identify subjects by subject 
identification and age at initial inform ed consent date of birth . In cases where the subject 
is not randomized into the study, the date seen and age at initial inform ed consent date of 
birth will be used .
17.11. Use of 
Information and 
PublicationText in strikethrough has been del eted, text in bold has been added :
‘key assessment parameters of the study will be used to determine a coordinating 
investigator for the study’ .
Changed the time for submitting combined results from the completed study for 
publication
‘within 18months af ter study end date 12months of the availability of the final data 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
12
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
(tables, listings, graphs) ’
Revised the text beginning ‘Authorship of publications...’
Abbreviations ICMJE has been added to the list of abbreviations.
Rationale: Minor errors w ere noted
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
Throughout the 
protocol‘anticancer’ has been replaced w ith ‘anti -myeloma’
Synopsis, Overview of 
Study Design;
3.1. Overview  of 
Study DesignText in bold has been added :
Subjects who discontinue study treatm entfor reasons other than disease progression must 
continue to have disease evaluations according to the Time and Events Schedule until 
confirmed disease progression (PD)(see Section 8.4, Subsequent T herapies) .
9.1.4. Follow -up 
PhaseText in bold has been added :
Subjects who discontinue study treatm entbefore disease progression must continue to 
have disease evaluations.
10.3. Withdraw al 
from the Study‘When a subject withdraws b efore completing the study’ has been revised to ‘ When a 
subject w ithdraws from the study’.
12.3.4. Pregnancy Text in strikethrough has been deleted :
Any subject who becomes pregnant during the study must discontinue further study 
treatment and promptly be withdrawn from the s tudy.
Redundant t ext in strikethrough has been deleted :
Follow -up information regarding the outcome of the pregnancy and any postnatal sequelae 
in the infant will be required .
Amendment INT -4(22May 2017)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment: To allow  subjects in Arm B (daratumumab + lenalidomide and 
dexamethasone [DRd]) to continue treatment with lenalidomide and dexamethasone (Rd) beyond the current 
protocol -specified 2 years.
Applicable Section(s) Description of Change(s)
Rationale: Subjects in Arm B will continue treatment with lenalidomide and dexamethasone (Rd) until disease 
progression or unacceptable toxicity .Based on data from the FIRST study, lenalidomide treatment until disease 
progression is emerging as the standard of care and is also consistent with the approved lenalidomide package insert .
Synopsis ;Time and 
Events Schedule, 
Dose Administration; 
3.1. Overview  of 
Study Design ; 6.2. 
Lenalidomide (Arm A 
and Arm B); 6.3. Subjects in both treatment arms will continue lenalidomide and dexamethasone (Rd) until 
disease progression or unacceptable toxicity .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
13
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
Dexamethasone 
(Arm A and Arm B)
6.2. Lenalidomide 
(Arm A and Arm B); 
6.3. Dexamethasone 
(Arm A and Arm B)
3.2. Study Design 
RationaleThe follow ing text is added t o manage the im plementation of this amendment : Subjects in 
Arm  B who discontinued treatm ent with Rd at 24 m onths may re-start treatm ent 
with Rd as per Am endment INT -4.
Text is added to support the modification of lenalidomide and dexamethasone dosing in 
Arm B. 
Rationale: With the anticipated improved survival for subjects in Arm B (d aratumumab ,lenalidomide, and 
dexamethasone [DRd]) ,who with this amendment will receive continuous lenalidomide and dexamethasone ( Rd)
regimen, the end of study and l ong-term survival Follow -up Phase areextended from 5 to 7 years in order to reach 
330 deaths as originally planned.
Synopsis; 3.1. 
Overvie w of Study 
Design; 9.1.4. 
Follow -up Phase; 
11.2. Sample Size 
Determination; 
17.9.1. Study 
Com pletionText is changed from 5 to 7 years.
Rationale: Most infusion -related reactions will occur with the first infusion. Because antihistamines have side 
effects in the elderly population, the benefit -risk ratio of continued prophylaxis with antihistamines during 
subsequent infusions should be considered.
6.1.3.1. Preinfusion 
MedicationThe follow ing text is added: After Cycle 6, if a subject has not developed an 
infusion -related reaction and is intolerant to antihistamines , modifications are acceptable as 
per investigator discretion.
Rationale: Clarify steroid administration.
8.3. Prohibited 
TherapiesClarify that steroids given for adverse events may exceed >10 mg prednisone if no other 
treatment options are available.
Rationale: Clarify the perm itted treatments for second primary malignancies and follow  up requirements .
10.2. Discontinuation 
of Study TreatmentThe follow ing text regarding second primary malignancies was edited and modified: A 
subject who experiences a second primary malignancy that can notbe treated by surgery 
alone must be withdrawn from the study . However, a subject who develops a malignancy 
that can be cured surgically may continue to receive the assigned study treatment and the 
subject should continue to be followed for subsequent progression of multiple myeloma . 
Subjects who require radiation therapy for treatm ent of second prim ary malignancy 
must have study treatm ent discontinued unless, upon consultation with the Sponsor 
and review of data, continuation is agreed upon . Subject swho require sys temic 
treatm ent of a new m alignancy m ust end study treatm ent but should continue to be 
followed for PFS2 and OS.
Rationale: Update the recommended course of action regarding lenalidomide dose adjustment to treat 
thrombocytopenia and neutropenia to be more consistent with the current package insert.
6.4.2.1. 
Thrombocytopenia 
(Table 4); Thrombocytop enia(Table 4) :
Platelet Count: When count returns to ≥30 x109/Lafter first fall to < 30 x109/L; 
Recommended Course of Action:  Resume lenalidomide at 15 mg the next lower dose
Platelet Count: When count returns to ≥30 x109/Lfor each subsequent drop in count to
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
14
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
6.4.2.2. Neutropenia 
(Table 5)<30 x109/L; Recommended Course of Action:  Resume lenalidomide at the next lower 
dose. level (10 mg or 5 mg) once daily. Do not decrease dose below  5 mg once daily.
Neutropenia (Table 5):
Neutrophil Count: When count first falls to <1.0 x109/L; Recommended Course of Action: 
Interrupt lenalidomide treat ment, start consider G-CSF treatment, follow c omplete blood 
count weekly; Neu trophil Count: When count returns to ≥1.0x109/Land neutropenia is 
the only observed toxicity; Recommended Course of Action:  Resume lenalidomide at 25 
mg once daily or init ial starting dose
Neutrophil Count: When count returns to ≥1.0 x109/Land dose- dependent hematological 
toxicities other than neu tropenia are observed; Recommended Course of Action:  Resume 
lenalidomide at 15 mg once daily the next lower dose
Neutrophil Count: When count returns to ≥1.0 x109/Lfor each subsequent drop in count to 
<1.0 x 109/L; Recommended Course of Action: Resume lenalidomide at the next lower 
dose level (15 mg, 10 mg, or 5 mg) once daily. Do not decrease dose below  5 mg once 
daily.
Rationale: Clarify that preinfusion medications are required.
6.1.3. Prevention of 
Infusion ReactionsRemove ‘guidelines’ from Section 6.1.3 header to clarify that preinfusion medications are 
required.
Rationale: Align text with Amendment INT -3 wh ich removed the whole blood samp le for MRD assessment.
Synopsis; 3.1.
Overvie w of Study 
Design; 9.5. 
BiomarkersThe follow ing text is modified: An assessment of MRD will be conducted onwhole blood
andbone marrow  samples.
The follow ing text is modified: In addition to planned bone marrow  aspirate assessments, a 
whole blood sample will be collected from subjects as outlined in the Time and Events 
Schedule for assessment of MRD and for processing to plasma and PBMCs.
Rationa le:Clarify the requirements to meet the primary endpoint of progression -free survival.
9.1.3. Treatment 
PhaseText is added: If disease progression has not occur red at the time of the End-of-Treatment 
visit, disease evaluations must continue until disease progression is confirmed. Subsequent 
anti-myeloma treatment will not be started until after disease progression is confirmed by 
the Sponsor.
Rationale: Clarify MRU procedures.
Time and Events 
Schedule Overview; 
9.6. Medical Resource 
UtilizationMRU is added to the Disease Evaluation portion of the Time and Events Schedule 
Overvie w. 
Text is modified : Medical resource utilization (MRU) data, principally number of 
hospitalizations, will be derived from data collected in the eCRF for all subjects thr oughout 
the study. Medical resource utilization (MRU) data, including prim ary non -protocol 
driven hospitalizations, outpatient visits, and em ergency room  visits, should be 
collected in the eCRF (Hospitalization/Outpatient Visits CRF) by the Investigator an d 
study -site personnel for all subjects throughout the study. Please see CRF com pletion 
guidelines.
Rationale: Minor errors w ere noted.
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
15
Approved , Date: 12 June 2019Amendment INT-3(2 November 2016 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: The International Myeloma Working Group (IMWG) has recently defined 
new categories of minimal residual disease ( MRD )–negativity and has clarified several aspects of disease response 
assessment along with clinical trial endpoints (Kumar , 201616). In order to align with the new  categor ies of MRD -
negativity, the time points for collection of bone marrow and whole blood for MRD assessment arerevised.
Applicable Section(s) Description of Change(s)
Rationale: Revision of th e time points for the assessment of MRD -negativity required to align with newly defined 
IMWG categories
Time & Events Schedule
(Bone marrow 
aspirate/biopsy; Blood 
sample for MRD)
9.2.1.5 Bone Marrow  
Examination (Table 9); 
9.2.1.6 Minimal Residual 
Disease Assessment ; 
9.2.2 EndpointsText is revised and added to clarify sample timing for MRD assessment: To confirm 
CR/sCR, assess MRD, and evaluate PD (if feasible).
Samples are request ed at time of suspected CR/sCR and at 12, 18, 24 and 30 months 
post C1D1 (+/ -1 month). If one of these time points occurs within 1 month of suspected 
CR, a repeat bone marrow  will not be requested. These bone marrow  tests will only be 
required if patient’s response is near CR or better by blood and urine evaluations .See 
Section 9.2.1.5 for additional information including timepoints.
The w hole blood sample for MRD assessment is removed from the protocol; t ext is 
deleted to align wi th other daratumumab protocols.
The follow ing text is modified in Section 9.2.1.5:
Additional bone marrow aspirates or biopsies (or both) will be performed to confirm 
sCR andCR, or relapse from CR (only one analysis is required, w ith either IHC or 
immunofluorescence or 2 -to 4-color flow  cytom etry included in the analysis) and to 
monitor for MRD at tim e points detailed in Table 9 . An additional bone marrow  
aspirate w ill be obtained 6, 12, and 18 months +/ -1 month after the achievement of CR 
to monitor for MRD.
Rationale: Secondary objectives modified for consistency with other daratumumab protocols.
Synopsis; 
2. Objectives and 
Hypothesis ; 9.2.2 
Endpoints ; 11.3 Efficacy 
AnalysesTime to response is added to objectives and endpoints.
This objective is modified: To assess the minimal residual disease (MRD) negative rate 
after treatment Changed to: MRD negativity rate
This corresponding endpoint is added: To assess MRD negativity rate, defined as the 
proportion of subjects assessed as MRD negative, at any timepoint after the date of 
randomization.
Durability of MRD negativity is added to exploratory objective s and endpoints.
The order of secondary objectives and efficacy endpoints has been modified for 
consistency with other daratumumab protocols
Rationale: Criteria modified for the timing of contraception, sperm donation, pregnancy, and fathering a child for 
consistency across daratumumab protocols.
4.1 Inclusion Criteria;
4.2 Exclusion Criteria;
4.3 Prohibitions and 
RestrictionsInclusion criterion 6: Contraception must continue for 3months after the last dose of 
daratumumab.
Inclusion criterion 7: Men must not donate sperm for 3months after the last dose of 
daratumumab.
Excusion criterion 15: R evised pregnancy timing and for men not to father a child for 
3months after last dose of daratumu mab.
The change to 3 months is also revised in Prohibition and Restriction 1 and 3.
Rationale: Minor clarification regarding use of dexamethasone.
4.2 Exclusion Criteria Exclusion criterion 3: the following text is revised: (equivalent of dexamethasone 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
16
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
40mg/day for a maximum 4 day s)
Rationale: Clarifications in the Dosage and Administration section
6. Dosage and 
AdministrationIn Figure 4 Schematic Overview  Study Treatment Administration , the parenthetical 
phrase is deleted for dexamethasone “For 1 yr, 20 mg thereafter” is removed from 
dexamethasone to align figure w ith text.
6.1.3.1 Preinfusion 
MedicationText in the third bullet regarding dexam ethasone is revised:
Dexamethasone 40 mg IV ( preferred ) or PO (only if IV is not available) , 
approximately 1 hour or less prior to daratumumab infusion. For subjects older than 
75years or underweight (body mass index [BMI] <18.5), dexamethasone 20 mg may 
be administered as appropriate (see Section 6.3). An equivalent intermediate -acting or 
long-acting corticosteroid may substitute (see Attachment 6 for conversion table). On 
days when subjects receive this dose of dexamethasone in the clinic, dexametha sone 
will not be self -administered at home. If weekly dexamethasone dosing has been 
reduced below 10 m g due to adverse events during study, a m inimum of 
dexamethasone 10 m g IV should continue to be administered prior to 
daratumumab infusions.
6.2 Lenalido mide (Arm 
A and Arm B)The follow ing text is modified: On daratumumab infusion days, it is recommended 
that lenalidom ide should be administered either prior to or at the same time 
(preferred) as the premedications. The daratumumab infusion should begin 
approximately 1 hour after the lenalidomide administration .
6.4.1.1 Daratumumab -
Related Toxicity 
ManagementThe follow ing text is modified : Other than on Day 1 of a cycle , if a daratumumab 
administration does not commence within the prespecified window  (Table 3 ) of the 
scheduled administration date, then the dose will be considered a missed dose.
Day 1 of a cycle should not be skipped; however , IfDay 1 of a cycle ismay be
delayed, and Day 1 of subsequent cycles should be adjusted accordingly to maintain the 
28-day cycle duration.
6.4.2 Lenalidomide Dose 
ReductionsThe follow ing text is added: After initiation of lenalidomide, subsequent lenalidomide 
dose adjustment is based on individual subject treatment tolerance. If the investigator 
determines that an adverse event may be related to lenalidomide, dose adjustment can 
be done even if not specified in this protocol.
6.4.2.3 Renal 
Impairm ent(Table 6, 
footnote a); 
Attachme nt3 Calculated 
and Measured Creatinine 
ClearanceText is added to specify that calculation of CrCl should be adjusted for body weightin 
subjects with a body mass index >30 kg/m2.  
6.4.2.4 Other Grade 3 or 
4 Adverse EventsHeading is modified to remove “Grade 3 or 4”and the follow ing text is added: Note 
that the dose modifications above are suggested, but physician discretion and clinical 
judgment should prevail.
6.4.3 Dexamethasone 
Dose ModificationsThe follow ing text is added: For other Grade 3 or 4 non-hematologic and non -renal 
toxicities judged by the investigator to be related to dexamethasone alone, treatment 
with dexamethasone should be interrupted and restarted at the next lower dose level 
once the toxicity has resolved to Grade 2 or less. Trea tment with daratumumab and 
lenalidomide may continue. For complete details on dexamethasone, refer to the most 
current local product prescribing information.
If weekly dexamethasone dosing has been reduced below  10 m g due to adverse events 
during study, a minimum  of dexamethasone 10 mg IV should continue to be 
administered prior to daratumumab infusions.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
17
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
Rationale: Text is added to clarify timing of urine collection for M -protein analysis.
9.2.1. 2Myeloma Protein 
Measurements in Serum 
and UrineThe follow ing text is added: If the 24 -h urine collection (UPEP) began before informed 
consent was obtained as part of routine patient care, the sample can be used in this 
study as long as it was sent to the central lab for analysis after the informed cons ent was 
obtained .
Rationale: Text is modified to clarify imaging assessments for lytic disease.
9.2.1.7 Assessment of 
Lytic DiseaseA complete skeletal survey (including skull, entire vertebral column, pelvis, chest, 
humeri, femora, and any other bones for which the investigator suspects involvement 
by disease) is to be performed and evaluated by the locally laboratory by  X-ray
roentgenography or the local standard of care imaging, eg, or low -dose CT during the 
Screening Phase.
Magnetic resonance imaging (MRI) may be included as an additional assessment at the 
discretion of the investigator; however, focal lesions identified by M RI alone cannot be 
counted as lytic disease.
Rationale: A list of anticipated events is added, consisten twith other dar atumumab studies.
12.3.1 All Adverse 
Events;
Attachment 10 
Anticipated Adverse 
EventsStandard text on reporting of anticipated adverse events is added.
The list of events is added to Attachment 10.
Rationale: Clarifications regarding CRAB criteria eligibility
Attachment 1 Modified 
IMWG Diagnostic 
Criteria for Multiple 
Myelom aThe follow ing text is added:
Note: Subjects only meeting SLiM CRAB are not eligible.
c) Hem oglobin measurement performed as part of standard of care within 42 days 
before randomization is acceptable for screening for CRAB criteria; but must be 
performed within 21 days before randomization for other eligibility requirements.
Rationale: Additional minor clarifications.
Time & Events 
Schedule ;
9.1.4 Follow -up PhaseIn Follow -up, a w indow  of ±2 w eeks is added for after PD (Q 16 w ks).
The follow ing text is added to the first paragraph in 9.1.4: Every 16 -week follow -up 
contacts should be scheduled from the date of confirmed progression. In subjects for 
whom disease progression will not be documented (eg, received subsequent anticancer 
treatment or refused disease evaluations, but agreed to follow -up contacts), the every 
16-week follow -up should be scheduled from the date of the End of Treatment Visit. 
8.1.5 Prophylaxis for 
Herpes Zoster 
ReactivationStandard text for herpes zoster reactivation text is added .
The follow ing is revised: Prophylaxis for herpes zoster reactivation is recommended 
during the Treatment Phase, as per institutional guidelines may be used at the 
discretion of the investigator.
9.2.1.1 Response 
CategoriesThe follow ing text is added: For patients with measurable disease by SPEP or UPEP at 
baseline, increases in serum free light chains (FLC) or the FLC ratio alone do not meet 
criteria for progressive disease
9.8 Safety Evaluations Minor changes in the serum chemistry panel:
-blood urea nitrogen (BUN) or urea
-total; direct bilirubin (not required except in case of congenital bilirubinemia, such 
as Gilbert disease)
New footnote: *Sodium and potassium assessment were added in Protocol Amendment 
2; how ever,collection of sodium and potassium results will be done retrospectively 
from the date of subject consent for the duration of the study, if collected as part of 
routine care
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
18
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
9.8 Safety Evaluations; 
11.9 Safety Analyses ; 
Time & Events ScheduleText is modi fied to clarify v ital signs : Descriptive statistics of baseline temperature, 
pulse/ heart rate , and blood pressure (systolic and diastolic) values and changes from 
baseline will be summarized.
17.5 Case Report Form 
Com pletionTemplate text is revised based on the current Janssen global protocol template.
References New  references are added:
Chapuy 2016
Kumar 2016
Attachment 7 Asthma 
GuidelinesTypo corrected for Persistent, Mild: >2days/w eek but not daily.
Attachment 8 
International Staging 
SystemTypo corrected for Stage III: Serum ß 2microglobulin ≥5.5 mg/L
Typo corrected for Note 2: Serum ß 2microglobulin 3.5 –5.4mg/L
Title page Janssen Sciences Ireland UC is added and Janssen Infectious Diseases BVBA is 
removed per the protocol template.
Abbreviations SLiM is defined
Rationale: Minor errors w ere noted.
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
Amendment INT -2(26August 2015 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union .
The overall reason for the amendment: To incorporate Indirect Antiglobulin ( Coom bs)Testing (IAT) during the 
Screening Phase due to the risk of daratumumab interference w ith blood typing , as well as make updates throughout 
the protocol to align with the other daratumumab Phase 3 protocols and to incorporate regulatory agency feedback.
Applicable Section(s) Description of Change(s)
Rationale: Due to risk of daratumumab interference with IAT testing, in addition to blood typing, subjects must also 
have IAT performed at screening.
Time and Events 
Schedule Overview; Blood type assessment (ABO, Rh) and IAT must be performed at screening and at 
C1D1 predose in Arm B only .
4.3 Prohibitions and 
Restrictions, Criterion #7 Removed the text pertaining to blood typing from here as this information is provided in 
Section 9.8 Safety Evaluations.
9.8 Safety Evaluations Updated the requirement for blood typing and IAT results to align with other Phase 3 
daratumumab protocols.
Rationale: Updated inclusion and exclusion criteria for clarity, to align with IMWG criteria, and to align with other 
Phase 3 daratumum ab protocols.
4.1 Inclusion Criteria
Criterion #2, bullet 2.1 Criterion m odified as per Amendm ent INT -2:
2.1 Subject must have documented multiple myeloma satisfying the CRAB (calcium  
elevation, renal insufficiency, anem ia and bone abnorm alities) criteria (see 
Attachment 1 ), monoclonal plasm a cells in the bone marrow ≥10% or presence of a 
biopsy proven plasmacytoma, and measurable disease.
 Measurable disease, as assessed by central laboratory , defined by any of the 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
19
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
following:
 IgG myeloma: Serum  monoclonal paraprotein (M-protein) level ≥1.0 g/dL or 
urine M -protein level ≥200 mg/24 hours; or
 IgA, IgM, IgD, or IgE multiple myeloma: serum M-protein level ≥0.5 g/dL 
or urine M -protein level ≥200 mg/24 hours; or
 Light chain multiple myeloma without measura ble disease in serum  or 
urine: Serum immunoglobulin free light chain ≥10mg/dL and abnormal 
serum immunoglobulin kappa lambda free light chain ratio.
Criterion #5, bullet g1 Creatinine clearance ≥30 mL/min (for lenalidomide dose adjustment for subjects with 
creatinine clearance 30 -50mL/min, refer to Section 6.2). Creatinine clearance can be 
calculated using the Cockcroft -Gault formula provided in Attachment 3 ; or for subjects 
with over -or underweight, creatinine clearance m ay be measured from a 24 -hour s 
urine collection using the formula provided in Attachment 3 ;--
Criterion #5, bullet h1
Criterion #6, bullet 6.1corrected serum calcium ≤14mg/dL ( ≤3.5 mM/L); or free ionized calcium ≤6.5mg/dL 
(≤1.6mM/L)(Attachment 4)
Women of childbearing potential must commit to either abstain continuously from 
heterosexual sexual intercourse or to use 2 methods of reliable birth control 
simultaneously . This includes one highly effective form of contraception (tubal ligation, 
intrauterine device [IUD], horm onal [progesterone -only birth control pills or 
injections or partner ’s vasectomy) and one additional effective contraceptive method 
(male latex or synthetic condom, diaphragm, or cervical cap). Contraception must begin 
4 weeks prior to dosing and must continue for 4 m onths after the last dose of 
daratumumab .Reliable contraception is indicated even where there has been a history 
of infertility , unless due to hysterectomy or bilateral oophorectomy . (Also see 
Attachm ent 5: Lenalidomide Global Pregnancy Prevention Plan).
4.2 Exclusion Criteria
Criterion #8.1 a and 
Criterion #8. 1bModified the criteria pertaining to subjects with COPD and severe persistent asthma to 
align with other Phase 3 daratumumab protocols.
8.1a) Subject has known chronic obstructive pulmonary disease (COPD) with a 
Forced Expiratory V olum e in 1 second (FEV1) <50% of predicted norm al. Note 
that FEV1 testing is required for subjects suspected of having COPD and subjects 
must be excluded if FEV1 <50% of predicted norm al.
8.1b) Subject has had known m oderate or severe persistent asthm a within the last 
2years (see Attachm ent 7), or currently has uncontrolled asthm a of any 
classification. (Note that subjects who currently have controlled interm ittent 
asthm a or controlled mild persistent asthma are allowed in the study).
Attachm ent 7: Asthma Guidelines was added.
Criterion #9.1 Subject is known to be seropositive for human immunodeficiency virus (HIV) or 
hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg] or
antibodies to hepatitis B surface and core antigens [anti- HBs and anti -HBc, 
respectively]) or hepatitis C ( anti-HCV antibody positive or HCV -RNA  quantitation 
positive).
Rationale: Clarified that the visit window  is not intended for all study visits, only intended for the start of a 
treatment cycle
Time and Events 
Schedule OverviewModified the second sentence: Study treatment should be initiated within 72 hours after 
randomization. Day 1 of each cycle Each study visit may occur ±3 days of the 
scheduled day in order to accommodate the schedule of the site or subject.
Rationale: Clarified that if a full chest CT has been done, it is not necessary to perform an additional chest X -ray
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
20
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
Time and Events 
Schedule Overview
9.1.2 ScreeningModified Procedures: Chest X -ray (or full chest CT scan)
Rationale: To clarify the timing of daratumumab PK sample collection on infusion days.
Time and Events 
Schedule Overview
6.1.2 Daratumumab 
AdministrationModified Laboratory Assessments for Daratumumab PK sampling: 
Arm B only. On dara infusion days, 1 sample to be collected before infusion start
(window  -2hrs) and 1 sample to be collected after end of infusion (window +2 
hrs).infusion
As noted in the Time and Events Schedule, vital signs should be monitored extensively 
on Cycle 1 Day 1 before, during, and after the first infusion of daratumumab. For all 
other infusions, vital signs should be measured before the start of infusion and at the 
end of the infusion. If a subject experiences any significant medical event, then the 
investigator should assess whether the subject should stay overnight for observation . 
Rationale: To clarify that vital signs 2 hours post end of infusion are not ne cessary
Time and Events 
Schedule, Dose 
AdministrationModified Vital Signs Notes: On Cycle 1 Day 1: Immediately before the start of dara 
infusion; at 0.5, 1, 1.5, 2, 3.5 hrs after the start of the infusion; at end of infusion; and 
0.5, and1 hrafter end of infusion.
Rationale: To allow  for flexibility if preinfusion medications are administered orally.
6.1.3.1 Time and Events 
Schedule, Dose 
Administration, Pre -
infusion medications An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but 
avoid IV use of promethazine) approxim ately 1hour prior to infusion (see 
Attachm ent 9 for list of antihistamines that m ay be used)
Added the sentence: If necessary, all PO preinfusion medications m ay be 
administered outside of the clinic on the day of the infusion, provided they are 
taken within 3 hours before the infusion.
Rationale: Removed the requirement that tracheostomy equipment needs to be available in case of infusion -related 
reactions .
6.1.4 Management of 
Infusion Related 
ReactionsTrained study staff at the clinic should be prepared to intervene in case of any infusion 
reactions occurring, and resources necessary for resuscitation (eg, agents suc h as 
epinephrine and aerosolized bronchodilator, also medical equipment such as oxygen 
tanks, tracheostom y equipment, and a defibrillator) must be available at the bedside . 
Attention to staffing should be considered when multiple subjects w ill be dosed at the 
same time.
Rationale: To reflect current practice, updated management of infusion -related reactions section to indicate that the 
infusion will be paused (not interrupted or slow ed down) if an infusion -related reaction occurs.
6.1.4 Management of 
Infusion Related 
ReactionsIf an infusion -related reaction develops, then the infusion should be paused temporarily 
interrupted or slow ed down .
If an infusion is paused or the infusion rate is decreased , then a longer -than-anticipated 
infusion time may occur.
Rationale: FEV1 measurement is not relevant for asthma assessment.
Time and Events 
Schedule Overview;
9.8 Safety EvaluationsFor subjects w ith COPD and /orasthm a, FEV1 should be measured at baseline.
6.1.3.2 Postinfusion 
MedicationsFor subjects w ith higher risk of respiratory complications (ie, subjects with m ild 
asthm a, or subjects with COPD who have a FEV1 <80%), the following postinfusion 
medications should be considered.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
21
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
Rationale: Updated protocol to align with Revlimid US Pack age Insert and EU SmPC
1.3 Lenalidomide
6.2 Lenalidomide (Arm 
A and Arm B)
6.4.2.3 Renal 
Impairm entAdded: REVLIMID® (lenalidomide) in combination with dexamethasone was 
approved by both U.S. Food and Drug Adm inistration and the European 
Commission for the treatm ent of adult patients with previously untreated multiple 
myeloma who are not eligible for transplant, on 18 February 2015 and 
20February 2015, respectively.
Lenalidomide will be self -administered at a dose of 25 mg PO each day on Days 1 
through 21 of each 28 day cycle for subjects with creatinine clearance >50 mL/min. If 
creatinine clearance is between 30 and 50mL/min, the dose of lenalidomide will be 10 
mg every 24 hours. Once the creatinine clearance is >50mL/min during the course of 
the treatment, lenalidomide can be increased to 25 mg.
Lenalidomide dose adjustment should be instituted for subjects with a creatinine 
clearance of 50mL/minute or less. The recommended doses for subjects with multiple 
myeloma and renal impairment are shown in Table 6 .
Table 6: Lenalidomide Dose Adjustment for Renal Impairment
Category Renal Function Dose
Moderate renal 
impairm entCrCl 30 -50mL/min 10mg every 24 hours
Severe renal 
impairm entCrCl < 30mL/min (not 
requiring dialysis)15mg every 48 hours
Rationale: To provide guidance on management of missed lenalidomide doses
6.2 Lenalidomide (Arm 
A and Arm B)Added the following 3rdparagraph:
If a daily lenalidomide dose is missed, it may be taken if <12 hours have elapsed since 
the time that it shoul d have been taken.  If the next dose is scheduled to be taken within 
12 hours, the missed lenalidomide dose should be skipped.
Rationale: Aligned language to be consistent with criteria in other Phase 3 protocols.
6.4.1.1 Daratumumab -
Related Toxicity 
ManagementThe criteria for dose delay due to hematologic toxicity have been revised.
 Grade 4 hem atologic toxicity thrombocytopenia or
 Grade 3 thrombocytopenia with bleeding
 Grade 4 neutropenia, if this is the second occurrence despite growth factor 
support
 Febrile neutropenia of any grade -----
----A missed dose will not be made up. ---
---Doses of daratumumab may be delayed up to 4 weeks (Cycle 1 to Cycle 6) or up to 6 
weeks (Cycle 7 and beyond). If Day 1 of a cycle is delayed, Day 1 of subsequent 
cycles should be adjusted accordingly to m aintain the 28 -day cycle duration.  
However, if a within -cycle dose is delayed, then the dates of the subsequent within -
cycle doses should not be adjusted.   Any adverse event deemed to be related to 
daratumumab tha t requires a dose hold of m ore than 4 weeks (Cycle 1 to Cycle 6) or 
more than 6 weeks (Cycle 7 and beyond) will result in perm anent discontinuation 
of daratumumab. ----
6.4.1.2 Daratumumab 
Interruption or Missed 
DosesSubjects whose dose was delayed for more than 4 w eeks (Cycle 1 to Cycle 6) or m ore 
than 6 weeks (Cycle 7 and beyond) should have study treatment discontinued, unless, 
upon consultation with the sponsor and the review of safety and efficacy, continuation 
isagreed upon.
Rationale: Changed per Irish Regulatory Authority request (aligned with lenalidomide SmPC and US Package 
Insert
6.4.2.2. Neutropenia Modified Table 5 as below :
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
22
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
Neutrophil Count Recommended Course of Action
When count first 
falls to 
<1.0109/L
When count returns 
to 1.0109/L 
and neutropenia is 
the only observed 
toxicityInterrupt lenalidomide treatment, start G -CSF 
treatment, follow complete blood count w eekly
Resume lenalidomide at 25 mg once daily
When count 
returns to 
1.0109/L and 
dose -dependent 
hematological  
toxicities other 
than neutropenia 
are observedResume lenalidomide at 15 mg once daily
For eac h 
subsequent drop in 
count to 
<1.0109/L
When count returns 
to 1.0109/LInterrupt lenalidomide treatment
Resume lenalidomide at the next lower dose level 
(15mg, 10 mg, or 5 mg) once daily. Do not decrease 
dose below  5mg once daily
Rationale: Updated recommended therapies to prevent deep vein thrombosis and pulmonary embolism to align with 
IMWG criteria.
8.1.1 Prevention of Deep 
Vein Thrombosis and 
Pulmonary EmbolismText in Section 8.1.1 rew orded.
Lenalidomide has been associated w ith increased incidence of deep vein thrombosis and 
pulmonary embolism. Therefore, prophylaxis of venous thromboembolism (VTE) 
for a ll subjects is recommended according to IMWG guidelines as well as at the 
investigator’s discretion (Palumbo 2008). Both individual and m yeloma -related 
risks of VTE should be taken into account in determining the type of 
thromboprophylaxis. In summary:
 If no risk factor, or any one risk factor is present, aspirin 81-325 mg once 
daily is recommended or dose per institutional standards
 If 2 or more risk factors are present, low molecular weight heparin (LMWH) 
(equivalent of enoxaparin 40 mg once daily) or full-dose warfarin, 
international norm alized ratio (INR) 2 -3, is recommended
 If any myeloma therapy -related risk factor is present, then LMWH 
(equivalent of 40 m g enoxaparin once daily) or full -dose warfarin (target INR 
2-3) is recommended
all subjects should be prophylactically treated with aspirin at a dose of 100 to 150 mg 
PO daily. Subjects at increased risk of thromboembolic events (based on their medical 
history) should be treated with enoxaparin at a dose of 40 mg subcutaneously daily (or 
other low  molecular heparin with equivalent dose and frequency for prophylaxis 
indication). The injection should be handled according to local practice.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
23
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
Rationale: Clarification of the use of bisphosphonate after Cycle 1
8.1.2 Bisphosphonate 
TherapyAfter Cycle 1, investigators should not prescribe bisphosphonates to subjects who have 
not received it before, unless it has been discussed with sponsor and there is no sign 
of disease progression.
Rationale: Modification of the dexamethasone dose in both treatment arms and provides guidance on management 
of missed doses.
Synopsis: Dosage and 
Administration
6.3Dexamethasone 
(Arm A and Arm B)Added sentence:
If a weekly dexamethasone dose is missed, it may be taken if <4 days have elapsed 
since the time that it should have been taken.  If the next dose is scheduled to be 
taken within 3 days, the missed dexamethasone dose should be skipped.
Rationale: Allows for flexibility in scheduling
6 Dosage and 
Administration ;
9.1.3 Treatment PhaseInserted following sentence in 1stparagraph :
In Cycles 1 through 6, weekly or bi- weekly daratumumab infusions may be given 
within ±1 day of the scheduled day in order to accommodate the schedule of the 
site or subject . In all cycles, weekly dexamethasone doses m ay be given within ±1 
day of the scheduled day in order to accommodate the schedule of the site or 
subject. Changes to within -cycle dosing should not impact Day 1 of the next cycle.
Also inserted new Figure 4: Schem atic Overview Study Treatm ent Administration
in Section 6
Rationale: Clarification of bone marrow examination requirements. Clinical staging must be done locally; no option 
for this to be done centrally.
9.2.1.5 Bone Marrow  
ExaminationBone marrow  aspirate or biopsy will be performed at Screening for clinical 
characterization (morphology, IHC or immunofluorescence or 2 -to 4-color flow 
cytom etry, and cytogenetics), to establish baseline multiple m yeloma clonality to 
monitor for MRD and to perform molecular subtyping to monitor daratumumab activity 
in high -risk molecular subgroups. Good quality slides are required for morphological 
examination to determine plasma cell percentage in the bone marrow . Assessment by 
flow cytometry alone is no t sufficient. Bone m arrow exam ination for disease 
assessment Clinical staging may will be performed locally; however, a portion of the 
bone marrow  aspirate must be sent to the central laboratory for analysis of MRD and 
molecular subtyping. A fresh bone mar row aspirate at screening is required if at all 
possible, by exception non -decalcified diagnostic tissue (bone marrow aspirate slides or 
FFPE tissue) may be supplied for MRD assessment instead.  Additional bone marrow  
aspirates or biopsies (or both) will b e performed to confirm sCR, CR, or relapse from 
CR (only one analysis is required, with either IHC or immunofluorescence or 2-to 4-
color flow cytom etry included in the analysis) and to monitor for MRD. An
additional bone marrow  aspirate w ill be obtained 6, 12, and 18 months +/ -1 month after 
the achievement of CR to monitor for MRD. If feasible, a bone marrow aspirate may be 
collected from subjects at disease progression to evaluate mechanisms of daratumumab 
resistance.
Inserted Table 9. Bone Marrow Testi ng
Rationale: Description of Daratumumab interference with Indirect Antiglobulin Test (IAT) results.
9.8 Safety Evaluations Inserted the following:
Daratum umab Interference with Indirect Antiglobulin Test (IAT) results :
Daratum umab interferes with the Indirect Antiglobulin Test (IAT), which is a 
routine pre -transfusion  test  perform ed  to identify a patient’s antibodies to minor 
antigens so that suitable donor blood can be given for transfusion. Daratumumab 
does not inte rfere with ABO/RhD typing .  CD38 is expressed at very low levels on 
erythrocytes.  Daratum umab binds to the CD38 on erythrocytes, which results in a 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
24
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
positive IAT (Indirect Coombs Test).   This positive result m asks the detection of 
antibodies to minor antigens and m ay prevent or delay blood banks from issuing 
donor blood for transfusion.  This effect occurs during daratum umab treatm ent
and for up to 6 m onths after treatm ent ends.  Subjects will receive a patient 
identification wallet card for the study that includes the blood profile (ABO, Rh, 
and IAT) determined before the first infusion of daratumumab along with 
inform ation on the IAT interference for healthcare providers/blood banks.  
Subjects are to carry this card throughout the treatm ent period and for at least 6 
months after treatm ent ends.  Blood banks can eliminate the daratum umab IAT 
interference by treating reagent RBCs with dithiothreitol (DTT) (Chapuy 2015).
Possible methods for blood banks to provide safe RBCs for transfusion to subjects 
recei ving daratumumab include:
a)    Providing ABO/RhD compatible, phenotypically or genotypically matched units
b) Providing ABO/RhD compatible, K-negative units after ruling out or identifying 
alloantibodies using dithiothreitol ( DTT )-treated reagent RBCs
Uncrossmatched, ABO/RhD compatible RBC units should be administered if 
transfusion is needed emergently as per local blood bank practice.
Despite daratumumab binding to CD38 on erythrocytes, no indication of clinically 
significant hemolysis has been observed in daratumumab studies. For additional details, 
refer to the Daratumumab IB. Blood type assessment
CD38 is expressed on erythrocytes to a minor extent. Hemolysis could occur following 
the infusion of daratumumab, which w ould confound the blood type assessm ent. To be 
cautious and in case of urgent need for blood transfusion, the subject’s blood type, 
including minor group, will be assessed before the first infusion of daratumumab. 
Subjects in Arm B should at all times carry a card w ith their blood type durin g the 
study.
Rationale: Inserted informat ion per Irish Regulatory request
12.1.1 Adverse Event 
Definitions and 
Classifications
12.3.3 Suspected 
Unexpected Serious 
Adverse ReactionsInserted:
Suspected Unexpected Serious Adverse Reactions (SUSARs)
If a serious and unexpected adverse event occurs for which there is evidence 
suggesting a causal relationship between the study treatment and the event (eg, 
death from  anaphylaxis), the event m ust be reported as a serious and unexpected 
suspected adverse reaction even if it is a component of the study endpoint (eg, all -
cause m ortality).  Refer to Section 12.3.3 for SUSAR Reporting Requirements.
If a serious and unexpected adverse event occurs for which there is evidence suggesting 
a causal relation ship betw een the study treatment and the event (eg, death from 
anaphylaxis), the event must be reported as a serious and unexpected suspected adverse 
reaction even if it is a component of the study endpoint (eg, all -cause mortality).
Added Section. The sp onsor assumes responsibility for appropriate reporting of all 
Suspected Unexpected Serious Adverse Reactions (SUSAR) [serious adverse events 
that are unlisted (unexpected) and associated with the use of the study drug] to the 
regulatory authorities in acco rdance with GCP. The sponsor will also report to the 
investigator (and the head of the investigational institute where required) all 
serious adverse events that are unlisted (unexpected) and associated with the use of 
the study drug. The investigator (or s ponsor where required) must report these 
events to the appropriate Independent Ethics Committee/Institutional Review 
Board (IEC/IRB) that approved the protocol unless otherwise required and 
documented by the IEC/IRB.
Rationale: Attachment 1 w as updated t o be consistent with other Daratumumab protocols
Attachment 1: Modified 
IMWG Diagnostic Entire attachment updated to be consistent with other Daratumumab protocols
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
25
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
Criteria for Multiple 
Myelom a
Rationale: Added for convenience by clinical operations (logistical purposes)
Time and Events 
Schedule, Overview: 
Blood sample for MRDFor subjects who maintain CR, whole blood sample will also be obtained at 6, 12, and 
18months ± 1 m onth after confirmed CR.
Rationale: Clarification of disease evaluation testing in Screening Phase
Time and Events 
Schedule, Overview: Added clarification on serum and urine disease evaluation at Screening in the Disease 
Evaluation section :
Serum disease evaluations (SPEP):      X (Repeat on C1D1 if not within 14 days prior to 
C1D1)
Urine disease evaluations (UPEP) :      X (Repeat on C1D1 if not within 14 days prior to 
C1D1)
Calcium, albumin, β 2-microglobulin :  X (Repeat calcium and albumin on C1D1 if not 
within 14 days prior to C1D1); don’t repeat β 2-microglobulin
Rationale: Miscellaneous updates for clarity.
Time and Events 
Schedule, Dose 
AdministrationRemoved the requirement to measure vital signs 2 hours after the end of infusion.
6.1.3.1 Preinfusion 
MedicationChange to bullet 3: An equivalent intermediate -acting or long-acting corticosteroid 
may substitute (see Attachment 6 for conversion table).
6.1.3.2 Postinfusion 
Medication Control medications for lung disease (eg, inhaled corticosteroids ± long -acting β 2
adrenergic receptor agonists for subjects w ith asthma; long -acting bronchodilators such 
as tiotropium or salbumatol salmeterol ± inhaled corticosteroids for subjects w ith 
COPD)
8.3Prohibited Therapies Concomitant administration of any other antineoplastic therapy for the intention of 
treating multiple myeloma and other cancers not defined in the study protocol is 
prohibited .
Nonsteroidal anti -inflammatory agents should be used with caution in order to prevent 
myeloma- related kidney disease.
9.2.1.8 Documentation 
of Extramedullary 
Plasm acytom asTo qualify for PR, the sum of products of the perpendicular diameters of the existing 
extramedullary plasmacytomas must have decreased by at least 50% or 25%, 
respectively , and new plasmacytomas must not have developed (see the disease 
response cr iteria in Table 8).
9.5 Biomarkers Biomarker assessments will focus on 2 main objectives including evaluating the ability 
of daratumumab + Rd to reduce MRD in subjects who achieve a complete response 
(compared to Rd alone) and to determine the clinical be nefit (ORR, PFS, and OS) of 
daratumumab + Rd in high -risk molecular subtypes (del17p, t(4;14), t(14;16 ), specific 
gene signatures, specific mutations).
Attachment 3: Calculated 
and Measured Creatinine 
Clearance
5 Treatment Allocation 
and BlindingAdded the formula to measure CrCL to the attachment:
Eligible subjects w ill be stratified by International Staging System (I vs II vs III see
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
26
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
6.1.3.1 Preinfusion 
MedicationAttachm ent 8), region (North America vs Other), and age (< 75 vs ≥75) and then 
randomized to treatment in a 1:1 ratio to either Treatment Arm A (Rd alone) or 
Treatment Arm B (daratumumab+Rd [DRd]). A new Attachment 8 was added.
An antihistamine (diphenhydramine 25 -50 m g IV or PO, or equivalent but avoid 
IV use of promethazine) approximately 1 hour prior to infusion (see Attachment 9) 
for list of antihistam ines that m ay be used). Added Attachment 9.
9.2.2 Endpoints, 
Secondary Endpoints
12.3.1 All Adverse 
Events Endpoints Overall response rate (ORR), defined as the proportion of subjects who 
achieve PR or better, according to the IMWG criteria, during or after the study 
treatment.
 Duration of response, calculated from the date of initial documentation of a 
respons e (PR or better) to the date of first documented evidence of progressive 
disease, as defined in the IMWG criteria. For subjects who have not progressed, 
data will be censored at the last disease evaluation before the start of any 
subsequent anti -myeloma th erapy.
Subjects (or their designees, if appropriate) w ill be provided with a "w allet ( study) card" 
and instructed to carry this card w ith them for the duration of the study and for at least 
6 months after treatm ent ends indicating the following: ---
Rationale: Hydrocortisone is not an adequate substitute for a glucocorticosteroid as it is a short acting 
corticoster oid.Per request of Swed ish HA , hydrocortisone has been replaced w ith betamethasone as an acceptable 
substitute for pre -medication with dex amethasone, due to the short duration of action of hydrocortisone .  Attachment 
6 is modified accordingly.
Attachment 6: 
Conversion Table for 
Glucocorticosteroid 
DoseRemoved hydrocortisone (20 mg) because it is short -acting and therefore not an 
adequate substitution.
Generic Name Oral or Intravenous
Dose (m g)
Dexamethasone 0.75
Hydrocortisone 20
Methylprednisolone 4
Prednisolone 5
Prednisone 5
Betam ethasone 0.6
Rationale: Minor errors w ere noted.
Throughout the protocol Minor grammatical, formatting, abbreviations or spelling changes were made.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
27
Approved , Date: 12 June 2019Amendment INT -1(29 October 2014 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment :To incorporate investigator feedback into the protocol and to further 
clarify MRD monitoring .
Applicable Section(s) Description of Change(s)
Rationale: To clarify that when a subject discontinues lenalidomide/dexamethasone study treatment on A rm B, they 
would still continue to receive dexamethasone as premedication.  
Synopsis ,Overview of 
Study Design ;
3.1Overview  of Study 
Design ; 
6.3Dexamethasone 
(Arm A and Arm B) Text w as added to indicate that s ubjects will continue to receive dexamethasone as a 
premedication for daratumumab administration even after the 
lenalidomide/dexamethasone treatment is discontinued .
Rationale: To allow  for a bone marrow  biopsy or aspirate (or both) to confirm CR .  
Time and Events 
Schedule Overview ;
9.2.1.5 Bone Marrow  
ExaminationAdditional bone marrow  aspirates or biopsies (or both) w ill be performed to confirm sCR, 
CR, or relapse from CR (IHC or immunofluorescence) and to monitor for MRD. Only 1 
bone marrow  sample is required, w ith either IHC or immunofluorescence included in the
analysis. For subjects who maintain CR, fresh aspirate will also be obtained at 6 and 
12months +/ -1 month after confirmed CR to monitor for MRD. A portion of all bone 
marrow  tissues may be used for other biomarker assessments
Rationale: To allow  for th e possibility of stopping treatment ≥24 months based on MRD status, an additional time 
point of 18 months was added for collection of fresh aspirate and a whole blood sample after confirmed CR to 
monitor MRD.   
Synopsis, Efficacy 
Evaluations/Endpoints;
Time and Events 
Schedule Overview;
9.2.1.5 Bone Marrow  
Examination;
9.2.1.6 Minimal 
Residual Disease 
Assessment;
9.2.2 EndpointsText w as added to indicate that for subjects with confirmed CR, a n additional bone 
marrow aspirate and whole blood sample will be obtained 6, 12, and 18 months +/ -
1month to monitor for MRD.
Rationale: To indicate that b one marrow aspirate or biopsy performed at Screening for clinical staging will be 
analyzed for morphology and via cytogenetics , only.
9.2.1.5 Bone Marrow  
ExaminationBone marrow  aspirate or biopsy will be performed at Screening for clinical staging 
(morphology and cy togenetics , and immunohistochemistry [IHC] or immunofluorescence 
or flow  cytom etry) to establish baseline multiple myeloma clonality, to monitor for MRD, 
and to perform molecular subtyping to monitor daratumumab activity in high -risk 
molecular subgroups.
Rationale: To clarify that good quality slides are required for morphological examination to determine plasma cell 
percentage in the bone marrow.
9.2.1.5 Bone Marrow  
ExaminationGood quality slides are required for morphological examination to determine plasma cells 
percentage in the bone marrow. Assessment by flow cytometry alone is not sufficient
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
28
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
Rationale: To include clarithromycin as a prohibited therapy because it may have potential anti -multiple myeloma 
effects when combined with lenalidomide and dexamethasone.   
8.3 Prohibited 
TherapiesAdded clarithromycin as a prohibited therapy.
Rationale: To exclude subjects with uncontrolled cardiac arrhythmias (thereby allowing participation of subjects 
with controlled cardiac arrhythmias). 
4.2 Exclusion Criteria Subject has clinically significant cardiac disease, including:
•myocardial infarction within 1 year before randomization, or an unstable or 
uncontrolled disease/condition related to or affecting cardiac function (eg, unstable 
angina, congestive heart failure, New  York Heart Association Class III IV
•uncontrolled cardiac arrhythmia (NCI CTCAE Version 4 Grade ≥2) or clinically 
significant ECG abnormalities
•screening 12 -lead ECG showing a baseline QT interval as corrected by Fridericia’s 
formula (QTcF) >470 msec
Rationale: To clarify that the secondary objective and secondary endpoint is to assess the MRD negative rate .
Synopsis, Secondary 
Objectives;
2.1 ObjectivesTo assess the MRD negative rate after treatment
Synopsis, Efficacy 
Evaluations/Endpoints;
9.2.2 EndpointsAssess MRD negative rate, as measured in subjects who achieve CR/sCR, at 6 and 
12months after confirmed CR .
Rationale: To align PRO and ECOG performance status evaluations with study visits .
Time and Events 
Schedule OverviewEvaluations will be conducted on D1 of Cycle 3, 6, 9, 12 for year 1; every 6th cycle 
thereafter until EOT (PD). Post -PD evaluations will be collected at Weeks 8 and 16.
Rationale: Adde d a PRO evaluation at Screening which will allow  the PRO assessment conducted during the stu dy 
to be compared w ith baseline.
Time and Events 
Schedule OverviewAdded an assessment during the Screening Phase for the PROs: EORTC -QLQ -30, 
EQ-5D-5L.
Rationale: To clarify that all PRO measures will be collected via an electronic device (ePRO ) and the mode of data 
transfer .
Time and Events 
Schedule Overview;
9.7 Patient Reported 
Outcomes All PRO measures will be collected via an electronic device (ePRO).
17.6 Data Quality 
Assurance/Quality 
ControlPRO data w ill be transmitted to the ePRO vendor database and then to the sponsor’s 
database.
Rationale: To clarify the administration schedule of daratumumab, in particular, starting at Cycle 7 and beyond, 
treatment will be every 4 weeks rather than monthly .
Synopsis, Overview of 
Study Design;
3.1 Overview  of Study 
DesignFor subjects assigned to DRd, daratumumab w ill be administered w eekly for the first 
8weeks (Cycles 1 -2) of treatment and then every other week for 16 w eeks (Cycles 3 -6), 
then every 4 weeks (from Cycle 7 and beyond) until disease progression or unacceptable 
toxicity.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
29
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
Rationale: To rev ise the inclusion criteria to align with the other protocols in the daratumumab program .
4.1 Inclusion Criteria total bilirubin ≤2.0x ULN, except in subjects with congenital bilirubinemia, such as 
Gilbert syndrome (direct bilirubin ≤2.0 xULN);
corrected serum calcium ≤14 mg/dL ( ≤3.5 mM/L); or free ionized calcium <6.5 m g/dL 
(<1.6 mM/L)
Rationale: To align the creatinine clearance calculation with the other protocols in the daratumumab program .
4.1 Inclusion Criteria g)Creatinine clearance ≥30 mL/min (for lenalidomide dose adjustment for subjects with 
creatinine clearance 30 -60 mL/m in, refer to Section 6.2). Creatinine clearance may be 
calculated using the Cockcroft -Gault formula provided in Attachment 3
Attachment 3 Added the Cockcroft -Gault formula for Calculated Creatinine Clearance .
Rationale: To align the criteria for a dose delay with the other protocols in the daratumumab program .
6.4.1.1 Daratumumab -
Related Toxicity 
ManagementGrade 4 thrombocytopenia was added to the criteria for a dose delay.
Rationale: To further clarify procedures not considered to be major surgeries .
4.2 Exclusion Criteria Included vertebroplasty as a procedure that is not considered to be a major surgery.
Rationale: To specify the timing of lenalidomide administration and to align with other protocols in the 
daratumumab program .
6.2 Lenalidomide 
(Arm A and Arm B)On daratumumab infusion days, lenalidomide w ill be administered at the same time as the 
premedications. The daratumumab infusion should begin approximately 1 hour after the 
lenalidomide administration.
Rationale: Fixed typographical errors whereby the sample size remained the same, but the assumptions were 
corrected .
Synopsis, Statistical 
Methods; 
11.2 Sample Size 
DeterminationThe sample size calculation is performed on the basis of the follow ing assumption. Based 
on the published data, the median PFS for Rd arm is assumed to be approximately 
246months. Assuming that DRd can reduce the risk of the disease progres sion or death 
by 25%, ie, as suming the hazard ratio (DRd vs Rd) of 0.75 0.724, a total of 390 PFS 
events is needed to achieve a pow er of 80% 85%to detect this hazard ratio w ith a 
log-rank test (tw o-sided alpha is 0.05). With a 21 -month accrual period and an additional 
24-month follow -up, the total sample size needed for the study is approximately 
730(365/arm) subjects. The sample size calculation has taken into consideration an 
annual dropout rate of 5%.
Rationale: Because dexamethasone in IV formulation is not available in some countries, the PO administration of 
dexamethasone is permitted (only when IV is not available).
Time and Events 
Schedule, Dose 
Administration;
6.1.3.1 Preinfusion 
MedicationDexamethasone 40 mg IV or PO (only if IV is not availab le)
Rationale: To make the administration of drug medication more convenient for patients .
6.2 Lenalidomide 
(Arm A and Arm B)On daratumumab infusion days, lenalidomide will be administered either prior to or at 
the same time (preferred) as the premedications. 
Rationale: To align w ith other protocols in the daratumumab program .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
30
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
14.4 Preparation, 
Handling, and StorageClarifi ed that daratumumab must be protected from light.
Clarified that daratumumab infusion solution prepared for administration does not need to 
be stored in a refrigerator.
Clarified that the daratumumab infusion solution does not need to be kept at room 
temperature for approximately 1 hour before the start of infusion and that the infusion 
does not have to be compl eted w ithin 24 hours of preparation.
Added that daratumumab will be diluted in a sterile, pyrogen -free physiological saline 
solution (0.9%NaCl) prior to IV administration.
Included that additional guidance can be found in the Investigational Product Prepar ation 
Instructions and Investigational Product Procedures Manual.
6.1.3.1 Preinfusion 
MedicationPreinfusion medications for subjects receiving daratumumab w ill be administered as 
described in the Time and Events Schedules. On daratumumab infusion days, subjects will 
receive the following medications prior to infusion:
•Acetaminophen (paracetamol) 650 -1000 mg IV or orally (PO) approximately 1 hour 
or less prior to daratumumab infusion
•An antihistamine (diphenhydramine 25 -50 m g IV or PO, or equivalent) approximately 
12 hours prior and again approximately 1 hour prior to infusion on Cycle 1 Day 1, for all 
subsequent infusions approximately 1 hour prior
•Dexamethasone 40 mg IV or PO, approxim ately 1 hour or less prior to daratumumab 
infusion. Dexamethasone 20 mg may be administered as appropriate [see Section 6.3]. An 
equivalent long -acting corticosteroid may substitute [see Attachment 6 for conversion 
table]. On days when subjects receive this dose of dexamethasone in the clinic, 
dexamethasone will not be self-administered at home.
Rationale: Miscellaneous grammatical, formatting, or spelling changes were made for consistency and clarification.
Time and Events 
Schedule, Dose 
Administration;
6.1.3.1 Preinfusion 
MedicationFor consistency with other parts of the protocol, added the below  bolded text and removed 
the text in strikeout .
Administer approximately 1 hour before daratumumab infusion. 
•Dexamethasone 40 mg IV or PO (only if IV is not available) . For subjects older 
than 75 years or underweight (BMI <18.5), see Section 6.3 . Substitutions for 
dexamethasone allowed, see Attachment 6. 
•An antihistamine (diphenhydramine 25 -50 m gIV or PO , or equivalent) on C1D1 
administer 12 hours before infusion and again 1 hr before infusion
•Acetaminophen (paracetamol) 650 -1000 mg IV or PO
Synopsis, Overview of 
Study Design;
3.1 Overview  of Study 
Design;
5 Treatment AllocationAmended the stratification factor w ording to “International Scoring Staging System” to 
be consistent with the proper nom enclature.
6.4.1.1 Daratumumab -
Related Toxicity 
ManagementTo em phasize the criteria when to stop daratumumab, bolded and underlined the following 
sentence: ONLY if any of the following criteria are met, and the event cannot be 
ascribed to lenalidomide, the daratumum ab infusion must be held to allow for 
recovery from  toxicity .
Clarified that any adverse event deem ed to be related to daratumumab and unrelated to 
lenalidomide that requires a dose hold of more than 4 weeks will result in perm anent 
discontinuation of daratumumab.
Time and Events 
Schedule OverviewClarified that both PRO questionnaires and ECOG performance status must be 
administered and completed prior to any other study procedures or assessments for that 
study visit.
Clarified that β 2-microglobulin will be evaluated at screening only.
Clarified that EOT is part of the Treatment Phase of the study.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
31
Approved , Date: 12 June 2019Applicable Section(s) Description of Change(s)
4.2 Exclusion Criteria Removed intolerance to lenalidomide from exclusion criteria 12 because subjects in this 
study are newly diagnosed multiple myeloma patients and have never been exposed to 
lenalidomide.
Synopsis, Overview of 
Study Design; 
Time and Events 
Schedule, Dose 
Administration;
3.1 Overview  of Study 
Design;
6.1.3.1 Preinfusion 
MedicationProvided the generic name for paracetamol (acetaminophen), as this is a global study
14.2 Physical 
Description of Study 
DrugClarified that the daratumumab supplied for this study is a colorless to slightly yellow  
liquid and sterile concentrate of 20 mg/mL in a vial.
1.1.3 Transplant -
ineligible Population; 
1.3 Lenalidomide;
3.2 Study Design 
RationaleUpdated the reference to the Frontline Investigation of Revlimid and Dexamethasone 
versus Standard Thalidomide (FIRST) study (previously referred to in protocol as 
MM-020study), with citation to the recently published NEJM publication.
Synopsis, Overview of 
Study Design;
Time and Events 
Schedule, Dose 
Administration;
3.1 Overview  of Study 
Design;
3.2 Study Design 
Rationale;
6.2 6.2 Lenalidomide 
(Arm A and Arm B) ;
6.3Dexamethasone 
(Arm A and Arm B)Tobe consistent throughout the protocol , text w as added that treatment w ould continue 
until disease progression or unacceptable toxicity .  
Rationale: Minor errors w ere noted .
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
32
Approved , Date: 12 June 2019SYNOPSIS
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide 
and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for 
High Dose Therapy
Daratumumab is a human IgG1 ĸ monoclonal antibody (mAb) that binds with high affinity to a unique 
epitope on CD38, a transmembrane glycoprotein. It is a targeted immunotherapy directed towards tumor 
cells that express high levels of CD38, such as plasma cells from patients with multiple myeloma. This 
target is distinct from those of other approved agents for multiple myeloma therapy.
OBJECTIVE SAND HYPOTHESIS
Primary Objective
The primary objective is to compare the efficacy of daratumumab when combined with lenalidomide and 
dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression- free 
survival (PFS) in subjects with newly diagnosed myeloma who are not candidates for high dose 
chemotherapy and autologous stem ce ll transplant.
Secondary Objective s
The secondary objectives are:
 To evaluate clinical outcomes including:
 Time to disease progression (TTP)
 CR rate
 MRD negativity rate
 PFS2 (defined as time from randomization to progression on the next line of therapy or death, 
whichever comes first) 
 Overall survival
 Time to next treatment
 Stringent CR (sCR) rate
 Overall response rate (partial response [PR] or better )
 Proportion of subj ects who achieve very good partial response (VGPR) or better
 Time to response
 Duration of response
 To assess the safety and tolerability of daratumumab when administered in combination with Rd. 
 To assess the pharmacokinetics of daratumumab in combination with Rd.
 To assess the immunogenicity of daratumumab. 
 To evaluate treatment effects on patient reported outcomes and heath economic/resource utilization
 To evaluate the clinical efficacy of daratumumab combination with Rd in high-risk molecular 
subgroups
Exploratory Objective s
 To explore biomarkers predictive of response orresistance to therapy
 To assess durability of MRD negativity
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
33
Approved , Date: 12 June 2019Hypothesis
The primary hypothesis of this study is that daratumumab in combination with Rd will prolong PFS as 
compared with Rd alone in subjects with newly diagnosed multiple myeloma who are ineligible for high 
dose chemotherapy and autologous stem cell transplant.
OVERVIEW OF STUDY DESIGN
This is a randomized, open -label, active controlled, parallel -group, multicenter study in subjects at least 
18years of age with newly diagnosed multiple myeloma who are not candidates for high dose 
chemotherapy and ASCT . Approxima tely 730subjects will be enrolled in this study with 365subjects 
planned per treatment arm.
Subject participation will include a Screening Phase, a Treatment Phase, and a Follow -up Phase. The 
Screening Phase will be up to 21days before Cycle 1, Day 1.  The Treatment Phase will extend from 
Day 1 of Cycle 1 until discontinuation of all study treatment . For subjects assigned to DRd, daratumumab 
will be administered weekly for the first 8 weeks (Cycles 1 -2) of treatment and then every other week for 
16 weeks (Cycles 3-6), then every 4 weeks (from Cycle 7 and beyon d) until disease progression or 
unacceptable toxicity . This will equate to 9 consecutive weeks of dosing at the start of the study and a 
total of 23 doses in the first year. Lenalidomide will be admi nistered at a dose of 25 mg orally (PO) on 
Days 1 through 21 of each 28 -day cycle, and dexamethasone will be administered at a dose of 40 mg once 
a week .Subjects inboth treatment arms will continue lenalidomide and dexamethasone until disease 
progression or unacceptable toxicity . Subjects in the DRd arm will continue on daratumumab until 
disease progression or unacceptable toxicity . Randomization will be stratified by International Staging 
System (I vs II vs III), region (North America vs Other), and age (<75 vs ≥75), using an equal allocation 
ratio of 1:1.
Measures to prevent infusion -related reactions will include preinfusion medication with dexamethasone,
acetaminophen ( paracetamol ), and an antihistamine before each daratumumab infusion. 
The Follow -up Phase will begin once a subject discontinues all study treatments . Subjects who 
discontinue study treatment for reasons other than disease progression must continue to have disease 
evaluations according to the Time and Events Schedule until confirmed disease progression (PD)(see 
Section 8.4, Subsequent Therapies) . After PD is documented, follow -up wil l be obtained at least every 
16weeks. Subsequent anti-myeloma therapy , PFS2 (per investigator judgment), second primary 
malig nancies, and survival will be recorded. The Follow -up Phase will continue until death, lost to follow 
up, consent withdrawal, or study end, whichever occurs first.
Two interim analyses are planned. The first interim analysis , with a purpose to evaluate safety ,will be 
performed after a total of approximately 100 subjects have been treated for at least 8 weeks or 
discontinued the study treatment. The second interim analysis will be performed when 234PFS events, 
which are60% of the total planned events, have been accumulated. The pu rpose of this interim analysis is 
to evaluate cumulative interim safety and efficacy data. The significance level at this interim analysis to 
establish the superiority of DRd over Rd with regard to PFS will be determined based on the observed 
number of PFS events at the interim analysis, using the O’Brien -Fleming boundaries as implemented by 
the Lan-DeMets alpha spending method. If the experimental arm (DRd) is numerically worse than the 
control arm in terms of PFS (observed hazard ratio >1 favoring the control arm), then the study may be 
terminated for futility .
As the superiority of DRd over Rd alone with respect to PFS was established at the second interim 
analysis, the interim PFS analysis will serve as the primary PFS analysis, which otherwise was to occur 
when approximately 390 PFS events had been observed. The first interim OS analys is wasperformed at 
the interim PFS analysis . The second interim OS analysis will now occur when approximately 260 deaths  
have occurred which will be about the same time the primary PFS analysis would have taken place . All 
applica ble available data prior to that time will be included in each of the respective analyses. 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
34
Approved , Date: 12 June 2019The date established for the primary PFS analysis (24 September 2018) will serve as the clinical cut-off 
date, after which subject monitoring in the study will be conducted as per Section 9.1.5. After the second 
interim OS analysis (ie, when 260deaths have occurred) subject monitoring will be conducted according 
to Section 9.1.6 . Investigators will be informed when each interim analysis is to occur.
The end of the study will occur when 330 subjects have died, or 7years after the last subject is 
randomized, whichever comes first. The sponsor will ensure that subjects benefiting from treatment with 
daratumumab will be able to continue treatment after t he end of the study.
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study to review 
efficacy and safety results at the planned interim analyses. After the interim review, they will make 
recommendations regarding the continuat ion of the study. In addition, the IDMC may also review 
cumulative safety data every 6 months besides the 2interim analyses .The IDMC will no longer review 
study data after the interim PFS analysis has been completed .
Assessment of tumor response and disease progression will be conducted in accordance with the 
International Myeloma Working Group (IMWG) response criteria. An assessment of MRD will be 
conducted on bone marrow samples. Safety evaluations will include adverse event monitoring, physical 
examina tions, electrocardiogram (ECG) monitoring, clinical laboratory parameters (hematology and 
chemistry), vital sign measurements, and Eastern Cooperative Oncology Group (ECOG) performance 
status. Blood samples will be drawn for assessment of pharmacokinetic p arameters.
Following the positive second interim analysis that established the superiority of DRd over Rd alone with 
respect to the primary endpoint (PFS), the sponsor will provide access to daratumumab for subjects 
randomized to Arm A (Rd) who have sponsor -confirmed disease progression (see Section 8.4, 
Subsequent Therapies) , if recommended by the investigator .
SUBJECT POPULATION
Key eligibility criteria include the following: subjects who are 18 years of age, have a confirmed 
diagnosis of symptomat ic multiple myeloma and measurable secretory disease, an ECOG performance 
status score of 0, 1, or 2, must be newly diagnosed and not considered candidates for high-dose 
chemotherapy with stem cell transplantation (SCT) .
DOSAGE AND ADMINISTRATION
Daratumum ab (16 mg/kg) will be administered by IV infusion to subjects in Arm B initially once every 
week for 8weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until 
documented progression, unacceptable toxicity, or study end.
Lenalido mide will be self-administered at a dose of 25 mg PO each day on Days 1 through 21 of each 
28day cycle .
Dexamethasone (or equivalent in accordance with local standards; see Attachment 6for conversion table) 
will be administered at a total dose of 40 mg w eekly .
EFFICACY EVALUATIONS/ENDPOINTS
Disease evaluations must be performed every 28 days for the first 2 years and then every 8 weeks until 
disease progression (or other reasons as per Section 10). A window of ±7 days is allowed. If treatment has 
been delayed forany reason, the disease evaluations must be performed according to schedule, regardless 
of any changes to the dosing regimen.
The primary endpoint is PFS, which is defined as the duration from the date of randomization to either 
progressive dis ease, or death, whichever occurs first. Disease progression will be determined according to 
the IMWG criteria .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
35
Approved , Date: 12 June 2019The secondary efficacy endpoints include:
 Time to disease progression (TTP) is defined as the time from  the date of randomization to the date 
of first documented evidence of PD, as defined in the IMWG criteria. For subjects who have not 
progressed, data will be censored at the date of the disease evaluation before the start of any 
subsequent anti -myeloma therapy.
 CR rate, defined as the percentage of sub jects achieving CR, as defined:
 Negative immunofixation of serum and urine, and
 Disappearance of any soft tissue plasmacytomas, and
 <5% plasma cell s (PCs)in bone marrow
 For those subjects with negative serum M-protein quantitation by electrophoresis ( SPEP) and 
suspected daratumumab interference on immunofixation, a reflex assay using anti-idiotype 
antibody will be utilized to confirm daratumumab interference and rule out false positive 
immunofixation. Patients who have confirmed daratumumab interfere nce, but meet all other 
clinical criteria for CR or sCR, will be considered CR/sCR.
 MRD negativity rate, defined as the proportion of subjects assessed as MRD negative, at any 
timepoint after the date of randomization .
 Progression- free Survival on Next line of Therapy (PFS2), defined as the time from randomization to 
progression on the next line of treatment or death, whichever comes first. Disease progression will be 
based on investigator judgment. For those subjects who are still alive and not yet progressed on the 
next line of treatment, they will be censored on the last date of follow -up.
 Overall survival (OS), measured from the date of randomization to the date of the subject’s death. If 
the subject is alive or the vital status is unknown, then the subject’s data will be censored at the date 
the subject was last known to be alive.
 Time to next treatment, defined as the time from randomization to the start of the next -line treatment.
 sCR rate, defined as the percentag e of subjects achieving CR in addition to having a normal free 
light chain (FLC)ratio and an absence of clonal cells in bone marrow by immunohistochemistry , 
immunofluorescence, 2- 4 color flow cytometry
 Overall response rate (ORR), defined as the proportio n of subjects who achieve PRor better ,
according to the IMWG criteria, during or after the study treatment.
 Proportion of subjects who achieve VGPR or better, defined as the proportion of subjects achieving 
VGPR and CR (including sCR) according to the IMW G criteria during or after the study treatment at 
the time of data cutoff.
 Time to response , defined as the time between the randomization and the first efficacy evaluation 
that the subject has met all criteria for PRor better . For subjects without respon se, data will be 
censored either at the date of progressive disease or, in the absence of progressive disease, at the last 
disease evaluation before the start of subsequent anti- myeloma therapy.
 Duration of response, calculated from the date of initial documentation of a response (PRor better )
to the date of first documented evidence of progressive disease, as defined in the IMWG criteria. For 
subjects who have notprogressed, data will be censored at the last disease evaluation before the start 
of any subsequent anti -myeloma therapy.
 To evaluate clinical efficacy of D Rdin high risk molecular subgroups compared to Rdalone .
 To evaluate the impact of DRd compared to Rd on patient -reported perception of global health .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
36
Approved , Date: 12 June 2019PHARMACOKINETIC AND IMMUNOGENICITY EVALUATIONS
For all subjects in Arm B, pharmacokinetic samples to determine serum concentration of daratumumab 
will be obtained according to the Time and Events Schedule. In the Follow -up Phase, for all subjects in 
Arm B (DRd ), samples are tobe collected 8weeks after the last dose of daratumumab, regardless of 
whether there has been confirmed disease progression. Venous blood samples (5 mL per sample) will be 
collected to determine serum concentration of daratumumab and the serum will be divided into 3 aliquots 
(1 aliquot for pharmacokinetic analysis, 1 aliquot for antibodies to daratumumab analysis [when 
appropriate], and 1 aliquot as a backup). 
BIOMARKER EVALUATIONS 
Bone m arrow aspirates will be collected at screening and following treatment as outlined in the Tim e and 
Events Schedule.  Baseline bone marrow aspirate samples will be subjected to DNA and RNA sequencing 
in order to classify subjects into high-risk molecular subgroups and to establish the myeloma clone for 
MRD monitoring.
In addition to planned bone marrow aspirate assessments, a whole blood sample will be collected from 
subjects as outlined in the Time and Events Schedule forprocessing to plasma and PBMCs.
SAFETY EVALUATIONS
Safety will be measured by adverse events, laboratory test results , ECGs, vital sign measurements, 
physical examination findings, and assessment of ECOG performance status score.
STATISTICAL METHODS
The sample size calculation is performed on the basis of the following assumption. Based on the 
published data, the median PFS for Rd arm is assumed to be approximately 24months. Assuming that 
DRd can reduce the risk of the disease progression or death by 25%, ie, assuming the hazard ratio (DRd 
vsRd) of 0.75, a total of 390PFS events is needed to achieve a power of 80% to detect this hazard ratio 
with a log- rank test (two -sided alpha is 0.05). With a 2 1-month accrual period and an additional 24 -month 
follow -up, the total sample size needed for the study is approximately 730 ( 365/arm) subjects. The sample 
size calculation has taken into consideration an annual dropout rate of 5%.
Long- term survival follow -up will continue until 330 deaths have been observed or 7 years after the last 
subject is randomized. Therefore, this study will achieve approximately 80% power to detect a 27% 
reduction in the risk of death (hazard ratio = 0.73) with a log -rank test (two- sided alpha = 0.05).
Response to study treatment and progressive disease will be evaluated by a computer algorithm. For the 
primary endpoint of PFS, the primary analysis willconsist of a stratified log rank test for the comparison 
of the PFS distribution between the 2 treatment arms. The Kaplan -Meier method will be used to estimate 
the distribution of overall PFS for each treatment. The treatment effect (hazard ratio) and itstwo-sided 
95% confidence intervals are to be estimated using a stratified Cox regression model with treatment as the 
sole explanatory variable.
Details of the 2 planned interim analyses are provided in the Synopsis, Overview of Study Design. After 
each interim review, the IDMC will make recommendations regarding the continuation of the study. The 
IDMC will no longer review study data after the interim PFS analysis has been completed .
As the superiority of daratumumab combined with Rd over Rd alone with respect to PFS wasestablished 
at the second interim analysis, the interim PFS analysis will serve as the primary PFS analysis, which 
otherwise was to occur when approximately 390 PFS events had been observed.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
37
Approved , Date: 12 June 2019TIME A ND EVENTS SCHE DULE OVERVIEW
NotesScreening 
Phase Treatment Phase Follow -up Phase
within 2 1
days before 
randomization Day 1 of each cycle (28 -day cycles)EOT
within 30 
days of 
last dosePrior to 
PDAfter PD 
(Q16wks)
±2 w ks
Study treatment should be initiated within 72 hours after randomization. Day 1 of each cycle may occur ±3 days of the scheduled day in order to accommodate the schedule of the site or subject. After 
EOT, subjects in both treatment arms prior to PD will continue to return for disease evaluations. After PD is documented, sub jects will be followed for survival , PFS2 ,second primary malignancies, and
subsequent anti -myeloma therapy. After the primary clinical cut -off date (24 September 2018) , subject monitoring will be conducted as per Section 9.1.5 .  After the second interim OS analysis and mPFS 
for DRd group has been confirmed , subject monitoring will be conducted according to Section 9.1.6 .
Procedures
Informed consent ICF must be signed before any study -related procedures
Eligibility criteria X
Demography/
Medical History X
Height X
Chest X -ray(or full 
chest CT scan)Acceptable for screening if performed as part of SOC within 
42 days before randomization X
PFT For s ubjects with COPD ,FEV1 should be measured X
ECOGPrior to any other study procedures planned for the same 
day XD1 of Cycle 3, 6, 9, 12 for year 1; every 6th month ±14 days thereafter until PD. Post -PD 
collect at Wks 8 and 16 . 
12-lead ECGAcceptable for screening if performed as part of SOC within 
42 days before randomization X C3D1, C6D1 X
Physical exam including neurological exam Xsymptom and disease directed exam 
as clinically indicated
Vital signs, weight X Please see following table for details.
Blood type and IATABO, Rh, and IAT.  A wallet card with the subject’s blood 
type and IAT will be provided to subjects randomized to 
Arm B. X C1D1 predose, Arm B only
Laboratory Assessments
Pregnancy testFor women of childbearing potential only . During screening, within 10 -14 days prior to first dose and again within 24 hrs prior to first 
dose. Minimum testing requirements during study: weekly during Cycle 1 and then monthly in women with regular menstrual cycles or 
every 2 weeks in women with irregular menstrual cycles . Please refer to Section 9.8for details.X
Hematology X Please see following table for details. X
Serum chemistry X Please see following table for details. X
HBV DNA TestingArm B subjects with known history of hepatitis B infection or 
positive hepatitis B serologies ( HBsAg,Anti -HBc and/or Anti-
HBs with exception of serologic findings suggestive of HBV Every 3 months during treatment ± 1 month until 6 months after last dose of daratumumab.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
38
Approved , Date: 12 June 2019NotesScreening 
Phase Treatment Phase Follow -up Phase
within 2 1
days before 
randomization Day 1 of each cycle (28 -day cycles)EOT
within 30 
days of 
last dosePrior to 
PDAfter PD 
(Q16wks)
±2 w ks
vaccination [Anti-HBs positivity as the only serologic 
marker ] and a known history of prior HBV vaccination ).
Daratumumab PK Arm B only. On dara infusion days, 1 sample to be collected 
before infusion start (window -2 hrs) and 1 sample to be 
collected after end of infusion (window +2 hrs). Samples to 
be sent to central laboratory. C1D1, C6D1, C12D1X8 wks after last dara 
dose Arm B ONLY
Daratumumab 
immunogenicityArm B only. No additional sample needed; will be taken 
from PK sample. If an infusion reaction occurs, obtain 
unscheduled blood sample as soon as possible. predose C1D1 onlyX 8 wks after last dara 
dose Arm B ONLY
Whole blood Plasma or PBMC biomarker assessments predose C1D1 only X
Disease Evaluations : Every e ffort should be made to conduct disease evaluations as per schedule ( window ± 7 days). Refer to Section 9.2for details on efficacy evaluations
After EOT, subjects in both treatment arms prior to PD will continue to return for disease evaluations. After PD is documente d, subjects will be followed f or survival, PFS2, second 
primary malignancies, and subsequent anti -myeloma therapy. After the primary clinical cut -off date (24 September 2018), subject monitoring will be conducted as per Section 9.1.5 .  
After the second interim OS analysis has occurred and the mPFS for DRd group has been confirmed, subject monitoring will be conducted according to Section 9.1.6 .
Serum disease 
evaluations (SPEP)Sample to be sent to central laboratory. IFE and FLC when 
CR is suspected or maintained. FLC every cycle for 
subjects with light chain only myeloma.X (Repeat on 
C1D1 if not 
within 14 days 
prior to C1D1) X (for first 2 years and then every 8 wks until PD)
Urine disease 
evaluations (UPEP)Sample to be sent to central laboratory. IFE when CR is 
suspected or maintained. X (Repeat on 
C1D1 if not 
within 14 days 
prior to C1D1) X (for first 2 years and then every 8 wks until PD)
Calcium, albumin, 
β2-microglobulinSample to be sent to central laboratory.
β2-microglobulin at screening only.X (Repeat 
calcium and 
albumin on 
C1D1 if not 
within 14 days 
prior to C1D1); 
don’t repeat β2 -
microglobulin calcium/albumin every cycle for first 2 years and then every 8wks until PD
Bone marrow 
aspirate/biopsyFor screening (up to 42 days before randomization) fresh 
aspirate or biopsy preferred. If not available, obtain non -
decalcified tissue according to Section 9.2.1.5 Table 9
and/or FFPE tissue . Fresh biopsy or aspirate (or both) 
required to confirm CR/sCR. Samples for biomarker 
analysis to be sent to central laboratory XTo confirm CR/sCR, assess MRD, and evaluate PD (if feasible). Samples are 
requested at time of suspected CR/sCR and at 12, 18, 24, 30, 36, 48, and 60
months post C1D1 (+/ -1 month). If one of these time points occurs within 1 
month o f suspected CR, a repeat bone marrow will not be requested. These 
bone marrow tests will only be required if patient’s response is near CR or better 
by blood and urine evaluations . See Section 9.2.1.5 for additional information 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
39
Approved , Date: 12 June 2019NotesScreening 
Phase Treatment Phase Follow -up Phase
within 2 1
days before 
randomization Day 1 of each cycle (28 -day cycles)EOT
within 30 
days of 
last dosePrior to 
PDAfter PD 
(Q16wks)
±2 w ks
including timepoints.
Quantitative Ig See Section 9.2.1.2 X every 16 weeks X
Assessment of lytic 
diseaseAcceptable for screening if performed within 42 days before 
randomization X As clinically indicated, using the same methodology as used at screening
Extramedullary 
plasmacytomasSubjects with history of plasmacytoma; acceptable for 
screening if performed within 42 days before randomization XIf applicable, by physical exam every 4 wks, by radiologic exam (if required) 
every 12 wks using same methodology as used at screening; for subjects with 
history of plasmacytoma assessed by physical exam, repeat assessment on 
C1D1 if not done within 14 days prior to randomization
PROEORTC -QLQ -30, EQ -5D-5L
Both questionnaires must be administered and completed 
prior to any other study procedures or assessments for that 
study visit.
All PRO measures will be collected via an electronic device 
(ePRO). XD1 of Cycle 3, 6, 9, 12 for year 1; every 6th month ±14 days thereafter until PD. Post- PD 
collect at Wks 8 and 16. 
MRU Continuous from C1D1 until End of Treatment (see Section 9.6)
Follow -up
Survival, PFS2, second primary malignancy, subsequent anti -myeloma 
therapy Q16wk
Ongoing Subject Review
Adverse Events See Section 12for detailed instructions. continuous from the time of signing of ICF until 30 days after last dose of last study drug
Concomitant 
Medications See Section 8for detailed instructions. continuous from the time of signing of ICF until 30 days after last dose of last study drug
Abbreviations for Time and Events Tables : 
AE=adverse event; Anti-HBc=antibodies to hepatitis B core antigen ; Anti -HBs=antibodies to hepatitis B surface antigen ; BMI=body mass index; C=cycle; COPD=chronic obstructive 
pulmonary disease; CR=complete response; ECOG=Eastern Cooperative Oncology Group; D=day; Dara=daratumumab; DRd= daratumumab with lenalidomide plus low- dose 
dexamethasone ; ECG=electrocardiogram; EOT= End -of-Treatment; ePRO= electronic patient reported outcomes; FEV1= Forced Expiratory Volume (in 1 second); FFPE=formalin -
fixed paraffin embedded; FLC=free light cha in; HBsAg =hepatitis B surface antigen ; HBV =hepatitis B virus ; IAT= indirect antiglobulin test; ICF=informed consent form; 
IFE=immunofixation; Ig=immunoglobulin; IV= intravenous; MRD=minimal residual disease; MRI=magnetic resonance imaging; MRU= medical resource utilization; OS=overall survival; 
PBMC= peripheral blood mononuclear cell ; PFT=pulmonary function test; PFS2= time from randomization to progression on the next line of therapy or death, whichever comes first; 
PK=pharmacokinetics; PD= disease prog ression ; PO= per oral ; PRO=patient reported outcomes; Q(3)(6)mo=every (3)(6) months; Q16wk=every 16 weeks; SAE=serious adverse 
event; sCR=stringent complete response; SIPPM= Site Investigational Product Procedures Manual (or equivalent document) ;SPEP=seru m M-protein quantitation by electrophoresis; 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
40
Approved , Date: 12 June 2019NotesScreening 
Phase Treatment Phase Follow -up Phase
within 2 1
days before 
randomization Day 1 of each cycle (28 -day cycles)EOT
within 30 
days of 
last dosePrior to 
PDAfter PD 
(Q16wks)
±2 w ks
UPEP=urine M -protein quantitation by electrophoresis;  Wk=week
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
41
Approved , Date: 12 June 2019TIME A ND EVENTS SCHE DULE , DOSE A DMINISTRA TION
NotesCycle 1 and Cycle 2 Cycle 3 to Cycle 6 Cycle 7 and after EOT
D1 D8 D15 D22 D1 D15 D1
The start of each cycle may occur ±3 days of the scheduled day in order to accommodate the schedule of the site or subject . The start of each cycle should be scheduled relative to Cycle 1 
Day 1 and should not change if visits have shifted within the allowed window .
HematologyFor Cycle 1 Day 1, no need to repeat tests if they have been 
performed w ithin the past 5 days. Testing may be performed 
up to 3days before other infusion days. Results of 
hematology tests must be evaluated before each study drug 
administration. Perform at additional timepoints, as clinically 
indicated. To be done by local lab.X X X X X X X X
Clinical 
ChemistryX X X X
WeightIf a subject’s weight changes by more than 10% from 
baseline, the dose of all study treatments willbe re -calculatedX X X
Vital SignsVital signs (blood pressure, temperature , pulse /heart rate )
measured in sitting position. On Cycle 1 Day 1 before the 
start of dara infusion; at 0.5, 1, 1.5, 2, 3.5 hrs after the start of 
the infusion; at end of infusion; and 0.5, and1 hr after end of 
infusion. For all other infusions, vital signs will be measured 
before infusion start and at end of dara infus ion.X X X X X X X
Diary review Accountability/exposure check X X X X X X X X
Pre-infusion Medications, Arm B only
DexamethasoneAdminister approximately 1 hour before dara infusion. PO 
preinfusion medications may be administered within 3 hours 
before the infusion.
 Dexamethasone 40 mg weekly IV (preferred) or PO . 
For subjects older than 75 years o r underweight (BMI
<18.5), see Section 6.3. Substitutions for 
dexamethasone allowed, see Attachment 6.
 An antihistamine (diphenhydramine 25 -50 mg IV or PO, 
or equivalent) 
 Acetaminophen (paracetamol) 650-1000 mg IV or POX X X X X X X
Antihistamine X X X X X X X
Acetaminophen 
(paracetamol )X X X X X X X
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
42
Approved , Date: 12 June 2019NotesCycle 1 and Cycle 2 Cycle 3 to Cycle 6 Cycle 7 and after EOT
D1 D8 D15 D22 D1 D15 D1
Study Drug Administration, Arm A and Arm B
LenalidomideDispense on Day 1 for self -administration .  In Arm B, on 
daratumumab infusion days, lenalidomide will be 
administered either prior to or at the same time (preferred) as 
the pre -infusion medications.25 mg daily, Day 1 -21 of each cycle
(until PD or unacceptable toxicity )
Dexamethasone Dispense on Day 1 for self -administration.40mg weekly PO; Day 1, 8, 15, 22 of each cycle. 
(until PD or unacceptable toxicity)
Not required in Arm B on daratumumab infusion days. 
Study Drug Administration, Arm B Only
DaratumumabRefer to SIPPM for recommendations on daratumumab 
infusion rate. For windows see Table 3.X X X X X X X
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
43
Approved , Date: 12 June 2019ABBREVIA TIONS
ADCC antibody -dependent cell -mediated cytotoxicity
ADCP antibody -dependent cellular phagocytosis
ALT alanine aminotransferase
Anti-HBc antibodies to hepatitis B core antigen
Anti-HBs antibodies to hepatitis B surface antigen
ASCT autologous stem cell transplantation
AST aspartate aminotransferase
BMI body mass index
BUN blood urea nitrogen
CDC complement -dependent cytotoxicity
CL total systemic clearance
Cmax maximum observed concentration
Cmin minimum observed concentration
COPD chronic obstructive pulmonary disease
CR complete response
CRAB calcium elevation, renal insufficiency, anemia and bone abnormalities
CrCl creatinine clearance
CT computed tomography
DLT dose limiting toxicity
DMC Data Monitoring Committee
DRd daratumumab w ith lenalidomide plus low -dose dexamethasone
DTT dithiothreitol
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
eDC electronic data capture
EOT end of treatment
ePRO electronic patient -reported outcome(s)
EU European Union
FCBP females of childbearing potential
FEV forced expiratory volume
FFPE formalin fixed paraffin embedded
FISH fluorescence in situ hybridization
FLC free light chain
GCP Good Clinical Practice
G-CSF granulocyte colony stimulating factor
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HIV human immunodeficiency virus
HR hazard ratio
IAT indir ect antiglobulin testing
ICF informed consent form
ICH International Conference on Harmonisation
ICMJE International Committee of Medical Journal Editors
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IFE immunofixation
Ig immunoglobulin
IHC immunohistochemistry
IMiD immunomodulatory agent
IMWG International Myeloma W orking Group
INR international normalized ratio
IRB Institutional Review Board
ITT intent -to-treat
IUD intrauterine device
IV intravenous
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
44
Approved , Date: 12 June 2019IWRS interactive web response system
LDH lactic acid dehydrogenase
LMWH low molecular weight heparin
mAb monoclonal antibody
MedDRA Medical Dictionary for Regulatory Activities
MP melphalan -prednisone
MPT melphalan -prednisone- thalidomide
MRD minimal residual disease
MRI magnetic resonance imaging
MRU medical resource utilization
MTD maximum tolerated dose
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
NGS next generation sequencing
NK natural killer
OR overall response
ORR overall response rate
OS overall survival
PBMC peripheral blood mononuclear cell
PC plasma cell
PCP pneumocystis carinii pneumonia
PD disease progression
PFS progression free survival
PFS2 time from randomization to progression on the next line of therapy or death, whichever comes first
PI proteasome inhibitor
PK pharmacokinetics
PO per oral
POEMS polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome
PQC Product Quality Complaint
PR partial response
PRO patient -reported outcome(s)
QD once daily
QIg quantitative immunoglobulins
QTcF QT corrected according to Fridericia's formula
RBC red blood cell
Rd lenalidomide plus low -dose dexamethasone
REMS Risk Evaluation and Mitigation Strategy
SAE serious adverse event
sCR stringent complete response
SCT stem cell transplantation
SIPPM Site Investigational Product Procedures Manual (or equivalent document)
SLiM 60% Plasmacytosis, Light chains >100, MRI 1 or more focal lesion
SPEP serum M -protein quantitation by electrophoresis
SUSAR Suspected Unexpected Serious Adverse Reactions
TTP time to disease progression
ULN upper limit of norm al
UPEP urine M -protein quantitation by electrophoresis
US United States
V volume of distribution
VD VELCADE -dexamethasone
VGPR very good partial response
VMP VELCADE -melphalan -prednisone
VTD VELCADE -thalidomide -dexamethasone
VTE venous throm boem bolism
WHO World Health Organization
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
45
Approved , Date: 12 June 20191. INTRODUCTION
1.1. Background
1.1.1. Multiple My eloma
Multiple my eloma is a malignant disorder of the plasma cells, characterized by  uncontrolled and 
progressive proliferation of a plasma cell clone. The disease leads to progressive morbidity  and 
eventual mortality  by lowering resistance to infection and causing significant skeletal destruction 
(with bone pain, pathological fractures, and hypercalcemia), anemia, renal failure, neurological 
complications and hy perviscosi ty syndrome.
The majorit y of patients with multiple myeloma produce a monoclonal protein, also called 
paraprotein, M-protein or M-component, which is an immunoglobulin (Ig) or a fragment of one 
that has lost its function (Kyle 2009 , Palumbo 2011).18,26Normal immunoglobulin levels are 
compromised, leading to susceptibility  of infections. The proliferating multiple myeloma cells 
displace the normal bone marrow leading to dysfunction in normal hematopoietic tissue and 
destruction of the normal bone marrow architecture, which is reflected by clinical findings such 
as anemia, paraprotein in serum or urine, and bone resorption seen as diffuse osteoporosis or 
lytic lesions shown in radiographs (Kyle 2003).17Furthermore, hypercalcemia, renal 
insufficiency  or failure, and neurological complications are frequently  seen (Palumbo 2011).26A 
small min ority of patients with multiple my eloma are non -secretory .
At the time of diagnosis, multiple myeloma is a heterogeneous disease, with a course that varies 
on the basis of both disease -and host -related factors (eg, age, renal function, stage, chromosomal 
abnormalities). Multiple myeloma causes significant morbidity  and mortality . It accounts for 
approximately  1% of all malignancies and 13% of hematologic cancers. Approximately  50,000 
patients per year are diagnosed with multiple myeloma in the EU and US, and 30,000 patients 
per year die due to multiple myeloma ( ACS 2013, Ferlay  2010).1,10
1.1.2. Treatment Options for Multiple My eloma
Treatment choices for multiple myeloma vary with age, performance status, comorbidity , the 
aggressiveness of the disease, and related prognostic factors (Palumbo 2011).26Newly  diagnosed 
patients with multiple myeloma are typically  categorized into 2 subpopulations usually  defined 
by their age and suitability  for the subsequent approach to treatment. Younger patients will 
typicall y receive an induction regimen followed by consolidation treatment with high-dose 
chemotherap y and autologous stem cell transplantation (ASCT ). For those not considered 
suitable for high-dose chemotherap y and ASCT, longer -term treatment with multi- agent 
combinations including alkylators, high-dose steroids, and novel agents are currentl y considered 
as standards of care.
The availability  of different efficacious multi- agent regimens has provided clinicians with the 
opportunity  of tailoring treatment for each patient. Selection is based on patients' comorbidities 
and biologic age, while at the same time, taking into account the expected toxicity  profiles of 
each treatment regimen ( Gay 2011 ).11
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
46
Approved , Date: 12 June 20191.1.3. Transplant -ineligible Population
In general, patients over the age of 65 or with significant comorbidities are usually  not 
considered eligible for more intensive forms of first line therapy , and as a result the treatment 
approach often favors longer, less-intensive/toxic treatments (Gay 2011).11Treatment 
traditionally  consists of systemic chemotherap y, with adjunctive use of radiation or surgery  in 
selected cases associated with extramedullary  disease (NCCN 2013, Palumbo 2009, 
Smith 2005).23,29,34For many  years, the oral combination melphalan -prednisone (MP) was 
considered the standard of care for patients with multiple myeloma who were not eligible for 
ASCT (Gay 2011).11The advent of immunomodulatory  agents (IMiDs)and proteasome 
inhibitors (PIs) has led to a multiplicity  of new treatment options for newly  diagnosed patients 
not considered suitable for transplant based therapy . 
The results of the Frontline Investigation of Revlimid and Dexamethasone versus Standard 
Thalidomide (FIRST) Study were presented at the American Societ y of Hematology  Meeting in 
December 2013 (Facon 2013),9and most recently  published in The New England Journal of 
Medicine (Benboubker 2014) .2In this open -label Phase 3 study , non- transplant eligible patients 
with newly  diagnosed myeloma were randomized to either melphalan -prednisone -thalidomide 
(MPT) or lenalidomide + low-dose dexamethasone (Rd). Patients who received Rd until disease 
progression had an improved outcome compared to those randomized to MPT, with a 28% 
reduction in the risk of progressive disease or death (median: 25.5 months, HR=0.72; 
p=0.00006). Secondary  endpoints including duration of response and overall response were 
superior in the Rd cohorts. The safety  profile of Rd was manageable, with reduced hematologic 
second primary  malignancies compared with MPT. In the oral presentation at ASH 2013, the 
authors indicat ed that overall survival for patients who received Rd until disease progression was 
59.4% , based on a preliminary  survival analysis at 4 y ears(Facon 2013, 2014) .9
1.2. Daratumumab
Daratumumab is a human IgG1 ĸ monoclonal antibody  (mAb) that binds with high affinity  to a 
unique epitope on CD38, a transmembrane glycoprotein. It is a targeted immunotherapy  directed 
towards tumor cells that express high levels of CD38, such as plasma cells from patients with 
multiple myeloma. This target is distinct from those of other approved agents for multiple 
myeloma therap y.
For the most comprehensive nonclinical and clinical information as well as Reference Safet y 
Information regarding daratumumab, refer to the latest version of the Investigator's Brochure 
(Daratumumab IB).13
1.2.1. Nonclinical Studies
Based on preclinical data, daratumumab may utilize multiple effector cell functions, resulting in 
immune mediated killing of tumor cells. In ex vivo experiments utilizing human bone marrow 
stromal cells co-cultured with primary  multiple myeloma cells, complement -dependent 
cytotoxicity  (CDC) occurs rapidl y and demonstrates maximal myeloma cell killing by 
daratumumab within 1 hour of antibody -mediated activation of the compl ement proteins 
(deWeers 2011).6Daratumumab- induced antibody -dependent cell-mediated cytotoxicity 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
47
Approved , Date: 12 June 2019(ADCC) is slower in its action, with maximal ADCC by daratumumab observed at 4 hours in 
vitro (de Weers 2011).6Daratumumab has also been shown to induce antibody -dependent 
cellular phagocy tosis (ADCP) in the presence of macrophages within 4 hours in vitro 
(Overdijk 2013).25The precise role of some or all of these effector functions in reducing tumor 
burden in patients is unknown.
In toxicology  studies in cynomolg us monkey s and chimpanzees, the major observed toxicities 
were cytokine release syndrome and thrombocy topenia. A minor decrease in red blood 
parameters was also observed. Cytokine release was seen only following the first dose and was 
markedl y reduced following implementation of a 10-mg predose of daratumumab. The effect on 
platelets and red blood cells was reversibl e.
1.2.2. Clinical Studies
1.2.2.1. Single -Agent Daratumumab Studies (GEN501 and MMY2002)
Two single -agent studies with daratumumab are ongoing (Studies GEN501 and MMY2002), as 
described in Table 1.
Table 1: Daratum umab Single -Agent Studies GEN501 and MMY2002
Study Number Study Design Number of subjects Treated/
Treat ment Regimen
GEN501 Open -label, Phase 1/2, first-in -human, 
single -agent study in subjects with
multiple myeloma whose disease is 
relapsed or refractory to at least 2 prior 
lines of therapies
Population was heavily treated with prior 
treatment, including ASCT, 
chemotherapy based regimens, IMiDs, 
and PIsPart 1
n=32 total treated with daratumumab we ekly
0.005 -1 mg/kg (n=17)
2 mg/kg (n=3)
4 mg/kg (n=3)
8 mg/kg (n=3)
16 mg/kg (n=3)
24 mg/kg (n=3)
Part 2
n=51 total treated
8 mg/kg (n=30)
Weekly for 8 weeks, 
followed by q2w for an 
additional 16 weeks, and 
monthly thereafter16 mg/kg (n=21)
First dose, followed by a 3 -
week resting period, followed 
by weekly doses for 7 weeks, 
then q2w for an additional 14 
weeks, and monthly 
thereafter
MMY2002 Open -label, multicenter, 2 -stage, Phase 2 
study of daratumumab for the treatment 
of subjects with multiple myeloma who 
have received at least 3 prior lines of 
therapy including a PI and an IMiD or 
whose disease is double refractory to 
both a PI and an IMiDn=34 total treated in Stage 1
8 mg/kg (n=18)
q4w16 mg/kg (n=16)
qw for 8 weeks, then q2w for 
another 16 weeks, and then 
q4w thereafter
ASCT= autologous stem cell transplantation; IMiD= immunomodulatory agent; PI=proteasome inhibitor; q2w=every 2 weeks; 
q4w=every 4 weeks
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
48
Approved , Date: 12 June 2019Among the 32 subjects treated in Part 1 of Study GEN501, the maximum tolerated dose (MTD) 
was not reached following intravenous (IV) infusions up to 24mg/kg. Two subjects experienced 
dose-limiting toxicities (DLTs) in the lower dose cohorts (a subject in the 0.1-mg/kg group had 
Grade 3 anemia and Grade 4 thrombocy topenia, and a subject in the 1.0-mg/kg group had 
Grade 3 aspartate aminotransferase increased). 
Among the 51 subjects treated in Part 2 of Study GEN501, serious adverse events (SAEs) were 
reported in 37% of subjects (43% of subjects in the 8-mg/kg group and 29% of subjects in the 
16mg/kg -group). The most frequentl y reported SAEs were pneumonia (6% subjects), and 
pyrexia (4% of subjects).
Among the 34 subjects treated in Stage 1 of Study MMY2002, SAEs were reported in 27% of 
subjec ts (33% of subjects in the 8 mg/ kg group, and 19% of subjects in the 16 mg/kg group). The 
most frequently  reported SAE was renal failure acute (6% of subjects).
1.2.2.2. Combination Daratumumab Studies
One study  of daratumu mab in combination with lenalidomide and dexamethasone 
(Study GEN503), and one study  of daratumumab in combination with various backbone 
treatment regimens (Study  MMY1001) are ongoing ( Table 2).
Table 2: Daratum umab Combination Studies GEN503 and MMY1001
Study 
NumberStudy Design Treatm ent RegimenStatus/Estim ated Start 
Date
Number of subjects 
Treated/Plann ed
GEN503Open -label, Phase 1/2 multicenter, dose -
escalating study investigating the safety 
of daratumumab in combination with 
lenalidomide and dexamethasone in 
subjects with relapsed or refractory 
multiple myelomaPhase 1: 
2-16 mg/kg daratumumab, in 
combination with lenalidomide 
(25mg daily Days 1 -21 of 28 
days) and dexamethasone (40 mg 
weekly)Part1: Ongoing (n=13 
subjects treated)
2 mg/kg (n=3)
4 mg/kg (n=3)
8 mg/kg (n=4)
16 mg/kg (n=3)
Phase 2: 
16 mg/kg daratumumab, in 
combination with lenalidomide 
(25mg daily Days 1 -21 of 28 
days) and dexamethasone (40 mg 
weekly)Part2:
n=18 subjects treated 
approximately 30 subjects 
planned
MMY1001 Open -label, non -randomized, multicenter, 
Phase 1b study to evaluate the safety, 
tolerability, and d ose regimen of 
daratumumab in combination with 
various backbone treatment regimens for 
multiple myeloma in either newly 
diagnosed or those who have received at 
least 2 prior therapies, depending on 
backbone treatment regimenDaratumumab 16 mg/kg (initially , 
with possibility to de -escalate, if 
necessary)
The backbone regimens to be 
combined with daratumumab 
include VELCADE -
dexamethasone (VD), VMP, 
VTD, and Pom -dexn=18 subjects treated1
VTD (n=6 )
VMP (n=5)
VD(n=1)
Pom-dex (n=6)
approximately 80 subjects 
planned
1. As of 21May2014
Pom-dex=pomalidomide -dexamethasone; VD= VELCADE -dexamethasone ; VMP -VELCADE -melphalan -prednisone; 
VTD=VELCADE -thalidomide -dexamethasone
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
49
Approved , Date: 12 June 2019Based on preliminary  efficacy  data, 15of 20efficacy  evaluable subjects in Study  GEN503 have 
achieved a PR or better following treatment with daratumumab in combination with 
lenalidomide and dexamethasone .
The safet y profile observed in Study GEN503 is consistent with historical safety  data for 
lenalidomide and dexamethasone. Doses ranged from 2 mg/kg to 16 mg/kg daratumumab, in 
combination with the approved doses of lenalidomide (25mg daily Days 1-21 of 28 days) and 
dexamethasone (40 mg weekl y). No dose-limiting toxicity  (DLT) drug-related safet y signals 
have been observed in this heavily  pre-treated population of subjects with advanced multiple 
myeloma. The Part 2 daratumumab dose was determined to be 16 mg/kg . Across all dose cohorts
in Part 1 and in the 16 mg/kg expansion cohort for Part 2, the most frequently  reported Grade 3 
or higher adverse event was neutropenia (6 subjects), which is a known toxicity  of lenalidomide. 
Eight SAEs have been reported. All SAEs were assessed by the investigator as not related to 
daratumumab. Four subjects experienced infusion -related reactions during the first infusion of 
daratumumab . These events were determined by the investigator to be related to daratumumab. 
In allinstances, daratumumab was interrupted temporarily  and restarted without complication or 
further incident.
Planned Phase 3 combination studies include a Phase 3 study  (MMY3003) comparing 
daratumumab, lenalidomide, and dexamethasone with Rd and a Phase 3 study  (MMY3004) 
comparing daratumumab, VEL CADE, and dexamethasone with VD. Both studies are in patients 
with relapsed or refractory multiple myeloma and are planned to start in the second half of 2014.
1.3. Lenalidomide
Lenalidomide is an immunomodulatory  (IMiD) agent that is thought to mediate antim yeloma 
activity  by 3 main mechanisms: 1)direct antitumor effect; 2)inhibition of the microenvironment 
support for tumor cells; and 3)an immunomodulatory  role (Kotla 2009).15Direct tumor effect is 
described both as growth inhibition of myeloma cell lines and induction of apoptosis. The 
microenvironment support is affected by downregulation of cell adhesion molecules 
(eg,intercellular adhesion molecule), thus inhibiting strom al cell interaction with tumor cells, 
and inhibition of growth factors (eg,insulin growth factor 1 and vascular endothelial growth 
factor) induced by myeloma cell adhesion. Finally , lenalidomide exhibits immunomodulatory  
activity  including inhibition of proinflammatory  signaling molecules (cytokines) such as tumor 
necrosis factor , IL-1, and IL-6, the latter of which is a known growth factor for myeloma 
cells (Vallet 2008).37
Importantly , it has also been shown that lenalidomide causes upregulation of natural killer (NK) 
cells in myeloma (Kotla 2009)15and enhan ces the effector cells of ADCC (Tai 2005, 
Tai2008).36,35
Lenalidomide is currently  approved in the US and EU for the treatment for relapsed/refractory  
myeloma. However, there is accumulating evidence that lenalidomide is an effective treatment 
strategy  for new diagnosed patients as well. The Eastern Cooperative Oncology  Group (ECOG) 
published a study in which patients with newly  diagnosed myeloma were randomized to either 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
50
Approved , Date: 12 June 2019high-dose (160 mg/week) or low-dose (40 mg/week) dexamethasone in combination with 
lenalidomide (Rajkumar 2010).31Patients randomized to the low-dose dexamethasone treatment 
arm had an improved overall survival at one year (96% vs 87%). In terms of response rates, 
patients in the low-dose cohort had an overall response rate (≥PR) of 68.3%. Median time to 
progression was 26.1 months in the low dose group.
Alarge, randomized Phase 3 study  (FIRST Study ) compared Rd given until disease progression
(Arm A) or for eighteen 28-day cycles (Arm B) with MPT (Arm C)in subjects newl y diagnosed 
with multiple myeloma (Facon 2013 , Benboubker 2014 ).9,2Continuous treatment with Rd 
(Arm A) significantl y improved the primary  endpoint of PFS compared with MPT (Arm C). 
Secondary  endpoints (overall response rate [ORR], defined as PR or better, duration of response , 
and PFS2) consistently  showed improvement in favor of Arm A over Arm C. The safety  profile 
of Rd was manageable, with reduced hematologic second primary  malign ancies compared with 
MPT .
REVLIM ID® (lenalidomide) in combination with dexamethasone was approved by both U.S. 
Food and Drug Administration and the European Commission for the treatment of adult patients 
with previously  untreated multiple myeloma who are not eligible for transplant, on 
18February 2015 and 20 February 2015 , respectively .
1.4. Lenalidomide and Daratumumab
Preclinically , using bone marrow mononuclear cells from patients with multiple myeloma, 
increased killing of tumor cells was demonstrated when daratumumab was combined with 
lenalidomide as compared with that of either agent alone as shown in (Figure 1A) 
(VanderVeer 2011 a).38Notably , daratumumab and lenalidomide acted in a synergistic fashion 
to generate an extra effect ( Figure 1B).
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
51
Approved , Date: 12 June 2019Figure 1: Impro vement of Daratumumab -induced Antibody -dependent Cell -mediated Cytotoxicity by 
Lenalidomide in Bone Marrow Mononuclear Cells from  Patients with Multiple Myelom a
Key: DARA =daratumumab; LEN =lenalidomide; MM =multiple myeloma.
(A)Bone marrow mononuclear cells of 14 patients with multiple myeloma were incubated for 47 hours with the control antibody, 
with lenalidomide (3 M), and/or daratumumab (0.1 g/mL). Surviving multiple myeloma cells were enumerated by 
Fluorescence -activated Cell Sorting analysis of CD138+ cells. The percentages of lysis of multiple myeloma cells treated 
with lenalidomide, daratumumab, and lenalidomide + daratumumab were calculated by the Tukey’s post hoc analysis of 
repeated measures analysis of variance.
(B)The observed effect (% lysis) of the combination treatment was compared with the expected additive effect (proportional) of 
the combined treatments. Mixed model analysis supported the conclusion that the combination treatment was synergistic.
Finally , it was demonstr ated that peripheral blood mononuclear cells isolated from patients 
during or just after lenalidomide treatment showed a significantl y increased capacity  to mediate 
daratumumab -dependent ADCC against multiple my eloma cells alone ( Van der Veer 2011 a).38
Thus, in this ex vivo clinical setting, daratumumab -mediated multiple myeloma tumor cell 
killing was demonstrated to be significantly  augmented by stimulating effector cells. In 
conclusion, preclinical data, both from the literature and the sponsor’s own ex vivo studies, 
support the combination of daratumumab with lenalidomide in the treatment of multiple 
myeloma.
1.5. Overall Rationale for the Study
Multiple myeloma remains incurable with standard chemotherap y, despite the availability  of 
multi agent therap y. Strategies directed at improving and maintaining response for longer periods 
of time and new treatment options directed at alternative mechanisms are also urgentl y needed 
for patients with multiple my eloma.
Recent studies have indicated that multiple drug combinations are superior over single -or 
double -agent combinations in treating multiple myeloma (Vander Veer 2011 b).39The addition 
of new drugs to available regimens can mediate their clinical benefit because of the induction of 
ahigher rate of initial CRs, which then improves relapse -freeand overall survival. Contingent on 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
52
Approved , Date: 12 June 2019the premise that the combined agents have non-overlapping and synergistic mechanism of 
actions, the immediate and effective targeting of the tumors with multiple agents appears to be a 
successful strategy  in improving the clinical outcome of multiple myeloma therapy . Such a 
strategy  is in agreement with the emerging concept that the genetic signature of multiple 
myeloma, and consequently  the patient’s susceptibility  to a specific agent, will be highl y 
heterogeneous, whic h may lead to drug resistance. Nevertheless, the CR rate of the best 
chemotherapeutic combinations is currentl y <50%, and all current combination therapies 
eventually induce drug resistance. 
Based on data from ongoing studies with and the safet y informati on in the label for lenalidomide, 
the expected safet y profile of daratumumab in this combination therap y study  is considered 
manageable. To date, 31subjects have been treated in Study  GEN503, an open -label, Phase 1/2 
multicenter, dose-escalating study  investigating the safet y of daratumumab in combination with 
lenalidomide and dexamethasone in subjects with relapsed or refractory  multiple myeloma. No
DLTs have been reported, and the safet y profile is consistent with what has been previousl y 
reported for lenalidomide monotherap y. Data from several clinical studies support the choice of 
16mg/kg as the daratumumab dose to be administered in this study .Based upon the pre-clinical 
synergy observed, and the promising clinical data in the relapsed/refractory  setting, this is a 
rational combination to investigate in newl y diagnosed patients .
2. OBJECTIVE SAND HYPOTHESIS
2.1. Objectives
Primary Objective
The primary objective is to compare the efficacy  of daratumumab when combined with 
lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in 
terms of progression- free survival (PFS) in subjects with newly  diagnosed myeloma who are not 
candidates for high dose chemotherap y and autologous stem cell transplant . 
Secondary Objectives
The secondary objectives a re:
To evaluate clinical outcomes including :
Time to disease progression (TTP)
CR rate
MRD negativity  rate
PFS2 (defined as time from randomization to progression on the next line of therap y or 
death, whichever comes first) 
Overall survival
Time to next treatment
Stringent CR (sCR) rate
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
53
Approved , Date: 12 June 2019Overall response rate (partial response [PR] rate or better )
Proportion of subjects who achieve very  good partial response (VGPR) or better
Time to response
Duration of response
To evaluate the clinical efficacy  of daratumumab combination with Rd in high-risk 
molecular subgroups
To evaluate treatment effects on patient reported outcomes and heath econom ic/resource 
utilization
To assess the safety  and tolerability  of daratumumab when administered in combination 
with Rd. 
To assess the pharmacokinetics of daratumumab in combination with Rd.
To assess the immunogenicity  of daratumumab. 
Exploratory Objectiv e
To explore biomarkers predictive of response orresistance to therapy
To assess durability  of MRD negativity
2.2. Hypothesis
The primary  hypothesis of this study  is that daratumumab in combination with Rd will prolong 
PFS as compared with Rd alone in subjects with newly  diagnosed multiple myeloma who are 
ineligible for high dose chemotherap y and autologous stem cell transplant .
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a randomized, open -label, active controlled, parallel- group, multicenter study  in subjects 
at least 18 years of age with newly  diagnosed multiple myeloma who arenot candidates for high 
dose chemo therap yand ASCT . Approximately  730subjects will be enrolled in this study  with 
365subjects planned per treatment arm.
A diagram of the study  design is provided in Figure 2.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
54
Approved , Date: 12 June 2019Figure 2: Schematic Overview of the Study
Subject participation will include a Screening Phase, a Treatment Phase, and a Follow -up Phase. 
The Screening Phase will be up to 21days before Cycle 1, Day 1. The Treatment Phase will 
extend from Day 1 of Cycle 1 until discontinuation of all study  treatment . For subjects assigned 
to DRd, daratumumab will be administered weekl y for the first 8 weeks (Cycles 1-2) of 
treatment and then every  other week for 16 weeks (Cycles 3-6), then every  4 weeks (from 
Cycle7 and beyond) until disease progression or unacceptable toxicity . This will equate to 
9consecutive weeks of dosing at the start of the study  and a total of 23 doses in the first year. 
Lenalidomide will be administered at a dose of 25 mg orally  (PO) on Days 1 through 21 of each 
28-day cycle, and dexamethasone will be administered at a dose of 40 mg once a week inboth 
treatment arms . Subjects in both treatment arms will continue lenalidomide and dexamethasone
until disease progression or unacceptable toxicity . In the DRd arm, subjects will continue on 
daratumumab until disease progression or unacceptable toxicity .Randomization will be stratified 
by International Staging System (I vs II vs III), region ( North America vs Other), and age (<75 
vs ≥75), using an equal allocation ratio of 1:1 .
Measures to prevent cytokine release syndrome will inc lude preinfusion medication with 
dexamethasone , acetaminophen (paracetamol ), and an antihistamine before each daratumumab 
infusion. 
The Follow -up Phase will begin once a subject discontinues all study  treatments . Subjects who 
discontinue study  treatment for reasons other than disease progression must continue to have 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
55
Approved , Date: 12 June 2019disease evaluations according to the Time and Events Schedule until confirmed disease 
progression (PD)(see Section 8.4, Subsequent Therapies) . After PDis documented , follow -up 
will be obtained at least every  16 weeks. Subsequent anti-myeloma therap y, PFS2 (per 
investigator judgment), second primary  malig nanc ies, and survival will be recorded . The Follow -
up Phase will continue until death, lost to follow up, consent withdrawal, or study  end, 
whichever occurs first.
Two interim analy ses are planned. The first interim analy sis, with a purpose to evaluate safet y,
will be performed after a total of approximately 100 subjects have been treated for at least 
8weeks or discontinued the study  treatment. The second interim analysis will be performed 
when 234PFS events, which is 60% of the total planned events, have been accumulated. The 
purpose of this interim analy sis is to evaluate cumulative interim safety  and efficacy  data. The 
significance level at this interim anal ysis to establish the superiority  of DRd over Rd with regard 
to PFS will be determined based on the observed number of PFS events at the interim analysis, 
using the O’Brien -Fleming boundaries as implemented by the Lan-DeMets alpha spending 
method. If the experimental arm (DRd) is numerically  worse than the control arm in terms of 
PFS (observed hazard ratio >1 favoring the control arm), then the study  may be terminated for 
futility .
As the superiorit y of DRd over Rd alone with respect to PFS was established at the second 
interim analysis, the interim PFS analysis will serve as the primary  PFS analysis, which 
otherwise was to occur when approximately  390 PFS events had been observed. The first interim 
OS anal ysis wasperformed at the interim PFS analy sis. The second interim OS analysis will now 
occur when approximately  260 deaths have occurred which will be about the same time the 
primary  PFS analy sis would have taken place . All applicable available data prior to that time will 
be included in each of the respective analy ses.
The date established for the primary  PFS analysis (24 September 2018) will serve as the clinical 
cut-off date, after which subject monitoring in the study  will be conducted as per Section 9.1.5 . 
After the second interim OS analysis(ie, when 260 deaths have occurred) subject monitoring
will be conducted according to Section 9.1.6 . Investigators will be informed when each interim 
analysis is to occur .
The end of the study  will occur when 330 subjects have died, or 7years after the last subject is 
randomized, whichever comes first. The sponsor will ensure that subjects benefiting from 
treatment with daratumumab will be able to continue treatment after the end of the study .
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study  to 
review efficacy  and safety  results atthe planned interim analyses. After the interim review, they 
will make recommendations regarding the continuation of the study . In addition, the IDMC may 
also review cumulative safet y data every  6 m onths besides the 2interim analy ses.The IDMC 
will no lo nger review study  data after the interim PFS analy sis has been completed .
Assessment of tumor response and disease progression will be conducted in accordance with the 
International Myeloma Working Group (IMWG) response criteria. An assessment of MRD will 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
56
Approved , Date: 12 June 2019be conducted on bone marrow samples . Safety  evaluations will include adverse event
monitoring, physical examinations, electrocardiogram (ECG) monitoring, clinical laboratory 
parameters (hematology and chemistry ), vital sign measurements, and ECOG performance 
status. Blood samples will be drawn for assessment of pharmacokinetic parameters.
Following the positive second interim analysis that established the superiority  of DRd over Rd 
alone with respect to the primary  endpoint (PFS), the sponsor will provide access to 
daratumumab forsubjects randomized to Arm A (Rd) who have sponsor -confirmed disease 
progression (see Section 8.4, Subsequent The rapies) , if recommended b y the investigator .
3.2. Study Design Rationale
Rationale for Duration of Lenalidomide Administration
Lenalidomide and dexamethasone are commonl y given in the front -line setting in the US. Based 
upon the FIRST Study (Facon 2013 , Benboub ker 2014 ),9,2the front -line treatment paradigm in 
the EU will likely  evolve to include Rd in the future. The Facon study  showed that treatment 
until progression conferred clinical benefit over treatment for a fixed duration of time. A 
retrospective analy sis of 2Phase 3 studies , one administering a lenalidomide based regimen and 
one administering a VELCADE based regimen, also showed that PFS1, PFS2, and overall 
survival (OS)were all significantly  longer following continuous treatment to progression 
(Palumbo 2014).27This was observed regardless ofthe particular chemotherap y backbone . 
Taken together ,these data support theprinciple of treatment until progression .
In the current study , treatment with Rd will continue until disease progression or unacceptable 
toxicity in the control arm (Arm A). This treatment duration is consistent with best current 
clinical practice based on the above published results.
In the experimental arm (Arm B), treatment with DRd will continue until disease progression or 
unacceptable toxicity . The protocol was initially designed to discontinue Rd after 24 months to 
isolate the efficacy  and safet y of daratumumab from continued exposure to Rd. Based on the data 
from the FIRST study , lenalidomide treatment until disease progression is emerging as the 
standard of care and is also consistent with the approved lenalidomide package insert
(Hulin 2016; Revlimid USPI  2017).14,33Continuous Rd is currentl y being used as the backbone 
therap y in many Phase 3 studies evaluating active compounds in patients with myeloma 
(eg,bortezomib [Durie 2017],8carfilzomib, ixazomib, and elotuzumab [ongoing ]).Results from 
the SWOG S0777 study  evaluating a combined patient population of transplant eligible and 
ineligible subjects demonstrated improved median PFS with the addition of 6 months of 
bortezomib treatment to continuous Rd (43 months vs 30 months) with an acceptable safet y 
profile despite the addition of a third agent to continuous Rd (Durie 2017).8Based on these 
developments, this amendment will allow for treatment to be consistent with the current standard 
of care.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
57
Approved , Date: 12 June 2019Rationale for Daratumumab Dose
CD38, the target for daratumumab, is expressed on NK cells an d clinical data has shown NK cell 
suppression to be a marker of on target drug activity . Clinical pharmacokinetic data have shown 
the 16 mg/kg dose to be the lowest dose that results in complete target suppression at all 
timepoints. This dose and schedule continuously  suppressed NK cells throughout dosing. 
Daratumumab maximal target suppression is presented in Figure 3.
Figure 3: Daratum umab Maxim al Target Suppression 
8mg/kg: Observed trough concentration 
values below  predicted 90% suppression 
throughout dosing
16mg/kg: Observed trough concentration 
values at 90% suppression throughout 
dosing
The ORR appeared higher for the 16mg/kg dose compared with the 8 mg/kg dose, based on 
early preliminary  data from Part 2 of Study  GEN501 and from Study  MMY2002 (both ongoing 
studies) as of a cutoff date of 24 January  2014. In Study  GEN501, the ORRs (ie, PR or greater) 
were 11% and 40% for the 8mg/kg (n=28) and 16mg/kg (n=15) dose regimens, respectivel y. 
For Study MMY2002, the unconfirmed ORRs for the 8 mg/kg and 16 mg/kg dose regimens were 
similar to those observed in GEN501. In addition, VGPRs were observed for 7 of 30subjects 
treated with the 16mg/kg dose in the 2 studies. VGPR had not been observed at lower dose 
levels. These preliminary  data support that full target saturation at the 16mg/kg dose is needed 
to achieve higher and deeper response rates. 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
58
Approved , Date: 12 June 2019Rationale for DNA and Biomarker Collection
Biomarker samples will be collected to evaluate the depth of clinical response to daratumumab 
through evaluation of MRD, using DNA sequencing of immunoglobulin genes, and to determine 
response rates in specific molecular subg roups of multiple myeloma, using DNA/RNA 
sequencing of multiple myeloma cells to allow for assessment of high–risk genomics such as 
deletion 17p, t(4;14), t(14;20), t(14;16), deletion13, GEP signatures such as UAMS -70, and 
mutations in p53, BRAF, FGFR, IGH , PI3K, or other molecular subt ypes associated with disease 
progression. Other biomarker goals include evaluation of potential mechanisms of resistance, 
inter-individual variability  in clinical outcomes or identification of population subgroups that 
respon d differentl y to treatment.
4. SUBJECT POPULA TION
Screening for eligible subjects will be performed within 21 days before randomization .
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following 2 subsections. If there is a question about the inclusion or exclusion criteria below, the 
investigator should consult with the appropriate sponsor representative before enrolling a subject 
in the study . 
For a discussion of the statistical considerations of subject select ion, refer to Section 11.2, 
Sample Size Determination.
4.1. Inclusion Criteria
Each potential subject must satisfy  all of the following criteria to be en rolled in the study . 
1. Subject must b e at least 18 years of age (or the legal age of consent in the jurisdiction in 
which the study  is taking place) .
2. Criterion modified as per Amendment INT -2
2.1 Subject must have documented multiple myeloma satisfy ing the CRAB (calcium 
elevation, renal insufficiency , anemia and bone abnormalities) criteria (see
Attachment 1),monoclonal plasma cells in the bone marrow ≥10% or presence of a 
biopsy  proven plasmacy toma, and measurable disease .
Measurable disease , as assessed by central laboratory , defined by any of the 
following:
IgG myeloma: Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL or 
urine M -protein level ≥200 mg/24 hours; or
IgA, IgM, IgD, or IgEmultiple myeloma: serum M-protein level ≥0.5 g/dL or 
urine M -protein level ≥200 mg/24 hours; or
Light chain multiple myeloma without measurable disease in serum or urine :
Serum immuno globulin free light chain ≥10mg/dL and abnormal serum 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
59
Approved , Date: 12 June 2019immunoglobulin kappa lambda free light chain ratio.
3. Newl y diagnosed andnot considered candidate for high-dose chemotherapy  with SCT 
due to:
Being age ≥65 y ears, OR
In subjects <65 years: presence of important comorbid condition(s) likely  to have a 
negative impact on tolerability  of high dose chemotherap y with stem cell 
transplantation. Sponsor review and approval of subjects under 65 years of age is 
required before randomization.
4. Subject must have an ECOG perform ance status score of 0, 1, or 2 (refer to 
Attachment 2).
5. Subject must have pretreatment clinical laboratory  values meeting the following criteria 
during the Screening Phase:
a)hemoglobin 7.5g/dL (mM/L; prior red blood cell [RBC] transfusion or 
recombinant human ery thropoietin use is permitted);
b)absolute neutrophil count 1.0 x 109/L(granulocy te colon y stimulating factor 
[GCSF ]use is permitted) ;
c)platelet count 70 x 109/L for subjects in whom <50% of bone marrow nucleated 
cells are plasma cells; otherwise platelet count >50 × 109/L(transfusions are not 
permitted to achieve this minimum platelet count);
d)aspartate aminotransferase ( AST )≤2.5 x upper limit of normal (ULN);
e)alanine aminotransferase (ALT) ≤2.5 xULN;
f)total bilirubin ≤2.0 x ULN, except in subjects with congenital bilirubinemia, 
such as Gilbert s yndrome (direct bilirubin ≤2.0 x ULN );
g)Criterion modified p er Amendment INT -2
g1)Creatinine clearance ≥30 mL/min (for lenalidomide dose adjustment for 
subjects with creatinine clearance 30-50 mL/min, refer toSection 6.2). 
Creatinine clearance can be calculated using the Cockcroft -Gault formula 
provided inAttachment 3;or for subjects with over-or underweight, creatinine 
clearance may be measured from a 24-hours urine collection using the formula 
provided in Attachment 3;
h) C riterion modified per Amendment INT -2
h1)corrected serum calcium ≤14mg/dL  (≤3.5 mM/L); or free ionized calcium 
≤6.5 mg/dL ( ≤1.6 mM/L) (Attachment 4)
6. Criterion modified per Amendment INT -3
6.1 Criterion modified per Amendment INT -2
6.2Contraceptive use by men or women should be consistent with local regulations 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
60
Approved , Date: 12 June 2019regarding the use of c ontraceptive methods for subject s participating in clinical studies.
Women of childbearing potential must commit to either abstain continuously  from 
heterosexual sexual intercourse or to use 2 methods of reliable birth control 
simultaneously . This includes one highl y effective form of contraception (tubal ligation, 
intrauterine device [IUD], hormonal [progesterone- only birth control pills orinjections
or partner ’s vasectom y) and one additional effective contraceptive method (male latex 
or synthetic condom, diaphragm, or cervical cap). Contraception must begin 4 weeks 
prior to dosing and must continue for 3months after the last dose of daratumumab . 
Reliable contraception is indicated even where there has been a history  of infertility , 
unless due to hysterec tomy  or bilateral oophorectom y.(Also see Attachment 5:
Lenalidomide Global Pregnancy  Prevention Plan).
7. A man who is sexually  active with a woman of childbearing potential must agree to use 
a latex or synthetic condom , even if hehad a successful vasectom y. All men must also 
not donate sperm during the study ,for 4 weeks after the last dose of lenalidomide, and 
for 3 months after the last dose of daratumumab.
8. A woman of childbearing potential must have 2 negative serum or urine pregnancy  tests 
at Screening, first within 10 to 14 days prior to dosing and the second within 24hours 
prior to dosing. For requirements during the T reatment Phase, please see Section 4.3.
9. Each subject (or their legall y acceptable representative) must sign an informed consent 
form (ICF) indicating that he or she understands thepurpose of and procedures required 
for the study  and are willing to participate in the study .Subject must be willing and able 
to adhere to the prohibitions and restrict ions specified in this protocol, as referenced in 
the ICF.
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study . 
1. Subject has a diagnosis of primary  amyloidosis, monoclonal gammopathy  of 
undetermined significance, or smoldering multiple myeloma. Monoclonal gammopath y 
of undetermined significance is defined by presence of serum M-protein <3 g/dL; 
absence of lytic bone lesions, anemia, hypercalcemia, and renal insuf ficiency  related to 
the M-protein; and (if determined) proportion of plasma cells in the bone marrow of 
10% or less (Kyle 2003).17Smoldering multiple myeloma is defined as asymptomatic 
multiple my eloma with absence of related organ or tissue impairment end organ damage 
(Kyle 2003, Ky le 2007).17,19
2. Subject has a diagnosis of Waldenström’ s disease, or other conditions in which IgM 
M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone 
lesions.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
61
Approved , Date: 12 June 20193. S ubject has prior or current systemic therapy  or SCT for multiple myeloma, with the 
exception of an emergency  use of a short course (equivalent of dexamethasone 
40mg/day  for 4 day s) of corticosteroids before treatment.
4. Subject has a history  of malignan cy (other than multiple myeloma) within 5years 
before the date of randomization (exceptions are squamous and basal cell carcinomas of 
the skin and carcinoma in situ of the cervix, or malignancy  that in the opinion of the 
investigator , with concurrence with the sponsor's medical monitor , is considered cured 
with minimal risk of recurrence within 5years).
5. Subject has had radiation therap y within 14 days of randomization.
6. Subject has had plasmapheresis within 28 day s of randomization.
7. Subject is exhibiting clinical signs of meningeal involvement of multiple my eloma.
8. Criterion modified as per Amendment INT -2
8.1a) Subject has known chronic obstructive pulmonary  disease (COPD) with a Forced 
Expirat ory Volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 
testing is required for subjects suspected of having COPD and subjects must be 
excluded if FEV1 <50% of predicted normal .
8.1b) Subject has had known moderate or severe persistent asthma within the last 
2years (see Attachment 7), or currentl y has uncontrolled asthma of any classification. 
(Note that subjects who currentl y have controlled intermittent asthma or controlled mild 
persistent asthma ar e allowed in the study ).
9. Criterion modified as per Amendment INT-2
9.1) Subject is known to be seropositive for human immunodeficiency  virus (HIV) or 
hepatitis B (defined by a  p ositive test for hepatitis B surface antigen [HBsAg] or 
antibodies to hepat itis B surface and core antigens [Anti-HBs and Anti-HBc, 
respectivel y]) or hepatitis C (Anti-HCV  antibody  positive or HCV -RNA  quantitation 
positive).
10. Subject has any concurrent medical or psychiatric condition or disease (eg, active 
systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary  disease ) 
that is likely  to interfere with the study  procedures or results, or that in the opinion of 
the investigator, would constitute a hazard for participating in this study .
11. Subject has clinically  significant cardiac disease, including:
myocardial infarction within 1 year before randomization, or an unstable or 
uncontrolled disease/condition related to or affecting cardiac function (eg, unstable 
angina, congestive heart failure, New York Heart Association Class III-IV
uncontrolled cardiac arrhy thmia (National Cancer Institute Common Terminology  
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
62
Approved , Date: 12 June 2019Criteria for Adverse Events [NCI CTCAE ]Version 4 Grade ≥3) or clinically  
significant ECG abnormalities
screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia’s 
formula (QTcF) >470 msec
12. Subject has known allergies, hypersensitivity ,or intolerance tocortic osteroids, 
monoclona l antibodies or human proteins, lenalidomide ,or their excipients (refer to 
respective package inserts or Investigator's Brochure), or known sensitivity  to 
mammalian -derived products.
13. Subject has plasma cell leukemia (according to World Health Organization [WHO ]
criterion: ≥20% of cells in the peripheral blood with an absolute plasma cell count of 
more than 2 × 109/L) or POEMS syndrome (polyneuropathy, organomegal y, 
endocrinopath y, monoclonal protein, and skin changes).
14. Subject is known or suspected of not being able to comply  with the study  protocol 
(eg,because of alcoholism, drug dependency , or psychological disorder). Subject has 
any condition for which, in the opinion of the investigator, participation would not be in 
the best interest of the subject (eg, compromise the well-being) or that could prevent, 
limit, or confound the protocol-specified assessments. Subject is taking any prohibited 
medications as per Section 8.3.
15. Subject is a woman who is pregnant, or breast- feeding, or planning to become pregnant 
while enrolled in this study , within 4 weeks after the last dose of lenalidomide, or within 
3months after the last dose of daratumumab . Or, subject is a man who plans to father a 
child while enrolled in this study , within 4 weeks after the last dose of lenalidomide, or 
within 3months after the last dose of daratumumab .
16. Subject has had major surger ywithin 2 weeks before randomization or has not fully 
recovered from surgery , or has surgery  planned during the time the subject is expected 
to participate in the study . Kyphoplast y or vertebroplast y is not considered major 
surgery .
17. Subject has received an investigational drug (including investigational vaccines) or used 
an invasive investigational medical device within 4 weeks before randomization or is 
currentl y enrolled in an interventional investigational study.
18. Subject has contraindications to required prophylaxis for deep vein thrombosis and 
pulmonary  embolism.
19. Incidence of gastrointestinal disease that may significantly  alter the absorption of oral 
drugs.
NOTE: Investigators should ensure that all study  enrollment criteria have been met at screening. 
If a subject's status changes (including laboratory  results or receipt of additional medical records ) 
after screening but before the first dose of study  treatment is given such that he or shenolonger
meet sall eligibility  criteria, then the subject should be excluded from participation in the study .
Section 17.4, describes the required documentation to support meeting the enrollment criteria .
Subjects who fail to meet the inclusion and exclusion criteria (ie, screen failures) may be 
rescreened once if their condition changes. Rescreening must be discussed with and approved by 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
63
Approved , Date: 12 June 2019the sponsor on a case-by-case basis. Subjects who are determined to be eligible for rescreening 
must sign a new ICF and willthen be assigned a new screening number.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study  to be eligible for participation. For restrictions related 
to concomitant medications, please refer to Section 8.3.
1. For women of childbearing potential, adequate contraception as specified in Section 4.1
must continue during the Treatment Phase, during any dose interruptions, for 4 weeks 
after the last dose of lenalidomide, and for 3months after the last dose of daratumumab.
All women must not donate ova during the study , for 4 weeks after the last dose of 
lenalidomide, and for 3months after the last dose of daratum umab.
2. During the Treatment Phase, pregnancy  tests are required weekl y during Cycle 1 and 
then monthly  in subsequent cycles in women with regular menstrual cycles or every  
2weeks in women with irregular menstrual cycles.A pregnancy  test is also required at 
the End-of- Treatment Visit .Additional pregnancy tests may be required, as specified in 
the local lenalidomide Risk Evaluation and Mitigation Strategy  (REMS) 
(where lenalidomide is supplied locally ) or the Lenalidomide Global Pregnancy  
Preventi on Plan in Attachment 5(where lenalidomide is supplied centrally  and no local 
lenalidomide REMS program exists).
3. A man who is sexually  active with a woman of childbearing potential must alway s use a 
latex or synthetic condom during the study, for 4 weeks after discontinuing 
lenalidomide, and for 3months after discontinuing daratumumab (even if he has
undergone a succe ssful vasectom y). All men must not donate sperm during the study , 
for 4 weeks after the last dose of lenalidomide, and for 3months after the last dose of 
daratumumab.
4. Because of the embry o-fetal risk of lenalidomide, all subjects must adhere to the local 
lenalidomide REMS program (when lenalidomide is supplied locally ), or the 
lenalidomide Global Pregnancy  Prevention Plan provided in Attachment 5
(when lenalidomid e is supplied centrall yand no local lenalidomide REMS program 
exists ).
5. Subjects must not donate blood during therap y and for at least 4 weeks following 
discontinuation of lenalidomide.  
6. Typically , IV contrast is NOT used in computed tomography  (CT) scanning of subjects 
with secretory  multiple myeloma because of the risk to the kidney . If administration of 
IV contrast is necessary , then adequate precautions including hy dration are indicated.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
64
Approved , Date: 12 June 20195. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation
Eligible subjects will be stratified by International Staging System (I vs II vs IIIsee 
Attachment 8), region (North America vs Other), and age (<75 vs ≥75) and then randomized to
treatment in a 1:1 ratio to either Treatment Arm A (Rdalone) or Treatment Arm B 
(daratumumab+ Rd [DRd ]). The method of randomization is randomly  permuted blocks. An 
interactive web response system (IWRS) will be used. Each subject will be assigned a unique 
subject number .
Blinding
As this is an open study , blinding procedures are not applicable.
6. DOSA GE A ND A DMINISTR ATION
In this protocol, the term “study  drug” refers to daratumumab only, and “study  treatment” refers 
to daratumumab, lenalidomide, and dexamethasone . Daratumumab is to be administered as 
described in the Time and Events Schedule. Each cycle is 28 days. The first visit of a cycle 
should be 4 weeks after the start of the previous cy cle.The start of each cycle may  occur ±3 day s 
of the scheduled day in order to accommodate the schedule of the site or subject. Day 1 of 
subsequent cycles should be adjusted accordingly  to maintain the 28-day cycle duration. In 
Cycles 1 through 6, weekly  or bi-weekl y daratumumab infusions may be g iven within ±1 day of 
the scheduled day in order to accommodate the schedule of the site or subject. In all cycles, 
weekl y dexamethasone doses may be given within ±1 day of the scheduled day in order to
accommodate the schedule of the site or subject. Changes to within -cycle dosing should not 
impact Day 1 of the next cycle.  Subjects will continue to receive study  treatment according to
the Time and Events Schedule until disease progression, unacceptable toxicity , or other reasons 
as listed in Section 10.2.
Subjects whose study  treatment isdelay ed for more than 4 weeks (Cycle 1 to Cycle 6) or more 
than 6weeks (Cycle 7 and beyond) should have study  treatment discontinued, unless, upon
consultation with the sponsor and the review of safety  and efficacy , continuation is agreed upon.
A schematic of stud y treatment administration is provided in Figure 4.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
65
Approved , Date: 12 June 2019Figure 4: Schematic Overview Study Treatm ent Administration
6.1. Daratumumab (Arm B Only )
6.1.1. Daratumumab Preparation
The infusion solution will be prepared on the day of the planned infusion. Detailed instructions 
for preparation and administration of daratumumab will be supplied in the Site Investigational 
Product Procedures Manual ( SIPPM )or equivalent document .
6.1.2. Daratu mumab A dministration
Daratumumab (16 mg/kg) will be administered b y IV infusion to subjects in Arm B initially  once 
every  week for 8weeks ; then once every  other week for 16 weeks ; thereafter once every  4 weeks 
until documented progression, unacceptable toxicity , or study  end.After the end of the study , the 
sponsor will ensure that subjects benefiting from treatment with daratumumab will be able to 
continue treatment.
Each subject’s dose will be calculated based on the subject’s weight rounded to the nearest 
kilogram. There is no cap on the absolute dose allowed, as long as the dose does not exceed 
16mg/kg. If a subject’s weight changes by more than 10% from baseline, the dose of 
daratumumab will be re-calculated. For recommendations on daratumumab infusion rate, please 
refer to the SIPPM . All infusions will be performed as outpatient visits. Subjects will receive 
preinfusion medications and postinfusion medications as outlined in Section 6.1.3 .
Every  effort should be made to keep subjects on the planned dosing schedule. Time windows for 
daratumumab administration are outlined in Table 3.
As noted in the Time and Events Schedule, vital signs should be monitored extensively  on 
Cycle1 Day  1 before, during, and after the first infusion of daratumumab. For all other in fusions, 
vital signs should be measured before the start of infusion and at the end of the infusion. If a
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
66
Approved , Date: 12 June 2019subject experiences any significant medical event, then the investigator should assess whether 
the subject should stay  overnight for observation. 
6.1.3. Prevention of Infusion Reactions
6.1.3.1. Preinfusion Medication 
Preinfusion medications for subjects receiving daratumumab will be administered as described in 
the Time and Events Dose Administration Schedule. On daratumumab infusion days, subjects
will receive the following medications prior to infusion:
Acetaminophen (paracetamol ) 650-1000 mg IV or orally (PO) approximately  1 hour or less 
prior to daratumumab infusion
An antihistamine (diphenhy dramine 25-50 mg IV or PO, or equivalent but avoid IV use of 
promethazine) approximately  1hour prior to infusion (see Attachment 9for list of 
antihistamines that may be used) ; after Cycle 6, if a subject has not developed an 
infusion- related reaction and is intolerant to antihistamines , modifications are acceptable as 
per investigator discretion.
Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior to 
daratumumab infusion. For subjects older than 75 years or underweight (body mass index 
[BMI ] <18.5 ), dexamethasone 20mg may be administered as appropriate (see Section 6.3). 
An equivalent intermediate -acting or long-acting corticosteroid may substitute (see 
Attachment 6for conversion table) . On days when subjects receive this dose of 
dexamethasone in the clinic, dexamethasone will not be self-administered at home. If 
weekl y dexamethasone dosing has been reduced below 10 mg due to adverse events during 
study , a minimum of dexamethasone 10 mg IV should continue to be administered prior to 
daratumumab infusions.
If necessary , all PO preinfusion medications may  be administered outside of the clinic on the day 
ofthe infusion, provided they  are taken within 3 hours before the infusion.
6.1.3.2. Postinfusion Medication
For subjects with higher risk of respiratory  complications (ie, subjects with mild asthma, or 
subjects with COPD who have a FEV 1 <80 %), the following postinf usion medications should be 
considered:
Antihistamine (diphenhydramine or equivalent)
Short -acting β 2adrenergic receptor agonist such as salbutamol aerosol 
Control medications for lung disease (eg, inhaled corticosteroids ± long -acting β2adrenergic 
receptor agonists for subjects with asthma; long -acting bronchodilators such as tiotropium or 
salmeterol ± inhaled corticosteroids for subjects with COPD)
In addition, these at-risk subjects may be hospitalized for monitoring for up to 2 nights after an 
infusion. If subjects are hospitalized, then their FEV 1should be measured before discharge. If 
these subjects are not hospitalized, then a follow up telephone call should be made to monitor 
their condition within 48 hours after all infusions. Ifthe subject has not experienced a significant 
medical event but is hospitalized overnight only for observation, then the hospitalization should 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
67
Approved , Date: 12 June 2019not be reported as a serious adverse event. Investigators may prescribe bronchodilators, 
antihistamines, and corticosteroids that are deemed necessary  to provide adequate supportive 
care in the event a bronchospasm occurs after subjects are released fro m the hospital/clinic. If an 
at-risk subject experiences no major infusion- related reactions, then these postinfus ion 
medications may  be waived after 4 full doses at the investigator’s discretion.
6.1.4. Management of Infusion- related Reactions
Subjects in Arm B should be carefully  observed during daratumumab infusions. Trained study  
staff at the clinic should be prepared to intervene in case of any  infusion reactions occurring, and 
resources necessary  for resuscitation (eg, agents such as epinephrine and aerosolized 
bronchodilator, also medical equipment such as oxygen tanks , and a defibrillator) must be 
available. Attention to staffing should be considered when multiple subjects will be dosed at the 
same time.
If an infusion- related reaction develops, then the infusion should be paused. Subjects who 
experience adverse events during the infusion must be treated according to the investigator’s 
judgment and best clinical practice. The following guidelines may  apply :
Subjects should be treated with acetaminophen, antihistamine, or corticosteroids. 
Intravenous saline may be indicated. For bronchospasm, urticaria, or dyspnea, subjects may 
require antihistamines, oxygen, corticosteroids, or bronchodilators. For hypotension, 
subjects may  require vasopressors.
In the event of a life-threatening infusion-related reaction (which may include pulmonary  or 
cardiac events), or anaphy lactic reaction, daratumumab should be discontinued and no 
additional daratumumab should be administered to the subject. Aggressive symptomatic 
treatment should be applied. 
If an infusion is paused, then a longer -than-anticipated infusion time may occur. Overnight stays 
at the hospital because of slow infusion times should not be reported as a serious adverse event.
However, if the underl ying cause of the delay ed infusion time is an adverse event or serious 
adverse event, then that should be reported as such .
6.1.4.1. Infusion -Related Events of Grade 1 or Grade 2
If the investigator assesses an adverse event to be related to the daratumumab infusion, then the 
infusion should be paused. When the subject’s condition is stable, the infusion may be restarted 
at the investigator’s discretion. Upon restart, the infusion rate should be half of that used before 
the interruption. Subsequently , the infusion ra te may  be increased at the investigator’s discretion. 
If the subject experiences a Grade 2 or higher event of laryngeal edema or a Grade 2 or higher 
event of bronchospasm that does not respond to systemic therapy  and does not resolve within 
6hours from t he onset, then the subject must be withdrawn from treatment.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
68
Approved , Date: 12 June 20196.1.4.2. Infusion -Related Reactions of Grade 3 or Higher
For infusion-related adverse events that are Grade 4, the infusion should be stopped and 
treatment with daratumumab will be discontinued for that s ubject.
For infusion-related adverse events that are Grade 3, the daratumumab infusion must be stopped, 
and the subject must be observed carefully  until the resolution of the adverse event or until the 
intensity  of the event decreases to Grade 1, at which point the infusion may be restarted at the 
investigator’s discretion. Upon restart, the infusion rate should be half of that used before the 
interruption. Subsequently, the infusion rate may  be increased at the investigator’s discretion.
If the intensity  of the adverse event returns to Grade 3 after restart of the infusion, then the 
procedure described in this section may be repeated at the investigator’s discretion. Should the 
intensity  of the adverse event increase to Grade 3 for a third time, then treatm ent with 
daratumumab will be discontinued for that subject.
6.2. Lenalidomide (Arm A and A rm B )
Lenalidomide will be self-administered at a dose of 25 mg PO each day  on Day s 1 through 21 of 
each 28 day cycle for subjects with creatinine clearance >50 mL/min. If creatinine clearance is
between 30 and 50 mL/min, the dose of lenalidomide will be 10 mg every  24 hours. Once the 
creatinine clearance is >50 mL/min during the course of the treatment, lenalidomide can be
increased to 25mg. In both treatment arms, subjects will continue on lenalidomide until 
progression of disease or unacceptable toxicity .Subjects in Arm B who discontinued treatment 
with Rd at 24 months may re-start treatment with Rd as per Amendment INT-4.
On daratumumab infusion days, it is recommen ded that lenalidomide should be administered 
either prior toor at the same time (preferred) as the premedications. 
If a daily  lenalidomide dose is missed, it may be taken if <12 hours have elapsed since the time 
that it should have been taken. If the next dose is scheduled to be taken within 12 hours, the 
missed lenalidomide dose should be skipped.
6.3. Dexamethasone (Arm A and Arm B)
Dexamethasone (or equivalent in accordance with local standards; see Attachment 6for 
conversion table) will be administered at a total dose of 40mg weekly .For subjects older than 
75years or underweight (BMI <18.5), the dexamethasone dose may  be administered at a dose of 
20 mg weekl y. Inboth treatment arms, dexamethasone will be administered until the subject 
experiences disease progression or unacceptable toxicity , whichever comes first. Subjects in 
Arm B who discontinued treatment with Rd at 24 months may re-start treatment with Rd as per
Amendment INT-4.
On dayswhen subject s in Arm Breceive an infusion of daratumumab, dexamethasone will not 
be self-administered but instead will be administered in the clinic . In this setting, dexamethasone 
will be utilized as the treatment dose of steroid for that particular day, as well as the required 
pre-medication prior to daratumumab infusion.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
69
Approved , Date: 12 June 2019If a weekly  dexamethasone dose is missed, it may be taken if <4 days have elapsed since the 
time that it should have been taken. If the next dose is schedul ed to be taken within 3 days, the 
missed dexamethasone dose should be skipped.
6.4. Dose Delay s and Dose Modification
Subjects who need to discontinue treatment with any one component of study  treatment 
(lenalidomide, dexametha sone, or daratumumab) may continue to receive treatment with the 
other components of study  treatment, as assigned.
6.4.1. Daratumumab Dose Modification
Dose modification of daratumumab is not permitted, but dose delay  is the primary  method for 
managing daratumumab -related toxicities. 
6.4.1.1. Daratumumab- Related Toxicity  Management
Refer to Section 6.1.3 for details on management of infusion- related reactions . ONL Y if any of 
the following criteria are met and the event cannot be ascribed to lenalidomide , the daratumumab 
infusion must be held to allow for recovery  from toxicity .The criteria for a dose delay  are:
Grade 4 hematologic toxicity
Grade 3 thrombocy topenia wit h bleeding
Febrile neutropenia 
Neutropenia with infection, of an y grade
Grade 3 or higher nonhematologic toxicities with the following exceptions : 
Grade 3 nausea that responds to antiemetic treatment within 7 day s
Grade 3 vomiting that responds to antiem etic treatment within 7 day s
Grade 3 diarrhea that responds to antidiarrheal treatment within 7 day s
Grade 3 fatigue that was present at baseline or that lasts for <7 days after the last 
administration of daratumumab
Grade 3 asthenia that was present at baseline or that lasts for <7 days after the last 
administration of daratumumab
Other than on Day 1 of a cycle, if a daratumumab administration does not commence within the 
prespecified window (Table 3) of the scheduled administration date, then the dose will be 
considered a missed dose. Administration may  resume at the next planned dosing date. A missed 
dose will not be made up.
Table 3: Daratum umab-Related Toxicity Managem ent
Cycles Frequency Dose Held Dosing Re-start
1 and 2 Weekly (q1wk) >3 days next planned weekly dosing date
3 to 6 Biweekly (q2wks)` >1 week next planned biweekly dosing date
7+ Every 4 weeks (Q4W) >2 weeks next planned every 4 weeks dosing date
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
70
Approved , Date: 12 June 2019Doses of daratumumab may be delay ed up to 4weeks (Cycle 1 to Cycle 6) or up to 6 weeks 
(Cycle7 and bey ond). Day 1 of a cy cle should not be skipped; however, D ay 1 of a cy cle may be 
delay ed, and Day 1 of subsequent cycles should be adjusted accordingly  to maintain the 28-day 
cycle duration. However, if a within -cycle dose is delay ed, then the dates of the subsequent 
within -cycle doses should not be adjusted. Any adverse event deemed to be related to 
daratumumab that requires a dose hold of more than 4 weeks (Cycle 1 to Cycle 6) or more than 
6weeks (Cycle 7 and beyond) will result in permanent discontinuation of daratumumab .If a 
dose delay  occurs, then pharmacokinetic and pharmacod ynamic assessments should be 
performed on the actual administration day of daratumumab, not on the original scheduled 
administration day .
6.4.1.2. Daratumumab Interruption or Missed Doses
A daratumumab dose that is held for more than the permitted time (Table 3)from the 
per-protocol administration date for any reason other than toxicities suspected to be related to 
daratumumab should be brought tothe attention of the Spon sor at the earliest possible time. 
Subjects whose dose was delay ed for more than 4 weeks (Cycle 1 to Cycle 6) or more than 
6weeks (Cycle 7 and beyond) should have study  treatment discontinued, unless, upon
consultation with the sponsor and the review of safety  and efficacy , continuation is agreed upon.
Infusion -related reactions may occur upon re-initiation of daratumumab after a prolonged delay 
in  treatment .
6.4.2. Lenalidomide Dose Reductions
Dose adjustments of lenalidomide will follow the approved labeling as follows:
Starting dose: 25 mg
Dose level 1: 15 mg
Dose level 2: 1 0mg
Dose level 3: 5 mg
Dose adjustments should be based on the highest grade of toxicity  that is ascribed to 
lenalidomide. After initiatio n of lenalidomide , subsequent lenalidomide dose adjustment is based 
on individual subject treatment tolerance. If the investigator determines that an adverse event 
may be related to lenalidomide, dose adjustment can be done even if not specified in this 
protocol. In the event of a dose adjustment, lenalidomide doses maybe re-escalated at the 
investigator’s discretion.
6.4.2.1. Thrombocytopenia
If the subject’s platelet count decreases, dose adjustments should be made according to the 
recommendations in Table 4.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
71
Approved , Date: 12 June 2019Table 4: Lenalidomide Dose Adjustment for Thrombocytopenia
Platelet Count Recommended Course of Action
 When count first falls to < 30109/L
 When count returns to 30109/L Interrupt lenalidomide treatment, follow complete blood 
count weekly
 Resume lenalidomide at the next lower dose
 For each subsequent drop in count to <30 109/L
 When count returns to 30109/L Interrupt lenalidomide tre atment
 Resume lenalidomide at the next lower dose 
6.4.2.2. Neutropenia
If the subject experiences neutropenia, the investigator should consider the use of growth factors 
in the subject’s management. If the subject’s neutrophil count decreases further, dose 
adjustments should be made according to the recommendations in Table 5 .
Table 5: Lenalidomide Dose Adjustment for Neutropenia
Neutrophil Count Recommended Course of Action
 When count first falls to < 1.0109/L
 When count returns to 1.0109/L and neutropenia is the 
only observed toxicity Interrupt lenalidomide treatment, consider G-CSF 
treatment, follow complete blood count weekly
 Resume lenalidomide at 25 mg daily or initial starting 
dose
 When count returns to 1.0109/L and dose-dependent 
hematological toxicities other than neutropenia are 
observed Resume lenalidomide at the next lower dose
 For eac h subsequent drop in count to < 1.0109/L
 When count returns to 1.0109/L Interrupt lenalidomide treatment
 Resume lenalidomide at the next lower dose level 
6.4.2.3. Renal Impairment
Because lenalidomide is primarily  excreted unchanged by the kidney , adjustments to the dose of 
lenalidomide are recommended to provide appropriate drug exposure in subjects with moderate 
or severe renal impairment. Lenalidomide dose adjustment should be instituted for subjects with 
a creatinine clearance of 50 mL/minute or less. The recommended doses for subjects with 
multiple my eloma and renal impairment are shown inTable 6.
Table 6: Lenalidomide Dose Adjustment for Renal Impairment
Category Renal FunctionaDose
Moderate renal impairment CrCl 30 -50mL/min 10mg every 24 hours
Severe renal impairment CrCl < 30mL/min (not requiring dialysis) 15mg every 48 hours
End-stage renal disease CrCl < 30mL/min (requiring dialysis) 5 mg once daily. On dialysis days, administer 
the dose after dialysis
Key: CrCl =creatinine clearance.
aEstimated by creatinine clearance as calculated by the Cockcroft -Gault equation and adjusted for body weight in subjects 
with a body mass index >30 kg/m2.
6.4.2.4. Other A dverse Events
For other Grade 3 or 4non-hematologic and non-renal toxicities judged by the investigator to be 
related to lenalidomide alone, treatment with lenalidomide should be interrupted and restarted at 
the next lower dose level once the toxicity  has resolved to Grade 2 or less. Treatment with 
daratumumab and dexam ethasone may  continue.
Note that the dose modifications above are suggested, but physician discretion and clinical 
judgment should prevail.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
72
Approved , Date: 12 June 20196.4.3. Dexamethasone Dose Modifications
Dexamethasone may be reduced, if necessary , according to Table 7.For other Grade 3 or 4 
non-hematologic and non-renal toxicities judged by the investigator to be related to 
dexamethasone alone, treatment with dexamethasone should be interrupted and restarted at the 
next lower dose level once the toxicity  has resolved to Grade 2 or less. Treatment with 
daratumumab and lenalidomide may  continue. In the event of a dose adjustment, dexamethasone 
doses maybe re-escalated at the investi gator’s discretion. For complete details on 
dexamethasone, refer to the most current local product prescribing information.
Note that Table 7represents suggested dose modifications of dexamethasone, but physician 
discretion and clinical judgment should prevail.
If weekl y dexamethasone dosing has been reduced below 10 mg due to adverse events during 
study , a minimum of dexamethasone 10 mg IV should continue to be administered prior to 
daratumumab infusions.
Table 7: Recommended Dose Reduction for Dexam ethasone
CTCAE Category Toxicity Dose Change
Gastrointest inal Grade 1 -2 Dyspepsia, gastric or 
duodenal ulcer, gastritis 
requiring medical managementTreat with H2 blockers, sucralfate, or omeprazole. If symptoms 
persist despite above measure, decrease dexamethasone dose by 
50%.
>=Grade 3 requiring 
hospitalization or surgeryHold dexamethasone until symptoms adequately controlled. 
Restart at 50% of current dose along with concurrent therapy with 
H2 blockers, sucralfate or omeprazole. If symptoms persist despite 
above measure, discontinue dexamethason e and do not resume.
Acute pancreatitis Discontinue dexamethasone and do not resume
Cardiovascular >= Grade 3 Edema limiting 
function and unresponsive to 
therapy or anasarcaDiuretics as needed and decrease dexamethasone dose by 25%; if 
edema persists despite above measures, decrease dose to 50% of 
initial dose; discontinue dexamethasone and do not resume if 
symptoms persist despite 50% reduction
Neurology/ 
Psychiatric>= Grade 2 interfering with 
function but not interfering with 
activities of daily living Hold dexamethasone until symptoms adequately controlled. 
Restart at 50% of current dose. If symptoms persist despite above 
measure, discontinue dexamethasone and do no t resume
Musculoskeletal >= Grade 2 Muscle weakness 
Symptomatic and interfering 
with function but not interfering 
with activities of daily livingDecrease dexamethasone dose by 25%; if weakness persists 
despite above measures, decrease dose to 50% of initial dose; 
discontinue dexamethasone and do not resume if symptoms persist 
despite 50% 
Metabolic >= Grade 3 Hyperglycemia Treatment with insulin or oral hypoglycemic agents as needed. If 
uncontrolled despite above measure, decrease dose by 25% 
decrements until levels are satisfactory
7. TREA TMENT COMPLIA NCE
Study  drug (daratumumab) will be administered by qualified site staff, and the details of each 
administration will be recorded in the electronic case report form (eCRF). Subjects will be 
provided with a treatment diary  which will be used to assess complian ce with lenalidomide and 
dexamethasone treatment . Additional details are provided in the SIPPM or equivalent document .
8. CONCOMITA NT THERA PY
Throughout the study , investigators may prescribe any concomitant medications or treatments 
deemed necessary  to provi de adequate supportive care except for those listed in Section 8.3. The 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
73
Approved , Date: 12 June 2019sponsor must be notified in advance (or as soon as possible thereafter) of any instances in which 
prohibited therapies are administered .
Routine systemic use of the following concomitant medications will be collected in the eCRF 
and recorded in the source documents beginning with signing of the ICF to 30 days after the last 
dose of the last study  treatment or until the start of subsequent anti-myeloma treatment, if earlier: 
growth factors, transfusions, anti- infectives (antibacterials, antivirals, and antimy cotics), steroids, 
anti-arrhythmics and other cardiac supportive therapy , anti- epileptics, centrally  acting ps ychiatric 
medication, anti-histami nes and other medications targeting postinfusion systemic reactions, 
bisphosphonates, and any anti-myeloma therapy  (including radiation). Concomitant medications 
to manage adverse event s and SAEs will be recorded as per Section 12.3.1 .
8.1. Recommended Therapies
8.1.1. Prevention of Deep Vein Thrombosis and Pulmonary  Embolism
Lenalidomide has been associated with increased incidence of deep vein thrombosis and 
pulmonary  embolism. Therefore, proph ylaxis of venous thromboembolism (VTE) for all subjects 
is recommended according to IMWG guidelines as well as at the investigator’s discretion
(Palumbo 2008).28Both individual and myeloma -related risks of VTE should be taken into 
account in determining the ty pe of thromboprophy laxis. I n summary :
If no risk factor, or any one risk factor is present, aspirin 81-325 mg once daily  is 
recommended or dose per institutional standards
If 2or more risk factors are present, low molecular weight heparin (LMWH )(equivalent of 
enoxaparin 40 mg once daily ) or full-dose warfarin, international normalized ratio (INR) 
2-3, is recommended
If any myeloma therapy -related risk factor is present, then LMWH (equivalent of 40 mg 
enoxaparin once dail y) or full -dose warfarin (target INR 2- 3) is recommended
8.1.2. Bisphosphonate Therapy
Bisphosphonate therapy  is recommended to be continued per treatment guideline s 
(NCCN 2013).23Commercially available IV bisphosphonates (pamidronate and zoledronic acid) 
are preferred when available, and should be used according to the manufacturer’s 
recommendations, as described in the prescribing information, for subjects with osteoly tic or 
osteopenic myelomatous bone disease. Oral bisphosphonates may be used as alternatives if IV 
bisphosphonates are not available at the stu dy site.
Subjects who are currently  using bisphosphonate therap y when they enter the study  should 
continue the same treatment. If clinicall y indicated, subjects may initiate bisphosphonate therap y 
as soon as possible during Screening and no later than the end of Cycle 1. After Cycle 1, 
investigators should not prescribe bisphosphonate s to subjects who have not received it before ,
unless it has been discussed with the sponsor and there is no sign of disease progression .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
74
Approved , Date: 12 June 20198.1.3. Therapy  for Tumor Lysis Syndrome
Subje cts should be monitored for symptoms of tumor lysis syndrome. Management of tumor 
lysis syndrome, including hydration and monitoring for abnormal laboratory  test results such as 
hyperkalemia, hyperuricemia, and hypocalcemia, are highly  recommended. It is also 
recommended that high-risk subjects, ie, those with a high tumor burden, be treated 
prophy lacticall y in accordance with local standards (eg, rehydration; diuretics; allopurinol 
300mg dail y and medication to increase urate excretion).
8.1.4. Prophy laxis for Pneumocy stis carinii
Pneumocy stis carinii pneumonia (PCP) prophy laxis should be considered, as per institutional 
guidelines.
8.1.5. Prophy laxis for Herpes Zoster Reactivation
Prophy laxis for herpes zoster reactivation is recommended during the Treatment Phase, asper 
institutional guidelines .
8.1.6. Prevention of Steroid Induced Gastritis
Dexamethasone and other steroids may induce gastritis. Medications to prevent gastritis are 
permitted per institutional guidelines, for example proton pump inhibitors (omeprazole or 
equivalent) or sucralfate , or H2 blockers (ranitidine or equivalent).
8.1.7. Management of Hepatitis B Virus Reactivation
Primary  antiviral proph ylaxis is permitted as per local standard of care. Per protocol, hepatitis B 
virus ( HBV )DNA testing by  polymerase chain reaction ( PCR) is required for subjects at risk for 
HBV reactivation ( see Section 9.8).
For subjects who are diagnosed with HBV reactivation while on treatment, study  treatment 
should be interrupted until the infection is adequately  controlled. If the benefits outweigh the 
risks, study  treatment may be resumed with concomitant antiviral prophy laxis as per local 
standard of care. Consult a liver disease specialist as clinically  indicated.
8.2. Permitted Therapies
Subjects are to receive full supportive care during the study . The following medications and 
supportive therapies are examples of support therapies that may  be used during the stud y:
Colony  stimulating factors, erythropoietin, and transfusion of platelets and red blood cells. If 
erythropoietin is given, then this should be given according to the local lenalidomide label, 
as there is an increased risk of thrombosis with lenalidomide.
It is important to prevent constipation (eg, adequate hydration, high-fiber diet, and stool 
softeners if needed)
Adequate h ydration is recommended for prevention of my eloma -related kidney  disease
Prophy lactic antiemetics, with the exception of corticosteroids
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
75
Approved , Date: 12 June 20198.3. Prohibited Therapies
Concomitant administration of any other antineoplastic therap y for the intention of treating 
multiple myeloma is prohibited prior to confirmation of disease progression, including 
medications that target CD38, as well as clarithromy cin(Ghosh 2013) .12For management of 
second primary  malignancies please see Section 10.2. Continuation of the study  treatment during 
or after emergency  orthopedic surgery  or radiotherapy  because of the subject’s benefit may  occur 
only in the absence of disease progression and after review by the sponsor. Such emergenc y 
radiotherap y may consist of localized radiotherapy  for pain control or for stabilization of an 
extensive bone lesion at high risk of pathologic fracture or damage to surrounding tissues in a 
subject in whom delay  of systemic therapy  is not appropriate. Such radiotherapy  is to occur 
within the first 2 cycles of treatment and the absence of evidence of disease progression is to be 
reviewed b y the sponsor.
Concomitant administration of investigational agents is prohibited. Administration of 
commerciall y available agents with activity  against or under investigation for multiple my eloma, 
including systemic corticosteroids (>10 mg prednisone per day or equivalent) should be avoided 
(other than those given for infusion-related reactions as described in Section 6.1.3.2 or for the 
treatment of adverse events [if no other treatment options are available] ). Nonsteroidal 
anti-inflammatory  agents should beused with caution in order toprevent myelom a-related 
kidney  disease. 
Typically , IV contrast is NOT used in computed tomograph y (CT) scanning of the subjects with 
secretory  multiple myeloma because of the risk to the kidney . If administration of IV contrast is 
necessary , then adequate precautions including hydration are indicated. The sponsor must be 
notified in advance (or as soon as possible thereafter) of any instances in which prohibited 
therapies are administered.
8.4. Subsequent Therapies
After discontinuatio n of study  therap y subjects should continue disease evaluations per the Time 
and Events Schedule until confirmed PD. Subsequent anti-myeloma therapy  cannot be started 
before disease progression is established per the IMWG criteria (Section 9.2.1.1 , Response 
Categories) and confirmed by  the sponsor.
After sponsor confirmation of PD, choice of subsequent therapy  is at the discretion of the
investigator. Subjects randomized to Arm A (Rd) may have the option to receive daratumumab
provided by the sponsor (in any  subsequent line of therapy ),if recommended by  the investigator.
Eligibility  for and administration of daratumumab including safet y management (eg,infusion-
related reactions and HBV monitoring) must be in accordance with local prescribing information 
and local regulations. For these subjects, daratumumab should not be added to an ongoing 
subsequent therapy  regimen until the subject has progressed on that regimen. Subjects in Arm A 
(Rd) who receive daratumumab after PD through the sponsor will remain in the Follow -up phase 
of the study . Serious adverse events must be reported for these subjects until 30 days after 
daratumumab is discontinued. Second primary  malignancies will continue to be reported until 
end of study .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
76
Approved , Date: 12 June 2019All subsequent therapy  for multiple myeloma (including start and end date, best response, and
date of progression to the subsequent therapy ) should be documented in the appropriate section
of the eCRF.
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy , 
pharmacokinetic, immunogenicity , biomarker, patient reported outcomes, and safet y 
measurements applicable to this study .
All visit-specific PRO assessments should preferably  be conducted/completed before any tests, 
procedures, or other consultations for that visit to prevent influencing subject perceptions. Refer 
to Section 9.7for details.
Blood collections for pharmacokinetic assessments should be kept as close to the specified time 
as possible. Other measurements may  be done earlier than specified timepoints if needed. Actual 
dates and times of assessments will be recorded in the source documentation.
Additional serum or urine pregnancy  tests may be performed, as determined necessary  by the 
investigator or required by local regulation, to establish the absence of pregnancy  at any time 
during the subject's participation in the study .
The blood volume for the study  is estimated at approximately  65 mL during screening and 
360mL during the first year(approximately  20-35mL per cycle for routine testing, plus 
additional PK and biomarker samples). In the Follow -up Phase, subjects prior to PD will 
continue to have approximately  20 mL blood drawn permonth for serum disease evaluations.
This includes laboratory  assessments associated with safety , efficacy , and pharmacokinetic 
evaluations, as well as scientific research samples. Repeat or unscheduled samples may be taken 
for safety  reasons or for technical issues with the samples.
9.1.2. Screening Phase
The signe d ICF must be obtained before any study -specific procedures are performed. The 
Screening Phase begins when the first screening assessment is conducted ( that was not 
performed as part of the subject’s standard of care). During the Screening Phase, eligibility  
criteria will be reviewed and a complete clinical evaluation will be performed as specified in 
Time and Events Schedule. Screening procedures will be performed within 21days before 
randomization; however, results of tests such as skeletal survey , radio logic tests (eg, magnetic 
resonance imaging [MRI] to document baseline size of known or suspected extramedullary  
plasmacy tomas; ECG; chest x rays [or full chest CT scan];or bone marrow aspirate or biopsy ) 
performed up to 6 weeks (42days) before randomiza tion as routine standard of care for the 
subject’s disease can be used. See Attachment 1for the modified IMWG Diagnostic Criteria.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
77
Approved , Date: 12 June 2019Subjects <65 yearsmust have known presence of important comorbid condition(s) likely  to have 
a negative effect on the tolerability  of high dose chemotherap y with SCT. Documentation of the 
condition, for example diagnosis of concomitant infectious disease(s), should be provided.
Sponsor review and approval of subjects under 65 y ears of age is required before randomization .
A negative pregnancy  test for women of childbearing potential must be documented twice, once 
within 10 -14 days before the first dose and a second time within 24 hours before the first dose of 
any component of the treatment regimen .
All attempts should be made to determine eligibility of the subject based on the central 
laboratory  results of Screening blood and urine M-protein measurements. In exceptional 
circumstances, the local laboratory  results of blood and urine M-protein measurements may be 
used to determine eligibility , but only if the results are clearly  (eg, 25% or more) above the 
thresholds for measurability .
9.1.3. Treatment Phase
Details of the procedures performed during the Treatment Phase are outlined in the Time and 
Events Schedule. Subjects should start study  treatment within 72 hours after randomization. A 
window of ±3days is allowed for Day 1 of each cycle visits to the clinic. Each cycle is 28days. 
The first visit of a cycle should be 4 weeks after the start of the previous cycle. The start of each 
cycle may occur ±3 days of the scheduled day in order to accommodate the schedule of the site 
or subject. Day 1 of subsequent cycles should be adjus ted accordingl y to maintain the 28-day 
cycle duration. In Cycles 1 through 6, weekly  or bi -weekl y daratumumab infusions may  be given 
within ±1 day of the scheduled day in order to accommodate the schedule of the site or subject. 
In all cycles, weekly  dexam ethasone doses may be given within ±1 day of the scheduled day in 
order to accommodate the schedule of the site or subject. Changes to within -cycle dosing should 
not impact Day 1  o f the next cycle.Subjects will be closely monitored for adverse events, 
laboratory  abnormalities, and clinical response. Clinical evaluations and laboratory  studies may 
be repeated more frequently , if clinically  indicated. If disease progression is diagnosed, then the 
subject will discontinue study  treatment, complete the End- of-Treatment Visit, and enter the 
Follow -up Phase .If disease progression has not occur red at the time of the End-of-T reatment 
visit, disease evaluations must continue until disease progression is confirmed. Subsequent 
anti-myeloma treatment will not be started until after disease progression is confirmed by the 
Sponsor.
End-of-Treatment Visits
Unless a subject withdraws consent for study participation or is lost to follow up, an 
End-of- Treatment Visit is to occur within 4 weeks after the last dose of all study  treatment s. 
Every  effort should be made to conduct the End-of-Treatment Visit before the subject starts 
subsequent treatment. If a subject is unable to return to the site for the End-of-Treatment Visit, 
then the subject should be contacted to collect information on adverse event s that occur up to 
30days after the last dose of study  treatment. Additional information on reporting of adverse 
event s is presented in Section 12.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
78
Approved , Date: 12 June 20199.1.4. Follow -upPhase
The Follow -up Phase will begin once a subject discontinues all study  treatments. Subjects who 
discontinue study  treatment before disease progression must continue to have disease 
evaluations. Ideally, the timin g of disease evaluation sshould follow the Time and Events 
Schedule until confirmed PD(see Section 8.4, Subsequent Therapies) , death, the start of a new 
anti-myeloma therap y, withdrawal of consent, lost to follow -up, or the end of the study . After
disease progression is documented, subsequent anti-myeloma therapy ,PFS2 (per investigator 
judgmen t), second primary  malignancies and survival status will be obtained at least every  
16weeks ±2weeks. Every  16-week follow -up contacts , as well as Week 8 and Week 16 post -PD 
ECOG and ePRO assessments ,should be scheduled from the date of confirmed progression
(ie,the date of the confirmatory  laboratory  assessment, not the date of confirmation by the 
sponsor) . In subjects for whom disease progression will not be documented (eg, received 
subsequent anti-myeloma treatment or refused disease evaluations, but agreed to follow-up 
contacts), the every  16-week follow -up should be scheduled from the date of the 
End-of- Treatment Visit.
If the information is obtained via telephone contact, written documentation of the 
communication must be available for review in the source documents. If the subject has died, the 
date and c ause of death will be collected and documented in the eCRF. 
The end of the study  occurs after 330 subjects have died, or for a maximum of 7years after the 
last subject is randomized, whichever occurs first.The sponsor will ensure that subjects 
benefitin g from treatment with daratumumab will be able to continue treatment after the end of 
the study .
9.1.5. Assessments Following the Positive Second Interim A nalysis of PFS
Following the positive second interim analy sis of PFS, subjects remaining in the study  will
continue to be monitored as follows until the next interim analy sis of OS (ie, when 260 deaths
have occurred):
Subjects who H ave had Disease Progression
For subjects whose disease has alread y progressed, every -16-week follow -up contacts should be
performed to capture:
Survival
Subsequent anti -myeloma therap y
New second primary  malignancies
These data may  be collected directl y from subject or indirectl y (eg, from medical correspondence 
or visits).
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
79
Approved , Date: 12 June 2019Subjects who H ave not had D isease P rogression
For subjects inthe randomized portion of the study  who have not experienced disease
progression, disease assessments will continue to occur per the Time and Events Schedule until 
disease progression is confirmed by  the sponsor.
ECOG and ePRO will be collected every  6 months (± 14 days)until PD. Also 8 and 16 weeks 
after PD (seeSection 9.1.4 ).
9.1.6. Assessments Following the Interim OS Analysis
Following the interim OS analy sis (ie, when 260deaths have occurred), subjects remaining in the
study  will continue to be monitored as follows until the study  end (ie, when 330 deaths have
occurred, or 7 years after the last subject is randomized, whichever comes first):
For subjects whose disease has alread y progressed at the time of the interim OS analy sis,
only survival, subsequent anti-myeloma therapy , PFS2 and all new second primary 
malignancy information will be collected, which may be obtained directly from subject or 
indirectly  (eg,from medical correspondence or visits ).
Once the interim OS analy sishas occurred and when the median PFS is reached in the DRd 
arm, the sponsor will notify  the investigators that from that point onward, disease 
evaluations are to be performed locall y per the site’s standard of care. Sponsor confirmation 
of disease progression will no longer be required prior to initiation ofsubsequent anti-
myeloma therap y.
For subjects who are continuing to receive study  treatment at the time of the interim OS 
analysis, dosing data and safet y information will be collected. Safety  information will 
include adverse events during treatment and within 30 days after last dose, concomitant 
medications associated with a serious adverse event, and information on all second primary 
malignancies.
9.2. Efficacy
9.2.1. Evaluations
Disease response and progression will be based on assessments from IMW G Guidelines as 
defined in Section 9.2.1.1 . Previous studies have demonstrated potential interference of 
therapeutic monoclonal antibodies with detection of endogenous myeloma M-protein on serum 
immunofixation (IFE)(McCudden 2010).22Daratumumab detection on serum immunofixation 
has been demonstrated in subjects treated with 16 mg/kg, and may interfere with the traditional 
IMW G criteria of negative serum IFE for complete response or stringent complete response. To 
mitigate this interference, the sponsor has developed a reflex assay  that utilizes anti-idioty pe 
antibody  to bind daratumumab and confirm its interference on IFE (see l aboratory  manual). For 
all subjects with VGPR, and a negative endogenous M-protein by serum M-protein quantitation 
by electrophoresis (SPEP ), reflex IFE testing will be performed to confirm the presence of 
daratumumab on IFE.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
80
Approved , Date: 12 June 20199.2.1.1. Response Categories
Disease evaluations must be performed every  28 daysfor the first 2 years and then every  
8weeks until disease progression (or other reasons as perSection 10). A window of ±7days is 
allowed. If treatment has been delay ed for any  reason, the disease evaluations must be performed 
according to schedule, regardless of an y changes to the dosing regimen.
Disease evaluations will be performed by a central laboratory  (unless otherwise specified). This 
study  will use the IMWG consensus recommendations for multiple myeloma treatment response 
criteria (Durie 2006, Rajkumar 2011 )7,32presented in Table 8. For quantitative immunoglobulin, 
M-protein, and immunofixation measurements in serum and 24 hour urine, the investigator will 
use results provided by the central laboratory .Subjects with positive serum IFE and confirmed 
daratumumab IFE interference, that meet all other clinical criteria for complete response or 
stringent complete response, will be considered CR/sCR.
Disease progression must be consistently  documented across clinical study  sites using the criteria 
in Table 8.For patients with measurable disease by SPEP or UPEP at baseline, increases in 
serum free light chains (FL C) or the FLC ratio alone do not meet criteria for progressive disease.
Table 8: International Uniform  Response Criteria Consensus Recommendations
Response Response Criteria
Stringent complete
Response (sCR) CR as defined below, plus
 Normal FLC ratio, and
 Absence of clonal PCs by immunohistochemistry, immunofluorescenceaor 2-to 4-color flow 
cytometry
Complete response 
(CR)* Negative immunofixation on the serum and urine, and
 Disappearance of any soft tissue plasmacytomas, and
 <5% PCs in bone marrow
Very good partial
Response 
(VGPR)* Serum and urine M -component detectable by immunofixation but not on electrophoresis, 
or
 ≥90% reduction in serum M -protein plus urine M -protein <100 mg/24 hours
Partial response 
(PR) ≥50% reduction of serum M -protein and reduction in 24 -hour urinary M -protein by ≥90% or to <200 
mg/24 hours
 If the serum and urine M -protein are not measurable, a decrease of ≥50% in the difference between 
involved and uninvolved FLC levels is required in place of the M -protein criteria
 In addition to the above criteria, if present at baseline, a ≥50% reduction in the size of soft tissue 
plasmacytomas is also required.
Stable disease 
(SD) Not meeting criteria for CR, VGPR, PR, or progressive disease
Progressive 
disease (PD)† Increase of 25% from lowest response value in any one of the following:
 Serum M -component (absolute increase must be ≥0.5 g/dL), 
 Urine M -component (absolute increase must be ≥200 mg/24 hours), 
 Only in subjects without measurable serum and urine M-protein levels: the difference between 
involved and uninvolved FLC levels (absolute increase must be >10 mg/dL)
 Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size 
of existing bone lesions or soft tissue plasmacytomas
 Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely 
to the PC proliferative disorder
FLC = free light chain; PC = plasma cell
All response categories (CR, sCR, VGPR, PR, and PD) require 2 consecutive assessments made at any time before the institution 
of any new therapy; CR, sCR, VGPR, PR, and SD categories also require no known evidence of progressive or new bone lesions 
if radiographic studies were performed. VGPR and CR categories requir e serum and urine studies regardless of whether disease 
at baseline was measurable on serum, urine, both, or neither.
Radiographic studies are not required to satisfy these response requirements. Bone marrow assessments need not be confirmed. 
For PD, serum M-component increases of more than or equal to 1 g/dL are sufficient to define relapse if starting M-component is 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
81
Approved , Date: 12 June 2019≥5 g/dL.
*Clarifications to IMWG criteria for coding CR and VGPR in subjects in whom the only measurable disease is by serum FLC 
levels: CR in such subjects indicates a normal FLC ratio of 0.26 to 1.65 in addition to CR criteria listed above. VGPR in such 
subjects requires a >90% decrease in the difference between involved and uninvolved FLC levels.
†Clarifications to IMWG criteria for coding PD: Bone marrow criteria for PD are to be used only in subjects without measurable 
disease by M protein and by FLC levels; “25% increase” refers to M protein, FLC, and bone marrow results, and does not refer 
to bone lesions, soft tissue plasmacytomas, or hypercalcemia and the “lowest response value” does not need to be a confirmed 
value. 
aPresence/absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by 
immunohistochemistry or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio 
reflecting presence of an abnormal clone is kappa/lambda of >4:1 or <1:2.
Clinical Relapse
Clinical relapse is defined using the definition of clinical relapse in the IMWG criteria (Durie 2006, Rajkumar 2011).7,32In the 
IMWG criteria, clini cal relapse is defined as requiring one or more of the following direct indicators of increasing disease or 
end-organ dysfunction that are considered related to the underlying plasma cell proliferative disorder:
1. Development of new soft tissue plasmacyto mas or bone lesions on skeletal survey, magnetic resonance imaging, or other 
imaging
2. Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is defined as a 50% (and at l east 
1cm) increase as measured serially by th e sum of the products of the cross -diameters of the measurable lesion
3. Hypercalcemia (>11.5 mg/dL; >2.875mM/L)
4. Decrease in hemoglobin of more than 2 g/dL (1.25 mM) or to less than 10 g/dL
5. Rise in serum creatinine by more than or equal to 2 mg/dL ( ≥177 mM/L)
6. Hyperviscosity
In some subjects, bone pain may be the initial symptom of relapse in the absence of any of the above features. However, bone 
pain without imaging confirmation is not adequate to meet these criteria in studies.
For continuation of treatment, the IMWG response will be determined on an ongoing basis by 
the investigator. For data analysis and reporting, however, the sponsor will use a validated 
computer algorithm that has been shown to provide consistent review of the data necessar y to 
determine disease progression and response according to the IMWG criteria . For CR/sCR, the 
IMWG criteria require subjects to have a negative SPEP and serum IFE. As an immunoglobulin, 
daratumumab can be picked up by SPEP and serum IFE and may cause false positi ve SPEP and 
IFE results. A reflex assay  has been developed by the sponsor to confirm daratumumab 
interference on thes e assay s.
Serum free light chain assay  test results will be analyzed by the central laboratory  for the 
assessment of stringent complete response (sCR), according to the most recently  published 
IMWG criteria (Durie 2006 ).7For subjects who discontinue study  treatment before disease
progression, disease evaluations should continue to be performed as described in the Time and 
Events Schedule, until confirmed disease progression (see Section 8.4,Subsequent Therapies) , 
death, the start of a new treatment for multiple myeloma, withdrawal of consent for study  
participation, lost to follow -up, or the end of study , whichever occurs first. Disease evaluations 
scheduled for treatment day s should be collected before study  treatment is administered. 
9.2.1.2. Myeloma Protein Measurements in Serum and Urine
Blood and 24-hour urine samples for M-protein measurements will be sent to and analyzed by a 
central laboratory . Onl y 1 serum and one 24 -hour urine sample per time point are required by  the 
central laboratory  to perform the following tests.If the 24-h urine collect ion (UPEP) began 
before informed consent was obtained as part of routine patient care, the sample can be used in 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
82
Approved , Date: 12 June 2019this study  as long as it was sent to the central lab for analysis after the informed consent was 
obtained.
Serum quantitative immunoglobulins ( QIgs)
All subjects will be evaluated for IgG, IgA, IgM, IgE, and IgD at Screening .Every  
16weeks during treatment and at the EOT visit, subjects with IgD or IgE disease will 
be evaluated for IgG, IgA, IgM, IgE, and IgD and subjects with IgG, IgA, or IgM 
disease will be evaluated for IgG, IgA, and IgM.
Serum M -protein quantitation by  electrophoresis (SPEP)
Serum immunofixation at Screening and thereafter when a CR is suspected or maintained . If 
daratumumab interference is suspected based on SPEP and IFE res ults, additional reflex IFE 
testing may  be performed.
Serum free light chain assay (monthl y for subjects with free light chain (FLC)disease, all 
others per Time and Events Schedule)
24-hour urine M -protein quantitation by  electrophoresis (UPEP)
Urine immu nofixation at Screening and thereafter when a CR is suspected or maintained.
Blood and 24-hour urine samples will be collected as specified in the Time and Events Schedule
until the development of confirmed disease progression. After subjects have complete d 
24months of study  treatment, the timing of collection for SPEP and UPEP (and the timing of 
collection of FLC for subjects with light chain multiple myeloma) will change from every  
4weeks to every  8weeks . Disease progression based on 1 of the laborator y tests alone must be 
confirmed by at least 1 repeat investigation performed at least 1 daylater. Disease evaluations 
will continue beyond relapse from CR until disease progression is confirmed. Serum and urine 
immunofixation test and serum free light chain assay  will be performed at Screening and 
thereafter when a CR is suspected (when serum or 24-hour urine M-protein electrophoresis [by 
SPEP or UPEP] are 0 or nonquantifiable) or maintained . However, for subjects with light chain 
multiple myeloma, serum free light chain assay  will be performed routinel y. Serum 
immunofixation (IFE) assay  samples will be split into 2 aliquots, with 1 reserved for potential 
follow -on testing if daratumumab interference with IFE is suspected. As daratumumab is a 
monoclonal IgG antibody , additional serum samples may be utilized to monitor for potential 
daratumumab interference with the IFE.
9.2.1.3. Serum Calcium Corrected for Albumin
Blood samples for calculating serum calcium corrected for albumin will be collected and 
analyzed centra lly(as specified in the Time and Events Schedules) until the development of 
confirmed disease progression. Development of hypercalcemia (corrected serum calcium 
>11.5 mg/dL or 2.8 mM /L) can indicate disease progression or relapse if it is not attributable to 
any other cause (see disease response criteria). Calcium binds to albumin and only the unbound 
(free) calcium is biologically  active; therefore, the serum calcium level must be adjusted for 
abnormal albumin levels (“corrected serum calcium”). The formu la for adjustment is presented 
inAttachment 4.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
83
Approved , Date: 12 June 2019Measurement of free ionized calcium is an acceptable alternative to corrected serum calcium for 
determ ining hypercalcemia. Free ionized calcium levels greater than the ULN (local laboratory 
reference ranges) are considered to be h ypercalcemic for this study .
9.2.1.4. β2-microglobulin and A lbumin
Blood samples for β2microglobulin and albumin are to be collected at Screening, and will be 
analyzed by the central laboratory .
9.2.1.5. Bone Marrow Examination
Bone marrow aspirate or biopsy  will be performed at Screening for clinical characterization 
(morphology , IHC or immunofluorescence or 2 -to 4-color flow cy tometry ,and cytogenetics) ,to 
establish baseline multiple myeloma clonality to monitor for MRD and to perform molecular 
subty ping to monitor daratumumab activity  in high-risk molecular subgroups . Good qualit y 
slides are required for morphological exami nation to determine plasma cellpercentage in the 
bone marrow. Assessment by flow cytometry  alone is not sufficient. Bone marrow examination 
for disease assessment will be performed locally ; however, a portion of the bone marrow aspirate 
must be sent to the central laboratory for analysis of MRD and molecular subty ping. A fresh 
bone marrow aspirate at screening is required if at all possible, by exception non-decalcified 
diagnostic tissue (bone marrow aspirate slides or FFPE tissue) may be supplied for MRD 
assessment instead. Additional bone marrow aspirates will be performed to confirm sCR andCR 
(only one analysis is required, with either IHC or immunofluorescence or 2-to 4-color flow 
cytometry included in the analy sis) and to monitor for MRD at time points detail ed in Table 9. If
feasible, a bone marrow aspirate may be collected from subjects at disease progression to 
evaluate mechanisms of daratumumab resistance .
Bone marrow assessments to be performed locall y and centrally are summarized in Table 9 .
Table 9: Bone Marrow Testing
Local Testing Central Testing
Screening Disease characterization (morphology, and 
either immunohistochemistry, 
immunofluorescence, or f low cytometry). 
Cytogenetic analysis by conventional 
karyotype or FISH.MRD and molecular subtyping: a portion of bone marrow 
aspirates collected at screening will be sent to a central 
laboratory.
If a fresh bone marrow aspirate will not be performed at 
screening because the procedure has already been done 
within 42 days prior to randomization, then the unstained 
or stained, non -decalcified diagnostic tissue (3 -5 bone 
marrow aspirate smears, or 3-5 touch -prep slides from 
biopsy, or 3 -5 bone marrow clot slides) should be 
collected for MRD assessment at baseline.
During Treatment At time of suspected CR /sCR :
Evaluate Plasma cell percentage in the bone 
marrow to confirm CR
Evaluate clonality of plasma cells (by flow 
cytometry, IHC or IF**) in the bone 
marrow to confirm sCR
(If sCR criteria are not met, repeat local 
testing for sCR with subsequent bone 
marrow testing .)A portion of bone marrow aspirates collected at time of 
suspected CR /sCR , and 12, 18, 24,30,36, 48, and 60
(+/-1) months post C1D1 ,will be analyzed for MRD*. 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
84
Approved , Date: 12 June 2019Disease Progression Not applicable. If feasible, a bone marrow aspirate is requested to be 
collected from subjects at disease progression and sent to 
central laboratory to evaluate mechanisms of 
daratumumab resistance.
CR=complete response; FISH=fluorescence in situ hybridization; MRD=minimal residual disease; sCR=stringent complete 
response
*If one of these time poin ts occurs within 1 month of suspected CR /sCR , a repeat bone marrow will not be requested. These 
bone marrow tests will only be required if patient’s response is near CR or better by blood and urine evaluations.
**Immunohistochemistry or immunofluorescence (both require kappa/lambda ratio from analysis of >100 plasma cells) or 2-to 
4-color f low cytometry are acceptable methods to evaluate plasma cell clonality.
9.2.1.6. Minimal Residual Disease A ssessment
Minimal Residual Disease (MRD) assessment by next-generation sequencing (NGS) is a 
relativel y new and effective tool in the assessment of patients with multiple myeloma 
(Ladetto 2014 ).20Several studies have demonstrated that MRD status is correlated with PFS and 
OS (Martinez -Lopez 2014).21In thisstudy , bone marrow samples will be collected when a bone 
marrow aspirate is performed at Screening and atthe subsequent timepoints outlined inTable 9
and Time and Events Schedule.
9.2.1.7. Assessment of Lytic Disease
A complete skeletal survey  (including skull, entire vertebral column, pelvis, chest, humeri, 
femora, and any other bones for which the investigator suspects involvement by disease) is to be 
performed and evaluated local lyby X-ray or low-dose CTduring the Screening Phase. Please 
note that the same methodology  used at Screening should be used throughout the study  for 
comparison purposes. During the Treatment Phase and before disease progression is confirmed, 
imaging should be performed whenever clinically  indicated based on symptoms, to document 
response or progression. Magnetic resonance imaging (MRI) may be included as an additional 
assessment at the discreti on of the investigator; however, focal lesions identified by MRI alone 
cannot be counted as lytic disease . If a radionuclide bone scan was used at Screening in addition 
to the complete skeletal survey , then both methods must be used to document disease status. 
These tests must be performed at the same time. However, a radionuc lide bone scan does not 
replace a complete skeletal survey .
Sometimes subjects present with disease progression manifested by symptoms of pain due to 
bone changes. Therefore, disease progression may be documented, in these cases, by skeletal 
survey  or other radiographs, depending on the symptoms that the subject experiences. If the 
diagnosis of disease progression is obvious by radiographic investigations, then no repeat 
confirmatory  imaging is necessary . In instances where changes may be more subtle, repeat 
imaging may  be performed in 1 to 3 weeks per investigator discretion .
9.2.1.8. Documentation of Extramedullary  Plasmacytomas
Sites of known extramedullary  plasmacy tomas must be documented during the Screening Phase. 
Clinical examination or MRI  may be used to document extramedullary  sites of disease. 
Computed tomograph y scan evaluations are an acceptable alternative if there is no 
contraindication to the use of intravenous contrast . Positron emission tomograph yscan or 
ultrasound tests are not acceptable to document the size of extramedullary  plasmacy tomas.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
85
Approved , Date: 12 June 2019Extramedullary  plasmacy tomas should be assessed for all subjects with a history  of 
plasmacy tomas or if clinically  indicated at Screening, by clinical examination or radiologic 
imaging. Assessment of measurable sites of extramedullary  disease will be performed and 
evaluated locall y every 4 weeks (byphysical examination) for subjects with a history  of 
plasmacy tomas or as clinically  indicated d uring treatment for other subjects until development of 
confirmed CR or confirmed disease progression. If assessment can only be performed 
radiologically , then evaluation of extramedullary plasmacy tomas may be done every  12 weeks. 
For every  subject, the methodology  used for evaluation of each disease site should be consistent 
across all visits. Irradiated or excised lesions will be considered not measurable, and will be 
monitored only  for disease progression.
To qualify  for PR, the sum of products of the perpendicular diameters of the existing  
extramedullary  plasmacytomas must have decreased by at least 50%, and new plasmacy tomas 
must not have developed (see the disease response criteria in Table 8). To qualify  for disease 
progression, either the sum of products of the perpendicular diameters of the existing  
extramedullary  plasmacy tomas must have increased by at least 50% or a new plasmacy toma 
must have developed. In the cases where not all existing extramedullary plasmacy tomas are 
reported, but the sum of products of the perpendicular diameters of the reported plasmacy tomas 
have increased b y at least 50%, this will also qualify  as disease progression.
9.2.2. Endp oints 
Primary Endpoints
The primary  endpoint is PFS, which is defined as the duration from the date of randomization to 
either progressive disease, or death, whichever occurs first. Disease progression will be 
determined according to the IMWG criteria (Durie 2006, Rajkumar 2011).7,32For subjects who
have not progressed and are alive, data will be censored at the last disease evaluation before the 
start of any subsequent anti-myeloma therapy . Relapse from CR by positive immunofixation or 
trace amount of M-protein is not considered to be progressive disease and is not included in the 
PFS calculation.  
As the superiorit y of DRd over Rdalone with respect to PFS was established at the second 
interim analysis, the interim PFS analysis will serve as the primary  PFS analysis, which 
otherwise was to occur when approx imately  390 PFS events had been observed.
Secondary Endpoints
The secondary  efficacy  endpoints include:
Time to disease progression (TTP) is defined as the time from the date of randomization to 
the date of first documented evidence of PD, as defined in the IMWG criteria. For subjects 
who have not progressed, data will be censored at the date of the disease evaluation before 
the start of an y subsequent anti -myeloma therap y.
CR rate, defined as the percentage of sub jects achieving CR, as defined:
Negative immunofixation of serum and urine, and
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
86
Approved , Date: 12 June 2019Disappearance of an y soft tissue plasmacy tomas, and
<5% plasma cells ( PCs)in bone marrow
For those subjects with negative SPEP and suspected daratumumab interference on 
immunofixation, a reflex assay using anti-idiotype antibody  will be utilized to confirm 
daratumumab interference and rule out false positive immunofixation. Subjects who 
have confirmed daratumumab interference, but meet all other clinical criteria for CR or 
sCR, will be considered CR/sCR.
MRD negativity  rate, defined as the proportion of subjects assessed as MRD negative, at any 
timepoint after the date of randomization.
Progression- free Survival on Next line of Therap y (PFS2), defined as the time from 
randomization to progression on the next line of treatment or death, whichever comes first. 
Disease progression will be based on investigator judgment. For those subjects who are still 
alive and not yet progressed on the next line of treatment, they will be censored on the last 
date of follow -up.
OS, measured from the date of randomization to the date of the subject’s death. If the 
subject is alive or the vital status is unknown, then the subject’s data will be censored at the 
date the subject was last known to be alive.
sCR rate, defined as the percentage of subjects achieving CR in addition to having a normal 
FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry , 
immunofluorescence, 2 -4 color flow cy tometry .
Time to next treatment, defined as the time from randomization to the start of the next-line 
treatment.
Overall response rate (ORR), defined as the proportion of subjects who achieve PRor better ,
according to the IMWG criteria, during or after the study  treatment.
Proportion of subjects who achieve VGPR or better, defined as the proportion of subjects 
achieving VGPR and CR (including sCR) according to the IMWG criteria during or after the 
study  treatment at the time of data cutoff.
Time to response ,defined as the time between the randomization and thefirst efficacy  
evaluation that the subject has met all criteria for CR or PR. For subjects without response 
(CR/PR), data will be censored either at the date of progressive disease or, in the absence of 
progressive disease, at the last disease evaluation before the start of subsequent 
anti-myeloma therap y.
Duration of response, calculated from the date of initial documentation of a response (PRor 
better )to the date of first documented evidence of progressive disease, as defined in the 
IMWG criteria. For subjects who have not progressed, data will be censored at the last 
disease evaluation before the start of an y subsequent anti -myeloma therap y.
To evaluate clinical efficacy  of DRdin high risk molecular subgroups compared to Rd
alone .
To evaluate the impa ct ofDRd compared to Rdon patient -reported perception of global 
health.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
87
Approved , Date: 12 June 2019Exploratory Endpoints
Biomarkers predictive of response or resistance to daratumumab .
Durability  of MRD negativity .
9.3. Pharmacokinetics and Immunogenicity
9.3.1. Evaluations
For all subjects in Arm B, pharmacokinetic samples to determine serum concentration of 
daratumumab will be obtained according to the Time and Events Schedule. In the Follow -up 
Phase, for all subjects in Arm B (DRd), samples are to be collected for PKasses sments 8 weeks 
after the last dose of daratumumab, regardless of whether there has been confirmed disease 
progression. Venous blood samples (5 mL per sample) will be collected to determine serum 
concentration of daratumumab and the serum will be divided into 3 aliquots (1 aliquot for 
pharmacokinetic analysis, 1 aliquot for antibodies to daratumumab analysis [when appropriate], 
and 1 aliquot as a backup). Samples collected for determining serum concentrations of 
daratumumab in this study  may be retained to address questions about drug characteristics that 
may arise at a later time point. 
The exact dates and times of blood sampling must be recorded. Refer to the Laboratory  Manual 
or equivalent document for sample collection requirements. Collected samples must be stored 
under the specified and controlled conditions for the temperatures indicated in the laboratory  
manual .
9.3.2. Analytical Procedures
Serum samples will be analy zed to determine concentrations of daratumumab or generation of 
antibodies to daratumumab using validated immunoassay  methods by  or under the supervision of 
the sponsor’s bioanal ytical facility .
9.3.3. Pharmacokinetic Parameters
The pharmacokinetic parameters are defined as:
CL Total sy stemic clearance of drug after IV administration
Cmax Maximum observed concentration
Cmin Minimum observed concentration
V Volume of distribution
Pharmacokinetic samples to determine serum concentration of daratumumab will be obtained 
from all subjects. Pharmacokinetic endpoints include:
Minimum observed concentra tion (C min)
Maximum observed concentration (C max)
If sufficient data are available, then other pharmacokinetic parameters may be calculated, 
including but not limited to total systemic clearance of drug after IV administration (CL) and 
volume of distributi on (V) .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
88
Approved , Date: 12 June 20199.3.4. Immunogenicity  Assessments (Antibodies to daratumumab )
Venous blood samples drawn from all subjects in the DRd arm will be assessed for the 
generation of antibodies to daratumumab (immunogenicity ), according to the Time and Events 
Schedule. In the Follow -up Phase, for all subjects in Arm B (DRd), samples are to be collected 
for immunogenicit y assessments 8 weeks after the last dose of daratumumab, regardless of 
whether there has been confirmed disease progression.
All samples collected for immunogenicity  analysis will also be evaluated for daratumumab 
serum concentration to ensure appropriate interpretation of immunogenicity  data. At each time 
point, immunogenicity  and serum daratumumab concentration analy ses will be performed on 
aliquots from the sa me blood draw and no additional sampling is required. Procedures for sample 
collection, preparation, identification, storage, and shipment will be provided in the Laboratory 
Manual or equivalent document. 
Serum samples will be screened for antibodies binding to daratumumab and serum titer will also 
be determined from confirmed positive samples using validated assay  methods by or under the 
supervision of the sponsor. Other immunogenicity  analyses (eg, assessment of neutralizing 
capabilities) may  be performe d to further characterize the immune responses that are generated. 
A blood sample should be drawn, if possible, for determination of antibodies to daratumumab 
any time an infusion reaction is observed or reported during the study . Daratumumab serum 
concen tration will also be determined from the same infusion reaction sample for the purpose of 
interpreting immunogenicity  data. These samples will be stored and evaluated if deemed 
necessary . If the infusion reaction results in treatment discontinuation, then subjects should 
undergo all scheduled safet y and efficacy  evaluations. Samples collected for the analysis of 
daratumumab immunogenicity /serum concentration may additionally  be used to evaluate safety 
or efficacy  aspects that address concerns arising during or after the study  period or for the 
evaluation of relevant biomarkers b y the sponsor or sponsor’s designee .
9.4. Pharmacokinetic/Pharmacody namic Evaluations
If sufficient data are available, then other pharmacokinetic/pharmacod ynamic modeling may be 
performed , including exploring the relationship between serum concentrations of daratumumab 
and endpoints of clinical efficacy . If these analy ses are performed, then the details and results 
will be presented in a separate report.
9.5. Biomarkers
Biomarker assessments will focus on 2 main objectives including evaluating the ability  of 
daratumumab + Rd to reduce MRD in subjects who achieve a complete response (compared to 
Rd alone) and to determine the clinical benefit (ORR, PFS, and OS) of daratumumab + Rd in 
high-risk molecular subty pes (del17p, t(4;14), t(14;16 ),specific gene signatures, specific 
mutations) . Bone marrow aspirates will be collected at screening and following treatment as 
outlined in the Time and Events Schedule.  Baseline bone marrow aspirate samples will be 
subjected to DNA and RNA sequencing in order to classify  subjects into high-risk molecular 
subgroups and to establish the myeloma clone for MRD monitoring. A fresh bone marrow 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
89
Approved , Date: 12 June 2019aspirate at Screening is required if at all possible, by exception non-decalcified diagnostic tissue 
(please see Table 9Bone Marrow Testing for further information )may be supplied for MRD 
assessment instead. For subjects who achieve a CR or sCR, bone marrow aspirates will be 
utilized for assessment of MRD by  next- generation sequencing (NGS) of immunoglobulin heavy 
and light chains (Vij 2013).40If this methodology  is unavailable, or determined to be 
scientifically  inferior, then alternative methods for MRD assessment may be utilized. In cases 
where daratumumab is suspected of interfering with serum IFE and preventing clinical CR 
response calls, subjects with VGPR will also be evaluated for MRD by  NGS .
Inaddition to planned bone marrow aspirate assessments, a whole blood sample will be collected 
from subjects as outlined in the Time and Events Schedule forprocessing to plasma and PBMCs. 
These samples may be used to evaluate specific subsets of immune cells such as cytotoxic 
Tcells, regulatory  T cells, MDSCs, and activated NK cells. Cells may  also be used for additional 
phenoty pic and functional profiling. Proteomic analy sis may also be used to evaluate changes in 
cytokines, complement proteins, soluble CD38, soluble CD59, IFNγ, granzy me, perforin, and 
other proteins associated with ADCC/CDC/ADCP to evaluate potential biomarkers of response 
and resistance .
Potential mechanisms of tumor resistance, such as changes in antigen (CD38) expression or 
increased expression in complement inhibitory  proteins (CD46, CD55, and CD59) in multiple 
myeloma cells, may be monitored in subjects if a bone marrow aspirate sample is deemed 
feasible for collection at progressive disease. In addition, changes in expression pattern s of genes 
associated with ADCC, CDC, or other mechanisms of action of daratumumab may  be evaluated.
Biomarker anal yses are dependent upon the availability  of appropriate biomarker assay s and may 
be deferred or not performed if during or at the end of the study  it becomes clear that the analy sis 
will have no scientific value, or if there are not enough samples or not enough responders to 
allow for adequate biomarker evaluation. In the event the study  is terminated early  or shows poor 
clinical efficacy , completion of biomarker assessments is based on justification and intended 
utility  of the data. Samples for biomarker evaluations will be collected as specified in the Time 
and Events Schedule.
9.6. Medical Resource Utilization
Medical resource utilization (MRU) data, including primary  non-protocol driven 
hospit alizations, outpatient visits, and emergency room visits, should be collected in the eCRF 
(Hospitalization/Outpatient Visits CRF) by the Investigator and study -site person nel for all 
subjects throughout the study . Please see CRF completion guidelines.
9.7. Patient Reported Outcomes
It is anticipated that the addition of daratumumab will provide benefits in terms of symptom 
reduction, improved functioning, and improved utilities. To measure functional status,
well-being, and symptoms, the EORTC QLQ -C30 and the EQ-5D- 5L instruments will be used. 
Both questionnaires will be completed at the timepoints outlined in the Time and Events 
Schedule .All visit-specific PRO assessments shoul d be conducted before any tests, procedures, 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
90
Approved , Date: 12 June 2019or other consultations for that visit to prevent influencing subject perceptions. All PRO measures 
will be completed using an electronic device (ePRO). For more details refer to the ePRO user 
manual .
The EORTC QLQ-C30 includes 30 items resulting in 5 functional scales (physical functioning, 
role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global 
Health Status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single 
items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The 
recall period is 1 week (the past week). The EORTC QLQ-C30 has been widel y used among 
cancer patients. Scores are transformed to a 0 to 100 sc ale. Administration time is approximately  
11minutes. Reliability , validity , and clinically  meaningful change have been demonstrated in 
multiple myeloma patients (Wisloff 1996, Wisloff 1997).41,42The focus of the PRO assessment 
will be the global health scale which is designated as a secondary  endpoint.  The remaining 
domains are included as exploratory  endpoints.
The EQ-5D- 5Lis a standardized instrument for use as a measure of health status. Forpurposes 
of this study , the EQ-5D-5L will be used to generate utility  scores for use in cost effective 
analyses. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility , 
self-care, usual activities, pain/discomfort and anxiety /depression plus a visual analog scale 
rating “health today ” with anchors ranging from 0 (worst imaginable health state) to 100 (best 
imaginable health state) (Herdman 2011).13The scores for the 5 separate questions are 
categorical and cannot be analy zed as cardinal numbers. However, the scores for the 
5dimensions are used to compute a single utility  score ranging from zero (0.0) to 1 (1.0) 
representi ng the general health status of the individual.
9.8. Safety  Evaluations
Safety  will be measured by adverse events, laboratory  test results, ECGs, vital sign 
measurements, physical examination findings, and assessment of ECOG performance status 
score. Any clinic ally relevant changes occurring during the study  must be recorded on the 
Adverse Event section of the eCRF. Any  clinically  significant abnormalities persisting at the end 
of the study /early  withdrawal will be followed by the investigator until resolution o r until a 
clinically  stable endpoint is reached.
Based on the previous human experience with daratumumab, in vitro studies, and animal 
toxicological findings, infusion- related reactions/allergic reactions, hemoly sis, and 
thrombocytopenia will be closel y monitored. As a biologic agent, immunogenicity  also will be 
monitored. Any of the safet y monitoring assessments may be performed more frequentl y, and 
adverse events should be evaluated by the investigator according to the standard practice, if 
clinically  indicated.
Adverse Events
Adverse events (with the exception of progression of multiple myeloma) will be reported by the 
subject (or, when appropriate, by a caregiver, surrogate, or the subject's legall y acceptable 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
91
Approved , Date: 12 June 2019representative) for the duration of the study. Adverse events will be followed by the investigator 
as specified in Section 12, Adverse Event Reporting.
Clinical Laboratory Tests 
Blood samples for serum chemistry  and hematology  will be collected. The investigator must 
review the laboratory  report, document this review, and record any clinically  relevant changes 
occurring during the study  in the adverse event section of the eCRF. The laboratory  reports must 
be filed with the source documents.
The tests below will be performed b y the local laboratory unless otherwise noted.
Hematology  Panel
-hemoglobin -white blood cell (WBC) count with absolute 
neutrophils and ly mphocy tes
-platelet count
Serum Chemistry  Panel
-blood urea nitrogen (BUN) or urea -alkaline phosphatase
-creatinine -lactic acid deh ydrogenase (LDH)
-glucose -uric acid
-aspartate aminotransferase (AST) -total; direct bilirubin ( not required except in case 
of congenital bilirubinemia, such as Gilbert 
disease)
-alanine aminotransferase (ALT)
-creatinine clearance (calculated or 
measured )-total protein
-sodium *
-potassium *
*Sodium and potassium assessment was added in Protocol Amendment 2, however collection of sodium and 
potassium results will be done retrospectively from the date of subject consent for the duration of the study, if 
collected as part of routine care .
Serum or U rine Pregnancy Testing
For women of childbearing potential only: lenalidomide is athalidomide analogue and is 
contraindicated for use during pregnancy . Birth defects have been observed in preclinical studies 
of lenalidomide similar to thalidomide in humans. Therefore, strict monitoring for pregnancy 
must be conducted during Screening and throughout the Treatment Phase, as specified in the 
Time and Events Schedule. Where lenalidomide is supplied locall y, subjects must adhere to the 
local lenalidomide REMS program. Where lenalidomide is supplied centrall y and no local 
lenalidomide REMS program exists, then subjects must adhere to thelenalidomide Global 
Pregnancy  Prevention Plan in Attachment 5.
If pregnancy  does occur, then study  treatment should be discontinued immediately  and the 
subject should be referred to an obstetrician experienced in reproductive toxicity  for further 
evaluation and counseling.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
92
Approved , Date: 12 June 2019Calcium and A lbumin A djusted C alcium:
These parameters will be part of the efficacy  evaluations as sp ecified in Section 9.2.1.3 , and will 
be analyzed by the central laboratory . Measurement of calcium and albumin should follow the 
schedule for disease assessments. Measurement of free ionized calcium is an acceptable 
alternative to corrected serum calcium for determining hypercalcemia .
Daratumumab Interference with Indirect Antiglobulin Test (IAT) results :
Daratumumab interferes with the Indirect Antiglobulin Test (IAT), which is a routine 
pre-transfusion test performed to identify  a patient’s antibodies to minor antigens so that suitable 
donor blood can be given for transfusion. Daratumumab does not interfere with ABO/RhD 
typing. CD38 is expressed at very low levels on erythrocy tes. Daratumumab binds to the CD38 
on erythrocytes, which results in a positi ve IAT (Indirect Coombs Test). This positive result 
masks the detection of antibodies to minor antigens and may prevent or delay  blood banks from 
issuing donor blood for transfusion. This effect occurs during daratumumab t reatment and for up 
to 6months after treatment ends. Subjects will receive a patient identification wallet card for the 
study  that includes the blood profile (ABO, Rh, and IAT) determined before the first infusion of 
daratumumab along with information on the IAT interference for healthcare providers/blood 
banks. Subjects are to carry  this card throughout the treatment period and for at least 6 months 
after treatment ends. Blood banks can eliminate the daratumumab IAT interference by treating 
reagent RBCs w ith dithiothreitol (DTT) (Chapu y 20154, Chapuy  2016 ).5
Possible methods for blood banks to provide safe RBCs for transfusion to subjects receiving 
daratumumab include:
Providing ABO/RhD compatible, phenoty pically  or genoty picall y matched units
Providing ABO/RhD compatible, K-negative units after ruling out or identify ing 
alloantibodies using dithiothreitol (DTT)- treated reagent RBCs
Uncrossmatched, ABO/RhD compatible RBC units should be administered if transfusion is 
needed emergentl y as per local blood bank practice.
Despite daratumumab binding to CD38 on erythrocy tes, no indication of clinically  significant 
hemoly sis has been observed in daratumumab studies. For additional details, refer to the 
Daratumumab IB.
Pulmonary Function Test
Subjects with known or suspected COPD must have a FEV 1test during screening. Refer to 
Section 6.1.3.2 for details on subjects with higher risk of respiratory  complications.
Electrocardiogram (ECG)
ECGs will be performed as specified in the Time and Events Schedule. During the collection of 
ECGs, subjects should be in a quiet setting without distractions (eg,television, cell phones). 
Subjects should rest in a supine position for at least 5minutes before ECG collection and should 
refrain from talking or moving arms or legs. If blood sampling or vital sign measurement is 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
93
Approved , Date: 12 June 2019scheduled for the same time point as ECG recording, then the procedures should be performed in 
the following order: ECG(s), vital signs, blood draw.
Vital Signs 
Vital signs (pulse /heart rate, temperature ,andblood pressure )will be performed as specified in 
the Time and Events Schedule. It is recommended that blood pressure (sitting) and pulse 
measurements be preceded by at least 5 minutes of rest in a quiet setting without distractions 
(eg,television, cell phones). Only vital signs associated with an adverse event will be entered in 
the eCRF; all measurements will be recorded in the source documents .
Physical Examination and ECOG Performance Status
A complete physical examination (including neurological examination) should be performed 
during the Screening Phase. Thereafter, only a symptom and disease directed physical 
examination is required. Height will be measured at screening only; weight will bemeasured 
regularl y as specified in the Time and Events Schedule .Abnormalities will be recorded in the 
appropriate sections of the eCRF . ECOG Performance Status (Attachment 2) will be used to 
evaluate the impact of the disease status on the activities of daily  living .When scheduled, ECOG 
assessments along with PRO questionnaires should be obtained prior to any other study 
procedures planned for the same day .
HBV Serol ogy and DNA Testing
Closely  monitor subjects with a known history  of hepatitis B infection or positive hepatitis B 
serologies (HBsAg, Anti- HBc and/or Anti- HBs with exception of serologic findings suggestive 
of HBV vaccination [Anti- HBs positivity  as the only serologic marker ]and a known history  of 
prior HBV vaccination )  who are enrolled in Arm B for clinical signs of active HBV infection 
and obtain serial testing for HBV DNA every  3 months during treatment and for 6 months 
following the last dose of daratumumab.
9.9. Sample Collection and Handling
If blood samples are collected via an indwelling cannula, an appropriate amount (1mL) of 
serosanguineous fluid slightl y greater than the dead space volume of the lock will be removed 
from the cannula and discarded before each blood sample is taken. After blood sample collection, 
the cannula will be flushed with 0.9% sodium chloride, United States Pharmacopeia 
(orequivalent)/sodium heparin of 10 U/mL  and charged with a volume equal to the dead space 
volume of the lock. If a mandarin (obturator) is used, blood loss due to discard is not expected.
Refer to the T ime and Events Schedule for the timing and frequency  of all sample collections.
For samples collected from the central laboratory, sample dates and times must be recorded on 
the laboratory  requisition form. Further instructions for the collection, handling, storage, and 
shipment of samples are found in the laboratory  manual that will be provided. Collection, 
handling, storage, and shipment of samples must be under the specified, and where applicable, 
controlled temperature conditions as indicated in the laboratory  manual .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
94
Approved , Date: 12 June 201910. SUBJECT COMP LETION/WITHDRA WAL
10.1. Completion
A subject will be considered to have completed the study  if he or she has finished all 
protocol -specified procedures before the end of the study , has not been lost to follow up, or has 
not withdrawn consent for study  participat ion before the end of the study .The study  end is 
defined as when 330 deaths have occurred, or 7 years after the last subject is randomized, 
whichever comes first .
10.2. Discontinuation of Study Treatment
If a subject's study  treatment must be discontinued befor e the end of the treatment regimen, this 
will not result in automatic withdrawal of the subject from the study . After treatment 
discontinuation, the subject will move intotheFollow -upPhase .The End -of-Treatment Visit and 
Follow -up visit assessments should continue as specified in the Time and Events Schedule. If 
study  treatment is discontinued for a reason other than disease progression, then disease 
evaluations will continue to be performed as specified in the Time and Events Schedule.
Subjects who need to discontinue treatment with any one component of study  treatment 
(lenalidomide, dexameth asone, or daratumumab) may continue to receive treatment with the 
other components of study  treatmen t, as assigned.
A subject's study  treatment should bediscontinue d if:
The investigator believes that for safet y reasons (eg,adverse event) it is in the best interest 
of the subject to discontinue study treatment
The subject becomes pregnant 
The subject (or the subject’s legall y acceptable representative) withdraws consent for 
administration of study  treatment
The subject initiates treatment with a prohibited medication
The subject received concurrent (non -protocol) treatment for multiple my eloma
The subj ect experiences unacceptable toxicity , including infusion -related reactions described 
in Section 6.1.4
The subject’s dose of daratumumab is held for more than 4 wee ksin Cy cles 1 -6 or for more 
than 6 weeks in C ycle 7 and beyond (unless Sponsor approves continuation)
The subject experiences disease progression (please see below) . Relapse from CR is not 
considered as disease progression
A subject who experiences a second primary  malignancy  that can be treated by surgery  may 
continue to receive the assigned study  treatment and the subject should continue to be followed 
for subsequent progression of multiple myeloma. Subjects who require radiation therap y for 
treatment of second primary  malignancy  must have study  treatment discontinued unless, upon 
consultation with the Sponsor and review of data, continuation is agreed upon. Subjects who 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
95
Approved , Date: 12 June 2019require systemic treatment of a new malignancy  must end study  treatment but shoul d continue to 
be followed for PFS2 and OS.
Before subjects discontinue study  treatment due to disease progression, sites will document 
disease progression (for example by completing a disease progression form or by contacting the 
IWRS) as soon as possible and within 48 hours. The medical monitor will confirm that treatment 
should be discontinued. After confirmation from the sponsor, study  treatment may be 
discontinued and the subject entered into Follow -up.
The primary  reason for discontinuation of study  treatment is to be recorded in the eCRF.
10.3. Withdrawal From the Study
A subject will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
Withdrawal of consent for study  participation
Death
The study  investigator or Sponsor, for anyreason, stops the study  or stops the subject’s 
participation in the study
Before a subject is considered lost to follow -up, every  reasonable effort must be made by the 
study  site personnel to contact the subject and determine the reason for 
discontinuatio n/withdrawal. The measures taken to follow up must be documented.
When a subject withdraws from the study , the reason for withdrawal is to be documented in the 
eCRF and in the source document. Study  treatment assigned to the withdrawn subject may  not be 
assigned to another subject. Subjects who withdraw will not be replaced. If a subject withdraws 
from the study , assessments outlined in the End -of-Treatment Visit should be obtained.
Withdrawal From the Use of Sample s in Future Research
The subject may withdraw consent for use of sample sfor future research ( refer to
Section 16.2.5 ). In such a case, samples will be destroy ed after they are no longe r needed for the 
clinical study . Details of the sample retention for researc h are presented in the main I CF.
11. STATISTICA L METHODS
Statistical analy sis will be done by the sponsor or under the authority  of the sponsor. A general 
description of the statistica l methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan.
11.1. Subject Information
The primary  analysis population will be the intent -to-treat (ITT) population, which will include 
all randomized subjects. Safety  will be evaluated for the population of all treated subjects. The 
pharmacokinetic analyses will be performed on the pharmacokinetic evaluable population. 
Continuous variables will be summarized using descriptive statistics such as mean, standard 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
96
Approved , Date: 12 June 2019deviation, and range. Categorical variables will be summarized using frequency  tables. For 
time-to-event variables, the Kaplan -Meier method will be used for descriptive summaries.
11.2. Sample Size Determination
The sample size calculation is performed on the basis of the following assumption. Based on the 
published data, the median PFS for Rd arm is assumed to be approximately  24 months. 
Assuming that DRd can reduce the risk of the disease progression or death by  25%, ie , assuming
the hazard ratio (DRd vs Rd) of 0.75, a total of 390PFS events is needed to achieve a power of 
80% to detect this hazard ratio with a log-rank test (two-sided alpha is 0.05). With a 21-month 
accrual period and an additional 24-month follow -up, the total sample size needed for the study 
is approximately  730 (365 /arm) subjects. The sample size calculation has taken into 
consideration an annual dropout rate of 5%.
Long -term survival follow -up will continue until 330 deaths have been observed or 7 years after
the last subject is randomized. Therefore, this study  will achieve approximately  80% power to 
detect a 27% reduction in the risk of death (hazard ratio = 0.73) with a log-rank test (two-sided 
alpha = 0.05).
11.3. Efficacy  Analyses
Response to study  treatment and progressive disease will be evaluated by a validated computer 
algorithm.
Primary Endpoint
For the primary  endpoint of PFS, the primary  analysis will consist of a stratified log rank test for 
the comparison of the PFS distribution between the 2 treatment arms. The Kaplan -Meier method 
will be used to estimate the distribution of overall PFS for each treatment. The treatment effect 
(hazard ratio) and its two-sided 95% confidence intervals are to be estimated using a stratified 
Cox regression model with treat ment as the sole explanatory  variable.
Secondary Endpoints
Other time-to-event efficacy  endpoints, including TTP, PFS2, OS, and time to subsequent anti 
myeloma treatment, will be anal yzed using the same method as for PFS . For overall survival, the 
final analy sis will occur after 330 deaths have been observed. Earlier analy ses, in which overall 
survival is analy zed, will be considered as interim analy ses. Even though the significance of PFS 
has alread y been established at the second interim analy sis, testing of OS will continue as 
planned until a definitive conclusion on OS is reached. The details about testing of OS over time 
are specified in Section 11.10 . The analysis of OS may be confounded by subjects from Arm A 
receiving daratumumab after disease progression. Exploratory  analysis may be performed to 
adjust for the effect daratumumab exposure may have on OS for the subjects who were 
randomized to Arm A (Rd).
Comparison between the 2 treatment arms of overall response rates, VGPR or better rate, CR or 
better rate, and other binary  endpoints will be conducted using the stratified Cochran Mantel 
Haenszel test. The Mantel -Haenszel odds ratio will be provided along with its two-sided 95% 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
97
Approved , Date: 12 June 2019confidence interval, and will be provided as the measure of treatment effect. Duration of 
response will be provided descriptivel y without formal statistical comparison .
Strong control of family wise Ty pe I error rate will be controlled at a two -sided significance level 
of 0.05 for the following major secondary endpoints: TTP, CR rate, MRD negativ ityrate, PFS2 
and OS.A sequential hierarchical testing procedure will be used. Details about thishierarchical 
procedure will be specified in the statistical analy sis plan for this study prior to any efficacy  
analysis.
11.4. Pharmacokinetic A nalyses
Pharmacokinetic analyses will be performed on the pharmacokinetic- evaluable population, 
defined as subjects who have received one dose of daratumumab and at least one postinfusion 
sample. All serum concentrations below the lowest quantifiable concentration or missing data 
will be labeled as such in the concentration data presentation. Concentrations below the lowest 
quantifiable concentration will be treated as zero in the summary  statistics. All subjects and 
samples excluded from the anal ysis will be clearly  documented in the study  report.
Descriptive statistics will be used to summarize daratumumab serum concentrations at each 
sampling time point and pharmacokinetic parameters of daratumumab such as Cmin and Cmax. 
If sufficient data are available, then other pharmacokinetic parameters may be calculated, 
including but not limited to CL  and V.
If sufficient data are available, then population pharmacokinetic analysis of serum concentration 
time data of daratumumab, will be performed using nonlinear mixed -effects modeling . The 
potential population PK analysis may also include PKdata from other studies . If the popula tion 
pharmacokinetic analysis is conducted, then details will be given in a population 
pharmacokinetic analysis plan and the results of the analysis will be presented in a separate 
report .
11.5. Immunogenicity  Analyses
The incidence of antibodies to daratumumab will be summarized for all subjects who receive a 
dose of daratumumab and have appropriate samples for detection of antibodies to daratumumab .
11.6. Pharmacokinetic/Pharmacody namic A nalyses
If sufficient data are available, then population pharmacokinetic anal ysis serum concentrations of 
serum concentration -time data of daratumumab will be performed using nonlinear mixed -effects 
modeling. If the population pharmacokinetic analy sis is conducted, then details will be given in a 
population pharmacokinetic analysis plan and results of the analysis will be presented in a 
separate report .
11.7. Biomarker A nalyses
Biomarker studies are designed to identify  markers predictive of response (or resistance) to 
daratumumab. Anal yses will beperformed and stratified by clinical covariates or molecular 
subgroups using the appropriate statistical methods (eg, parametric or non-parametric, univariate 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
98
Approved , Date: 12 June 2019or multivariate, analysis of variance, or survival analysis, depending on the endpoint). 
Correlation of baseli ne expression levels or changes in expression levels with response or 
time-to-event endpoints will identify  responsive (or resistant) subgroups in addition to genes and 
pathway s attenuated following treatment with daratumumab. In order to remove any 
confou nding influence of prognostic factors, any predictive biomarker identified in this study 
could be verified in a prospective clinical stud y with a control treatment arm.
Any biomarker measure s will be listed, tabulated, and where appropriate, plotted. Subje cts will 
be grouped b y prescribed dose. Complete responders will be utilized to investigate the prognostic 
effect of MRD on PFS. MRD analysis will include evaluation of data from other studies to 
determine if decreased MRD is seen with daratumumab + Rdbased chemotherap y regimen 
compared with the Rdbased chemotherap y alone . 
Results of biomarker and pharmacod ynamic analy ses may be presented in a separate report. 
Planned analyses are based on the availability  of clinically  valid assay s and may be deferred i f 
emerging study  data show no likelihood of providing useful scientific information.
In addition, due to the small sample sizes of high-risk subgroups within the multiple myeloma 
subject population, a meta -analyses may be performed across daratumumab Phase 3 studies to 
evaluate clinical efficacy  of daratumumab with standard of care agents in pre-specified 
subgroups of multiple myeloma subjects . The meta -analysis protocol will pre-specify  the 
objective of the meta -analy sis, the criteria for inclusion and exclusion of studies, the hypotheses 
and endpoints, and statistical methods including a method for investigation of heterogeneity . 
This meta -analy tic approach, supported by high-quality  data from the individual studies , should 
be able to provide definitive evidence on the effectiveness of daratumumab in the subpopulation 
of multiple myeloma subjects with high-risk molecular abnormalities. In a similar fashion, a 
meta -analysis examining MRD negativity  in daratumumab treated subjects in frontline, newly  
diagnose d multiple my eloma (MMY3006, MMY3007, MMY3008) may  also be performed .
11.8. Patient Reported Outcomes
EORTC -QLQ -C30 scores will be evaluated for all domains except “financial problems” among 
subjects with at least one post-baseline assessment and 50% completion of the relevant items for 
a domain. Descriptive analy ses followed by mixed model repeated measures will be used to 
analyze each domain score. No adjustment for multiple comparisons will be made.
EQ-5D- 5L scores will be summarized at each time point.
11.9. Safety Analyses
Adverse Events
The verbatim terms used in the eCRF by investigators to identify  adverse events will be coded 
using the Medical Dictionary  for Regulatory  Activities (MedDRA). The severit y assessment for 
an adverse event or serious adverse event sh ould be completed using the NCI  CTCAE Version 4. 
All reported adverse events with onset during the treatment phase (ie, treatment -emergent 
adverse events, and adverse events that have worsened since baseline) will be included in the 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
99
Approved , Date: 12 June 2019analysis. For each adverse event, the percentage of subjects who experience at least 1 occurrence 
of the given event will be summarized by  treatment arm.
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjec ts who die, who discontinue treatment due to an adverse event, or who experience a severe 
or a serious adverse event.
Clinical Laboratory Tests
Laboratory  data will be summarized by type of laboratory  test. Reference ranges and markedl y 
abnormal results (specified in the Statistical Analy sis Plan) will be used in the summary  of 
laboratory  data. Descriptive statistics will be calculated for each laboratory  analyte at baseline 
and for observed values and changes from baseline at each scheduled time point. Changes from 
baseline results will be presented in pre -versus post treatment cross -tabulations (with classes for 
below, within, and above normal ranges). Frequency  tabulations of the abnormalities will be 
made . A listing of subjects with any laboratory results outside the reference ranges will be 
provided. A listing of subjects with any markedly  abnormal laboratory results will also be 
provided.
Parameters with predefined NCI CTCAE toxicity  grades will be summarized. Change from 
baseline to the worst toxici ty grade experienced by the subject during the study  will be provided 
as shift tables. Worst toxicity  grade during treatment will be presented, according to 
NCI CTCAE (version 4). Clinically  relevant changes (i.e. causing a treatment intervention and/or 
need for concomitant therap y) will be also recorded on the adverse event eCRF. All other lab 
abnormalities need not be recorded as adverse events .
Electrocardiogram (ECG)
Electrocardiogram data will be summarized and listed.
Vital Signs
Descriptive statistic s of baseline temperature , pulse/heart rate, and blood pressure (systolic and 
diastolic) values will be summarized.
11.10. Interim A nalysis
Two interim analy ses are planned. The first interim analy sis, with a purpose to evaluate safet y,
will be performed after a total of approximately 100 subjects have been treated for at least 
8weeks or discontinued the study  treatment. The second interim analysis will be performed 
when 234PFS events, which is 60% of the total planned events, have been accumulated. The 
purpo se of this interim analy sis is to evaluate cumulative interim safety  and efficacy  data. The 
significance level at this interim anal ysis to establish the superiority  of DRd over Rd with regard 
to PFS will be determined based on the observed number of PFS events at the interim analysis, 
using the O’Brien -Fleming boundaries as implemented by the Lan-DeMets alpha spending 
method. If the experimental arm (DRd) is numerically  worse than the control arm in terms of 
PFS (observed hazard ratio >1 favoring the contro l arm), then the study  may be terminated for 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
100
Approved , Date: 12 June 2019futility , with a conditional power of less than 20% under the alternative hypothesis given the 
observed interim data .
As the superiorit y of DRd over Rd alone with respect to PFS was established at the second 
interim analysis, the interim PFS analysis will serve as the primary  PFS analysis, which 
otherwise was to occur when approximately  390 PFS events had been observed. The first interim 
OS anal ysis wasperformed at the interim PFS analy sis. The second interim OS analysis will now 
occur when approximately  260 deaths have occurred which will be about the same time the 
primary  PFS analy sis would have taken place . All applicable available data prior to that time will 
be included in each of the respective analy ses.
11.11. Data Monitoring Committee
An IDMC, consisting of 2clinicians and 1 statistician who are independent experts not otherwise 
participating in the study , will be established to review efficacy  and safet y results at the planned 
interim analy ses. After the interi m review, they will make recommendations regarding the 
continuation of the study . In addition, the IDMC may alsoreview cumulative safety  dataevery 
6months besides the 2interim analyses. The IDMC will no longer review study  data after the 
interim PFS analy sis has been completed . The details will be provided in a separate IDMC 
charter.
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory  agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinica l studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigational) product. (Definition per 
International Conf erence on Harmonisation [I CH])
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
101
Approved , Date: 12 June 2019Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.1 , All Adverse Events, for time of last adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disabilit y/incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is also appro priate in other situations, such as important medical events that may 
not be immediately  life threatening or result in death or hospitalization but may jeopardize 
the subject or may require intervention to prevent one of the other outcomes listed in the 
definition above. These should usually  be considered serious.
Suspected Unexpected Serious Adverse Reactions (SUSARs)
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  treatment and the event (eg, death from anaphy laxis), the event 
must be reported as a serious and unexpected suspected adverse reaction even if it is a 
component of the study  endpoint (eg, all-cause mortality ). Refer to Section 12.3.3 for SUSAR 
Reporting Requirements.
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safety  information. For daratumumab , the expectedness of an 
adverse event will be determined by whether or not it is listed within the Reference Safet y 
Inform ation included in the Investigator's Brochure. 
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel yby the d efinitions listed in Section 12.1.2 .
12.1.2. Attribution Definitions
Not Related
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
102
Approved , Date: 12 June 2019An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed by dechallenge). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by an alternative explanation, eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
The severity  assessment for an adverse event or serious adverse event should be completed using 
the NCI CTCAE Version 4.Any adverse event or serious adverse event not listed in the 
NCI CTCAE Version 4 will be graded according to investigator clinical judgment by using the 
standard grades as follows:
Grade 1(Mild) : Awareness of symptoms that are easily tolerated, causing minimal discomfort 
and not interfering with every day activities.
Grade 2 (Moderate) :Sufficient discomfort is present to cause interference with normal activity .
Grade 3(Severe):Extreme distress, causing significant impairment of functioning or 
incapacitation. Prevents normal every day activities.
Grade 4: Life -threatening of disabling adverse event
Grade 5: Death related to the adverse event
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
103
Approved , Date: 12 June 201912.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a sponsor study  drug . No MTD has been reached for daratumumab. However, if 
the dose exceeds the maximum tested dose of 24 mg/kg, then it will be considered as 
overdose in this study .
Suspected abuse/m isuse of a sponsor study  drug
Inadvertent or accidental exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject exposure to the 
sponsor study  drug , eg, name confusion)
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the adverse event page of the 
eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICFis obtained until 30 days after the last dose of 
study  treatment, unless the subject withdraws consent for study  participation, or start s subsequent 
anti-myeloma therap y.For subject s who have received subsequent treatment with therapeutic 
intent for multiple myeloma during the adverse event reporting period, only adverse event s that 
are considered to be possibly , probabl y, or definitely  related to daratumumab need to be 
reported . Ser ious adverse events, including those spontaneousl y reported to the investigator 
within 30days after the last dose of study  treatment, must be reported using the Adverse Event 
Form. The sponsor will evaluate any safety  information that is spontaneously  reported by an 
investigator bey ond the time frame specified in the protocol.
Expected progression of disease should not be considered an AE (or SAE). However, if 
determined by the investigator to be more likely  related to the study  treatment than the 
underly ing disease, the clinical signs or symptoms of progression and the possibility  that the 
study  treatment is enhancing disease progression, should be reported per the usual reporting 
requirements (see Section 12.1).Death should not be recorded as an adverse event or serious 
adverse event, but as the outcome of an adverse event. The adverse event that resulted in the 
death should be reported as a serious adverse event. All events that meet the definition of a 
serious adverse event will be reported as serious adverse events, regardless of whether they are 
protocol -specific assessments. Anticipated events will be recorded and reported as described in 
Attachment 10.
All adverse events, regardless of seriousness, severit y, or presumed relationship to study  
treatment , must be recorded using medical terminology  in the source documen t and the eCRF. 
Whenever possible, diagnoses should be given when signs and symptoms are due to a common 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
104
Approved , Date: 12 June 2019etiology  (eg, cough, runny  nose, sneezing, sore throat, and head congestion should be reported as 
"upper respiratory  infection"). Investigators must record in the eCRF their opinion concerning 
the relationship of the adverse event to study  therap y. All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (SUSARs) . For 
anticipated events reported as individual serious adverse events the sponsor will make a 
determination of relatedness in addition to and independent of the investigator’s assessment. The 
sponsor will periodicall y evaluate the accumulating data and, when there is sufficient evidence 
and the sponsor has determined there is a reasonable possibility  that the drug caused a serious 
anticipated event, they  will submit a safety  report in narrative format to the investigators (and the 
head of the investi gational institute where required). The investigator (or sponsor where 
required) must report these events to the appropriate Independent Ethics Committee/I nstitutional 
Review Board (IEC/IRB) that approved the protocol unless otherwise required and documented 
by the IEC/IRB .
Subject s (or their designees, if appropriate) will be provided with a "wallet (study )card" and 
instructed to carry  this card with them for the duration of the study and for at least 6 months 
(Arm B) after treatment ends indicat ing the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name and 24-hour contact telephone number
Local sponsor's name and 24 -hour contact telephone number (for medical staf f onl y)
Site number
Subject number
Blood ty pe (and IAT testing as described in Section 9.8for subjects in Arm B)
12.3.2. Serious A dverse Events
All serious adverse events occurring during thestudymust be reported to the appropriate sponsor 
contact person b ystudy -site personnel within 2 4hours of their knowledge of the event.
Information regarding serious adverse events will be transmitted to the sponsor using the Serious 
Adverse Event Form, which must be completed and signed by a physician from the study  site, 
and transmitted to the sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax) .
All serious adverse events that have not resolved by the end of the study , or that have not 
resolved upon discontinuation of the subject's participation in the study , must be followed until 
any of the following occurs:
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
105
Approved , Date: 12 June 2019The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow- up ef forts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospitalization (or prolongation of hospitalization) 
that occurs during the course of a subject's participatio n in a study  must be reported as a serious 
adverse event, except hospitalizations for the following:
If the subject has not experienced a significant medical event but is hospitalized overnight 
only for observation following infusion of daratumumab, then the hospitalization should not 
be reported as a serious adverse event.
Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons 
such as pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospitalizations that were planned before the signing of the ICF, and where 
the underl ying condition for which the hospitalization was planned has not worsened ,will 
not be considered serious adverse events. Any  adverse event that results in a prolongation of 
the originall y planned hospitalization is to be reported as a new serious adverse event.
12.3.3. Suspected Unexpected Serious A dverse Reactions
The sponsor assumes responsibility  for appropriate reporting of all Suspected Unexpected 
Serious Adverse Reactions (SUSAR) [serious adverse events that are unlisted (unexpected) and 
associated with the use of the study  drug] to the regulatory  authorities in accordance with GCP. 
The sponsor will also report to the investigator (and the head of the investigational institute 
where required) all serious adverse events that are unlisted (unexpected) and associated with the 
use of the study  drug. The investigator (or sponsor where required) must report these events to 
the appropriate Independent Ethics Committee/I nstitutional Review Board (IEC/I RB) that 
approved the protocol unless otherwise required and documented b y the IEC/I RB.
12.3.4. Pregnancy
All initial reports of pregnancy  must be reported to the sponsor by the study -site personnel
within 24 hours of their knowledge of the event using the appropriate pregnancy  notification 
form. Abnormal pregnancy  outcomes (eg, spontaneous abortion, stillbirt h, and congenital 
anomaly ) are considered serious adverse events and must be reported using the Serious Adverse 
Event Form . Any subject who becomes pregnant during the study  must discontinue further study  
treatment .The subject should be referred to a phys ician experienced in teratology  for evaluation 
and advice. Investigators should follow the local label for guidance on subject education and 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
106
Approved , Date: 12 June 2019ensure that all subjects adhere to the local lenalidomide REMS program (when lenalidomide is 
supplied locally ), or the lenalidomide Global Pregnancy  Prevention Plan provided in Attachment 
5(when lenalidomide is supplied centrall y and no local lenalidomide REMS program exists).
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required.
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male subjects 
included in the study  will be reporte d by the study -site personnel within 24 hours of their 
knowledge of the event using the appropriate pregnancy  notification form
12.4. Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues or questions regarding the study  are listed on the Contact Information 
page(s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliabilit y of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor , and are mandated by regulatory  agencies worldwide. The sponsor has 
establis hed procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
13.1. Procedures
All initial PQC s must be reported to the sponsor by  the study -site personnel within 24 hours after 
being made aware of the event.
If the defect is combined with a serious adverse event, the study -site personnel must report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for furt her investigation if requested by  the sponsor .
13.2. Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality  issues are listed on the Contact Information page(s), which will be 
provided as a separate document.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
107
Approved , Date: 12 June 201914. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug
Thedaratumumab supplied for this study  is a colorless to yellow liquid and sterile concentrate of 
20 mg/mL  in a vial. It will be manufactured and provided under the responsibility  of the sponsor .
Refer to the Investigator's Brochure for a list of excipients.
14.2. Packaging
Daratumumab is supplied in glass vials containing daratumumab at a concentration of 
20mg/mL .
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory  requirements. Each 
vial will contain a study -specific label with a unique identification number.
14.4. Preparation, Handling, and Storage
All study  drug vials must be stored in the original carton in a refrigerator ranging from 2°C to 8°C 
and must not be utilized after the expiry  date printed on the label. The product must be protected 
from light and must not be frozen. Daratumumab does not contain preservatives; therefore any 
unused portion remaining in the vial must be discarded. 
Daratumumab will be diluted in a sterile, pyrogen -free physiological saline solution (0.9% NaCl) 
prior to IV administration. Refer to the Investigational Product Preparation Instructions and 
Investigational Product Procedures Manual for details regarding dose preparation, storage, and 
handling of diluted solutions.
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study . The study  drug administered to the subject must be 
documented on the drug accountability  form. All study  drug will be stored and disposed of 
according to the sponsor's instructions. Study -site personnel must not combine contents of the 
study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate
environmental conditions. Unused study  drug must be available for verification by the sponsor's 
study  site monitor during on-site monitoring visits. The return to the sponsor of unused study 
drug, or used returned study  drug for destruction, will be docum ented on the drug return form. 
When the study  site is an authorized destruction unit and study  drug supplies are destroy ed 
on-site, this must also be documented on the drug return form.
Potentially  hazardous materials such as used ampules, needles, syringe s and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes. 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
108
Approved , Date: 12 June 2019Study  drug should be dispensed under the supervision of the investigator or a qualified membe r 
of the study -site personnel, or by a hospital/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Study  drug may not be relabeled or reassigned for use by 
other subjects. The investigator agrees neither to dispense the study  drug from, nor store it at, 
any site other than the study  sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Investigator Brochure for daratumumab
Site I nvestigational Product Procedures Manual
Laboratory  manual
PRO questionnaires and user guidelines
eCRF completion guidelines
Sample I CF
Subject diaries
Subject wallet card indicating blood t ype(and IAT testing for Arm B; see Section 9.8)
Other manuals and guidance documents as needed
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
The primary  safety profile of daratumumab is consistent with infusion -related reactions; see 
Section 6.1.3 for prevention details. Based on the mode of action of daratumumab, a potential risk 
could be infection; therefore the protocol requires the review of hematological laboratory  results 
prior to daratumumab infusion. CD38 is distributed in erythrocy tes and platelets. A significant 
reduction of platelets was reported in an animal study . In a human clinical study  (Study GEN501), 
thrombocy topenia was also reported. However, safety laboratory  monitoring did not show a 
clinicall y meaningful reduction of platelets . Anemia was also reported in Study GEN501. Free 
hemoglobin was mildl y elevated, but other parameters did not support hemol ysis. No bleeding 
events were observed. Routine safety  laboratory  measurement of RBCs and platelets will be 
closel y monitored in this study .
Potential subjects will be fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potentia l adverse events of the study , and provide their consent voluntaril y will be enrolled.
The blood volume for the study  is estimated at approximately  65 mL during screening and 
360mL during the first year(approximately  20-35mL per cycle for routine testin g, plus 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
109
Approved , Date: 12 June 2019additional PK and biomarker samples). In the Follow -up Phase, subjects prior to PD will 
continue to have approximately  20mL blood drawn permonth for serum disease evaluations.
These blood volumes are not burdensome and fallwithin the normal range of a single blood 
donation.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and a pplicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Complia nce with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the study  data are credible.
16.2.2. Independent Ethic s Committee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents (as required by local 
regulations):
Final protocol and, if applicable, amendments
Sponsor -approved ICF (and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name o f the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/I RB has given full approv al of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct), the ICF, applicable recruiting materials, and 
subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly  identify  the IEC/I RB and the documents being 
approved.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
110
Approved , Date: 12 June 2019During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC /IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to I CF and any  other written materials to be provided to su bjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochur e and amendments/addenda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investiga tor is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences forsubjects, data or study  conduct) , the amendment and applicable ICF revisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
Furthermore, where required, progress reports/written summaries of the study status will be 
submitted to the IRB/IEC annually , or more frequently  if requested.
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion (if applicable, the notification will be submi tted through the head of 
investigational institution). 
16.2.3. Informed Consent
Each subject (or a legall y acceptable representative) must give written consent according to local 
requirements after the nature of the study  has been fully  explained. The ICF(s) must be signed 
before performance of any study-related activity . The ICF(s) that is/are used must be approved 
by both the sponsor and by  the reviewing IEC/IRB and be in a language that the subject can read 
and understand. The informed consent should be in accordance with principles that originated in 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
111
Approved , Date: 12 June 2019the Declaration of Helsinki, current ICH and GCP guidelines, applicable regulatory  
requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
person nel must explain to potential subjects or their legall y acceptable representatives the aims, 
methods, reasonabl y anticipated benefits, and potential hazards of the study ,and any discomfort 
participation in the study  may entail. Subjects will be informed that their participation is 
voluntary  and that they may withdraw consent to participate at any time. They  will be informed 
that choosing not to participate will not affect the care the subject will receive for the treatment 
of his or her disease. Subjects will be told that alternative treatments are available if they refuse 
to take part and that such refusal will not prejudice future treatment. Finally , they will be told 
that the investigator will maintain a subject identificatio n register for the purposes of long-term 
follow up if needed and that their records may be accessed by health authorities and authorized 
sponsor personnel without violating the confidentiality  of the subject, to the extent permitted by 
the applicable law(s ) or regulations. By signing the ICF the subject or legall y acceptable 
representative is authorizing such access , including permission to obtain information about his or 
her survival status, and agrees to allow his or her study  physician to recontact the subject for the 
purpose of obtaining consent for additional safet y evaluations, if needed, and subsequent 
disease -related treatments, or to obtain information about his or her survival status.
The subject or legally  acceptable representative will be given sufficient time to read the ICF and 
the opportunity  to ask questions. After this explanation and before entry  into the study , consent 
should be appropriatel y recorded by means of either the subject's or his or her legall y acceptable 
representative's persona lly dated signature. After having obtained the consent, a copy of the ICF 
must be given to the subject.
If the subject or legally  acceptable representative is unable to read or write, an impartial witness 
should be present for the entire informed consent process (which includes reading and explaining 
all written information) and should personally  date and sign the ICF after the oral consent of the 
subject or legall y acceptable representative is obtained.
When prior consent of the subject is not possible and the subject's legally  acceptable 
representative is not available, enrollment procedures should be described in the protocol with 
documented approval/favorable opinion by the IEC/I RB to protect the rights, safety , and 
well-being of the subject and to ensur e compliance with applicable regulatory  requirements. The 
subject or legall y acceptable representative must be informed about the study  as soon as possible 
and give consent to continue.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
112
Approved , Date: 12 June 2019disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place . Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identit y of subjects confidential.
The informed consent obtained from the subject (or his or her legall y acceptable representative) 
includes explicit consent for t he processing of personal data and for the investigator/institution to 
allow direct access to his or her original medical records (source data/documents) for 
study -related monitoring, audit, IEC/IRB review, and regulatory  inspection. This consent also 
addresses the transfer of the data to other entities and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  biomarker/PK/immunogenicity  research is not conducted under standards 
appropriate for the return of data to subjects. In addition, the sponsor cannot make decisions as to 
the significance of any findings resulting from exploratory  research. Therefore, exploratory  
research data will not be returned to subjects or investigators, unless required by law or local 
regulations. Privacy  and confidentiality  of data generated in the future on stored samples will be 
protected b y the same standards applicable to all other clinical data.
16.2.5. Long -Term Retention of Samples for A dditio nal Future Research
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand daratumumab , to 
understand multiple myeloma, to understand different ial drug responders, and to develop 
tests/assays related to daratumumab and multiple my eloma.  The research may begin at any time 
during the stud y or the post -study  storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer to Section 10.3, Withdrawal From the Study  (Withdrawal From the Use 
of Samples in Future Research).
16.2.6. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product , unless explicitly  addressed as a specific ethical 
consideration in Section 16.1, Study -Specific Design Considerations.
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mend ments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by  the sponsor, and signed and dated by 
the investigator. Protocol amendments must not be implemented without prior IEC/IRB 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
113
Approved , Date: 12 June 2019approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RBand relevant competent authority . 
Documentation of amendment approval by  the investigator and IEC/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IRB (and IEC where required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative (see Contact Information page(s) provided separatel y). Except in emergency 
situations, this contact should be made before implementing any departure from the protocol. In 
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and 
agree on an appropria te course of action. The data recorded in the eCRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  drug to the 
study  site:
Protocol and amendment(s), if an y, signed and dated by the principal investigator
A copy of the dated and signed (or sealed, where approp riate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) b y the chairman or authorized designee.
Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates accor ding to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member ofthe IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
114
Approved , Date: 12 June 2019Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial agreement
Any other documentation required by  local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all subinvestigators
Docum entation of subinvestigator qualifications (eg, curriculum vitae)
Name and address of any local laboratory  conducting tests for the study , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by the 
sponsor study -site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study  file. To ensure subject confidentialit y, no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by subject identification 
and age at initial informed consent . In cases where the subject is not randomized into the study, 
the date seen and age at initial informed consent will be used .
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source documentation must be available for the following to confirm data 
collected in the eCRF: subject identification, eligibility , and study identification; study  
discussion and date of signed informed consent; dates of visits; results of safety  and efficacy  
parameters as required by the protocol; record of all adverse events and follow -up of adverse 
events; concomitant medication; drug receipt/dispensing/return records; study  treatment
administration information ; and date of study  completion and reason for early discontinuation of 
study  treatment or withdrawal from the study , if applicable. 
In addition, the author of an entry  in the source documents should be identifiable.
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly  recorded at the study  site as a basis for standard medical care. 
Specific details required as source data for the study  will be reviewed with the investigator 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
115
Approved , Date: 12 June 2019before the study  and will be described in the monitor ing guidelines (or other equivalent 
document).
Subject -and investigator -completed scales and assessments designated by the sponsor 
(EORTC QLQ -C30 and EQ-5D- 5L) will be recorded directl y into an electronic device or other 
tool and will be considered source data.
The minimum source documentation requirements for Section 4.1, Inclusion Criteria and 
Section 4.2, Exclusion Criteria that specify  a need for documented medical history  are as 
follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by subject interview or other protocol required assessment (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
17.5. Case Report Form Completion
Case report forms are provided for each subject in electronic format. 
Electronic Data Capture (eDC) will be used for this study . The study  data will be transcribed by 
study -site personnel from the source documents onto an eCRF, and transmitted in a secure
manner to the sponsor within the timeframe agreed upon between the sponsor and the study  site. 
The electronic file will be considered to be the eCRF.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksh eets will become part of the subject's source documentation. Data must be entered 
into eCRFs in English. Study  site personnel must complete the eCRF as soon as possible after a 
subject visit, and the forms should be available for review at the next schedul ed monitoring visit.
All subjective measurements (eg, pain scale information or other questionnaires) will be 
completed by the same individual who made the initial baseline determinations whenever 
possible. The investigator must verify  that all data entries in the e CRF s are accurate and correct.
All eCRF entries, corrections, and alterations must be made by the investigator or other 
authorized study -site personnel. If necessary , queries will be generated in the eDC tool. The 
investigator or stud y-site personnel must adjust the eCRF (if applicable) and complete the query.
If corrections to an eCRF are needed after the initial entry  into the eCRF , this can be done in 3 
different way s:
Study  site personnel can make corrections in the eDC tool at their own initiative or as a 
response to an auto query (generated b y the eDC tool).
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
116
Approved , Date: 12 June 2019Study  site manager can generate a query  for resolution by  the study -site personnel.
Clinical data manager can generate a query  for resolution by  the study -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , and periodic monitoring visits by the sponsor, and direct 
transmission of clinical laboratory  data from a central laboratory  into the sponsor's database , and 
direct transmission of PRO data to the ePRO vendor database and then to the sponsor’s data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study -site personnel before 
the start of the study .The sponsor will review eCRFs foraccuracy  and completeness during 
on-site monitoring visits and after transmission to the sponsor; any  discrepancies will be resolved 
with the investigator or designee, as appropriate. After upload of the data into the study database 
they will be verified for accuracy  and consistency  with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRFs 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by the applicable regulatory  requirement(s). 
The investigator/institution will take measures to prevent acciden tal or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICHregion or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by the applicable regulatory  requirements or by an 
agreement with the sponsor. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocat e or dispose of any study  
documents before having obtained written approval from the sponsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator/institution must permit access to such 
reports.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
117
Approved , Date: 12 June 201917.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study  site. The first 
post-initiatio n visit will be made as soon as possible after enrollment has begun. At these visits, 
the monitor will compare the data entered into the eCRFs with the hospital or clinic records 
(source documents). The nature and location of all source documents will be identified to ensure 
that all sources of original data required to complete the eCRF are known to the sponsor and 
study -site personnel and are accessible for verification by the sponsor study -site contact. If 
electronic records are maintained at the study  site, the method of verification must be discussed 
with the study -site personnel. 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data recorded in the eCRF are consistent with the original sourc e data. Findings 
from this review of eCRFs and source documents will be discussed with the study -site personnel. 
The sponsor expects that, during monitoring visits, the relevant study -site personnel will be 
available, the source documentation will be acces sible, and a suitable environment will be 
provided for review of study -related documents. The monitor will meet with the investigator on a 
regular basis during the study to provide feedback on the study conduct.
17.9. Study Completion/Termination
17.9.1. Study Completio n
The study  is considered completed after 330 deaths have occurred or 7years after the last subject 
is randomized, whichever is first. The final data from the study  site will be sent to the sponsor (or 
designee) after completion of the final subject at th at study  site, in the time frame specified in the 
Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study  site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study  sites will be closed upon study  completion. A 
study  site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of a study  site by the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  the investigator
Discontinuation of further study  drug development
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
118
Approved , Date: 12 June 201917.10. On-Site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection and comparison with the eCRFs. Subject 
privacy  must, however, be respected. The investigator and study -site personnel are responsible 
for being present and available for consultation during routinely  scheduled study -site audit visits 
conducted b y the sponsor or its designees. 
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the sponsor if he or she has 
been contacted b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All informati on, including but not limited to information regarding daratumumab or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not 
previously  published, and any data, including exploratory  biomarker research data, generated as 
a result of this study , areconsidered confidential and remain the sole property  of the sponsor. 
The investigator agrees to maintain this information in confidence and use this information only 
to accomplish this study , and will not use it for other purposes without the sponsor's prior written 
consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of daratumumab , and thus may be 
disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by the sponsor and 
will contain eCRF data from all study  sites that participated in the study , and direct transmission 
of clinical laboratory  data from a central laboratory  into the sponsor's database. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator for the study . Results of exploratory  
biomarker analyses performed after the Clinical Study  Report has been issued will be reported in 
a separate report and will not require a revision of the Clinical Study  Report. Study  subject 
identifiers will not be used in publication of results. Any work created in connection with 
performance of the study  and contained in the data that can benefit from copyright protection 
(except any publication by the investigator as provided for below) shall be the prope rty of the 
sponsor as author and owner of cop yright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
119
Approved , Date: 12 June 2019and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study ,a copy  of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
writing, the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. Formulticenter study  designs and substudy  approaches, secondary  results generall y 
should not be published before the primary  endpoints of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicenter study by not submitti ng for publication 
data derived from the individual study  site until the combined results from the completed study
have been submitted for publication, within 18 months after study  end date, or the sponsor 
confirms there will be no multicenter study  public ation. Authorship of publications resulting 
from this study  will be based on the guidelines on authorship, such as those described in the
ICMJE Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly 
Work in Medical Journals, which state that the named authors must have made a significant 
contribution to the conception or design of the work; or the acquisition, analy sis, or interpretation 
of the data for the work; and drafted the work or revised it critically  for important intellect ual 
content; and given final approval of the version to be published; and agreed to be accountable for 
all aspects of the work in ensuring that questions related to the accuracy  or integrit y of any part 
of the work are appropriately  investigated and resolv ed.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
120
Approved , Date: 12 June 2019REFERENCES
1. American Cancer Society (ACS). Cancer Facts & Figures 2012. Atlant a: American Cancer Society; 2012. 
Available from: http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/multiple -myeloma- key-
statistics. Accessed on 25 March 201 3.
2. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J et al. Lenalidomide and Dexameth asone in 
Transplant -Ineligible Patients with Myeloma. N Engl J Med .2014;371:906 -17.
3. Burtis CA, Ashw ood ER. Tietz textbook of clinical chemistry, 3rd ed. Philadelphia; WB Saunders, 1999 .
4. Chapuy C, Nicholson R, Aguad MD, et al. Resolving the daratumumab int erference with blood compatibility 
testing. Transfusion. 2015;55:1545 -1554.
5. Chapuy C, Aguad MD, Nicholson RT, et al. International validation of dithiothreitol (DTT) -based method to 
resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;00:1 -9.
6. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal 
antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 
2011;186(3):1840 -1848.
7. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. 
Leukemia. 2006;20:1467 –73. Corrigenda/Erratum in: Leukemia. 2007;21:1134 -1135.
8. Durie BG, Hoering A, Abidi MH, et al. Bortezomib w ith lenalidomide and d examethasone versus lenalidomide 
an ddexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous 
stem -cell transplant (SWOG S0777): a randomized, open -label, phase 3 trial. Lancet. 2017;389:519 -527.
9. Facon T, Dimopou los MA, Dispenzieri A, et al. Initial Phase 3 Results Of The First (Frontline Investigation Of 
Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM -020/IFM 07 01) In New ly 
Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT). Blood. 
October 21, 2013 vol. 122 no. 21 2. ASH 2013 Meeting Abstract. 
http://bloodjournal.hematologylibrary.org/content/122/21/2.abstract?sid=06133b3d -094e- 452b -aeb2 -
f12d2a83ce53. Accessed on 16 January 2014. 
10. Ferlay J, Shin HR, Bray  F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J 
Cancer. 2010;127(12):2893 -2917.
11. Gay F and Palumbo A. Management of older patients with multiple myeloma. Blood Reviews. 2011;25:65 -73.
12. Ghosh N, Tucker N, Zahurak M, et al. Addition of clarithromycin to lenalidomide and dexamethasone (BiRd) 
is effective in MM after progression on lenalidomide and dexamethasone. Session 653. Myeloma: Therapy, 
excluding Transplantation. American Society of Hematology (ASH) 2013 meeting. Abstr act 1960.
13. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five -level version of 
the EQ- 5D (EQ -5D-5L). Qual Lif Res. 2011;20:1727 -1736.
14. Hulin C, Belch A, Shustik C, et al. Updated outcomes and impact of age with lenalidomi de and low -dose 
dexamethasone or melphalan, prednisone, and thalidomide in the randomized, Phase III FIRST trial. J Clin 
Oncol. 2016;34:3609 -3617.
15. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. 
JHemat ol Oncol. 2009;2:36.
16. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response 
and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328 -346.
17. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. 
Mayo Clin Proc. 2003;78(1):21 -33. 
18. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple 
myeloma. Leukemia. 2009;23:3 -9.
19. Kyle RA, Remst ein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) 
multiple myeloma. N Engl J Med. 2007;356(25):2582 -2590.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
121
Approved , Date: 12 June 201920. Ladetto M, Bruggemann M, Monitello L, et al. Next -generation sequencing and real -time quantitative PCR for 
minima l residual disease detection in B -cell disorders. Leukemia. 201 4.doi: 10.1038/leu.2013.375.
21. Martinez -Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal 
residual disease detection in multiple myeloma. Blood, prepublished online March 19, 2014: 10.1182/blood -
2014 -01-55020.
22. McCudden CR, Voorhees PM, Hainsworth SA, et al. Interference of monoclonal antibody therapies with serm 
protein electrophor esis tests. Clin Chem .2010;56(12): 1897 -1899.
23. National Comprehensive Cancer Netw ork. NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines): Multiple Myeloma, version 2.2013. Fort Washington, PA: National Comprehensive Cancer 
Netw ork.
24. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the East ern Cooperative Oncology 
Group. Am J Clin Oncol. 1982;5(6):649 -655.
25. Overdijk MB, Verploegen S, Bogels M, et al. Phagocytosis is a potent mechanism of action for the therapeutic 
human monoclonal antibody daratumumab in lymphoma and multiple myeloma. Submitt ed to Blood. 
13May 2013. 
26. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046 -1060.
27. Palumbo A, Gay F, Musto P, et al. Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly 
diagnosed myeloma patients: PFS1, PFS2, OS endpoints. J Clin Oncol .325s, 2014 (suppl; abstr 8515).
28. Palumbo A, Rajkumar S, Dimopoulos M, et al. Prevention of thalidomide -and lenalidomide -associated 
thrombosis in myeloma. Leukemia. 2008;22:414 -423.
29. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of 
multiple myeloma patients ineligible for standard high -dose chemotherapy with autologous stem cell 
transplantatio n. Leukemia. 2009 ;23:1716 -1730.
30. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. Internatio nalMyeloma Working Group updated criteria for 
the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538 -48
31. Rajkumar SV, Greipp PR, Jacobus S, et al. Lenalidomide plus high -dose dexamethasone versus lenalidomide 
plus low -dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open -label 
randomised controlled trial. Lancet Oncol. 2010;11(1):29 –37.
32. Rajkumar SV, Harousseau J -L, Durie B, et al. Consensus recommendations for the uniform reporting of 
clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;4691 -4695.
33. Revlimid [package insert]. Summit, NJ: Celgene Corporation; 2017.
34. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma. Br J 
Haem atol. 2005 ;132:410 -451.
35. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell 
adhesion and induces antibody -dependent cellular cytotoxicity in the bone marrow  milieu. Blood. 
2008;112(4):1329 -1337.
36. Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, et al. Immunomodulatory drug lenalidomide (CC 
5013, IMiD3) augments anti CD40 SGN 40 -induced cytotoxicity in human multiple myeloma: clinical 
implications. Cancer Res. 2005;65(24):11712 -11720.
37. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: mechanism -based 
potential drug combinations. Leuk Lymphoma. 2008;49(7):1238 -1245.
38. Van der Veer M, de Weers M, van Kessel B. Tow ards effective immunotherapy of myeloma: enhanced 
elimination of myelom a cells by combination of lenalidomide w ith the human CD38 monoclonal antibody 
daratumumab. Haematol. 2011 a:96(2):284 -290.
39. Van der Veer M, de Weers M, van Kessel B. The therapeutic human CD38 antibody daratumumab improves 
the anti -myeloma effect of newly e merging multi -drug therapies. Blood Cancer Journal. 2011 b; 1e41. 
Doi:10.1038/bcj.2011.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
122
Approved , Date: 12 June 201940. Vij R, Mazumder A, Klinger M, et al. Deep sequencing reveals myeloma cells in peripheral blood in majority 
of multiple myeloma patients, Clinical Lymphoma, Myeloma and Leukemia (2013), doi: 
10.1016/j.clml.2013.09.013.
41. Wisloff F, Eika S, Hippe E, et al. Measurement of health -related quality of life in multiple myeloma. Nordic 
Myelom a Study Group. Br J Haematol .1996;92:604 -613.
42. Wisloff F, Hjorth M. Health -related quality of life assessed before and during chemotherapy predicts for 
survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol .1997;97:29 -37.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
123
Approved , Date: 12 June 2019Attachment 1:Modified IMWG Diagnostic Criteria for Multiple Myeloma
Clonal bone marrow plasma cells ≥10% or biopsy -proven bony or extramedullary plasmacytomaaAND 
any one or more of the following myeloma defining events: 
Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, 
specifically:
 Hypercalcemia: serum calcium >0.25 mM/L (>1 mg/dL) higher than ULN or >2.75 mM/L 
(>11 mg/dL)
 Renal insufficiency: creatinine clearanceb<40mL/min or serum creatinine >177 µM/L 
(>2mg/dL)
 Anemia: hemoglobin >2 g/dL below the lower limit of normal or hemoglobin <10 g/dLc
 Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET -CTd
Note: Subjects only meeting SLiM CRAB are not eligible.
Footnotes:
a) Clonality should be established by showing /light-chain restriction on flow cytometry, 
immunohistochemistry, or immunofluorescence. Bone marrow plasma cell percentage should 
preferably be estimated from a core biopsy specimen; in case of a disparity between the aspirate and 
the core biopsy, the highest value should be used. 
b) Measured or estimated by validated equations.
c) Hemoglobin measurement performed as part of standard of care within 42 days before 
randomization is acceptable for screening for CRAB criteria; but must be performed within 21 days 
before randomization for other eligibility requirements. 
d) If bone marrow has less than 10% clonal plasma cells, more than one bone lesion is required to 
distinguish from solitary plasmacytoma with minimal marrow involvement.
Reference: Rajkumar 2014 30
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
124
Approved , Date: 12 June 2019Attachment 2:ECOG Performance Status Scale
Grade ECOG Performance Status 
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, eg, light house work, office work
2 Ambulatory and capable of all selfcare but unab le to carry out any work activities. Up 
and about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking 
hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
Reference:  Oken 198224
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
125
Approved , Date: 12 June 2019Attachment 3:Calculated and Measured Creatinine Clearance
Cockcroft -Gault formula:
To calculate the subject’s creatinine clearance (CrCl), use the following Cockcroft -Gault formula:
CrCl = (140 -age [in years]) x weight (kg) (x 0.85 for females)
(72 x serum creatinine [mg/dL])
If the serum creatinine is obtained using the International System of Units (SI) (ie, micromol/L), use the 
following formula to convert SI units to conventional (mg/dL) units (Manual of Laboratory & Diagnostic 
Tests, 2004):
• serum creatinine (micromol/L) divided by 88.4 = serum creatinine (mg/dL)
Formula to measure creatinine clearance:
CrCl = U Crx U vol
PCr x T min
Corrected CrCl = CrCl  x 1.73
BSA
Notes: UCr, Urine creatin ine concentration; Uvol, Urine volume from 24hrs collection; PCr, plasma
creatinine concentration; Tmin, collection time in minutes (24h x 60 min); BSA, body surface area .
If the body mass index of a subject is >30kg/ m2, lenalidomide dosing should be based on the CrCl 
calculated with adjusted body weight .
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
126
Approved , Date: 12 June 2019Attachment 4: Serum Calcium Corrected for A lbumin
If calcium is expressed in mg/dL and albumin is expressed in g/dL:
Corrected calcium (mg/dL) = 
serum calcium (mg/dL) + 0.8•(4 -serum albumin [g/dL])
If calcium is expressed in m M/L and albumin is expressed in g/L:
Corrected calcium (m M/L) = 
serum calcium (m M/L) + 0.02•(40 - serum albumin [g/L])
Source: Burtis 19993
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
127
Approved , Date: 12 June 2019Attachment 5:Lenalidomide Global Pregnancy Prevention Plan
Where lenalidomide is supplied locally, subjects must adhere to the local lenalidomide REMS progr am. 
Where lenalidomide is supplied centrally and no local lenalidomide REMS program exists, then subjects 
must adhere to the lenalidomide Global Pregnancy Prevention Plan provided in this attachment. 
Within this attachment only, use of the phrase “study d rug” refers to lenalidomide. 
1.1 Pregnancy Prevention Risk Management Plans
1.1.1 Lenalidomide Pregnancy Prevention Risk Management Plan
1.1.1.1 Lenalidomide Pregnancy Risk Minimisation Plan for Celgene Clinical Trials 
This attachment applies to all pati ents receiving lenalidomide therapy. The following Pregnancy Risk 
Minimisation Plan documents are included: 
1)Lenalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control 
Methods (Section 1.1.1.2 ); 
2)Lenalidomide Education and Counseling Guidance Document (Section 1.1.1.3 ); 
3)Lenalidomide Information Sheet (Section 1.1.1.4 ).
1.The Lenalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth 
Control Methods document (Section 1.1.1.2) provides the following information:
Potential risks to the fetus associated with lenalidomide exposure
Definition of Female of Childbearing Potential
Pregnancy testing requirements for patients receiving Lenalidomide who are females of 
childbearing potential
Acceptable birth control methods for both female of childbearing potential and male patients 
receiving Lenalidomide in the study
Requirements for counseling of all study patients receiving Lenalidomide about pregnancy 
precautions and the potential risks of fetal exp osure to lenalidomide
2.The Lenalidomide Education and Counseling Guidance Document (Section 1.1.1.3) must be 
completed and signed by either a trained counselor or the Investigator at the participating clinical 
center prior to each dispensing of lenalidomide study treatment. A copy of this document must be 
maintained in the patient records.
3.The Lenalidomide Information Sheet (Section 1.1.1.4) will be given to each patient receiving 
lenalidomide study therapy. The patient must read this document prior to start ing lenalidomide 
study treatment and each time they receive a new supply of study drug.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
128
Approved , Date: 12 June 20191.1.1.2 Lenalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth 
Control Methods)
Risks Associated with Pregnancy
Lenalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic active 
substance that causes severe life -threatening birth defects. An embryofetal development study in animals 
indicates that lenalidomide produced malformations in the offsprin g of female monkeys who received the 
drug during pregnancy. The teratogenic effect of lenalidomide in humans cannot be ruled out. Therefore, 
a risk minimization plan to prevent pregnancy must be observed.
Criteria for females of childbearing potential (FCB P)
This protocol defines a female of childbearing potential as a sexually mature woman who: 1) has not 
undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal 
(amenorrhea following cancer therapy does not rule out chi ldbearing potential) for at least 24 consecutive 
months (i.e., has had menses at any time in the preceding 24 consecutive months).
Counseling
For a female of childbearing potential, lenalidomide is contraindicated unless all of the following are met 
(i.e., all females of childbearing potential must be counseled concerning the following risks and 
requirements prior to the start of lenalidomide study therapy): 
She understands the potential teratogenic risk to the unborn child
She understands the need for eff ective contraception, without interruption, 4 weeks before 
starting study treatment, throughout the entire duration of study treatment, dose interruption 
and 28 days after the end of study treatment
She should be capable of complying with effective contrac eptive measures
She is informed and understands the potential consequences of pregnancy and the need to 
notify her study doctor immediately if there is a risk of pregnancy
She understands the need to commence the study treatment as soon as study drug is di spensed 
following a negative pregnancy test
She understands the need and accepts to undergo pregnancy testing based on the frequency 
outlined in this protocol (Section 1.1.1.2)
She acknowledges that she understands the hazards and necessary precautions ass ociated with 
the use of lenalidomide
The investigator must ensure that for females of childbearing potential:
Complies with the conditions for pregnancy risk minimization, including confirmation that 
she has an adequate level of understanding
Acknowledge the aforementioned requirements
For a female NOT of childbearing potential, lenalidomide is contraindicated unless all of the following 
are met (i.e., all females NOT of childbearing potential must be counseled concerning the following risks 
and requiremen ts prior to the start of lenalidomide study therapy): 
She acknowledges that she understands the hazards and necessary precautions associated with 
the use of lenalidomide
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
129
Approved , Date: 12 June 2019Traces of lenalidomide have been found in semen.  Male patients taking lenalidomide m ust meet the 
following conditions (i.e., all males must be counseled concerning the following risks and requirements 
prior to the start of lenalidomide study therapy):
Understand the potential teratogenic risk if engaged in sexual activity with a pregnant female 
or a female of childbearing potential
Understand the need for the use of a condom even if he has had a vasectomy, if engaged in 
sexual activity with a pregnant female or a female of childbearing potential.  
Contraception
Females of childbearing pot ential (FCBP) enrolled in this protocol must agree to use two reliable forms of 
contraception simultaneously or to practice complete abstinence from heterosexual contact during the 
following time periods related to this study: 1) for at least 28 days befor e starting study drug; 2) while 
participating in the study; 3) dose interruptions; and 4) for at least 28 days after study treatment 
discontinuation. 
The two methods of reliable contraception must include one highly effective method and one additional 
effective (barrier) method. FCBP must be referred to a qualified provider of contraceptive methods if 
needed. The following are examples of highly effective and additional effective methods of contraception:  
Highly effective methods:
Intrauterine device (IU D)
Hormonal (birth control pills, injections, implants)
Tubal ligation
Partner’s vasectomy
Additional effective methods:
Male condom
Diaphragm
Cervical Cap
Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking 
lenalidomide and dexamethasone, combined oral contraceptive pills are not recommended. If a patient is 
currently using combined oral contraception the patient should switch to one of the effective method 
listed above. The risk of venous thromboembolism contin ues for 4 to 6 weeks after discontinuing 
combined oral contraception. The efficacy of contraceptive steroids may be reduced during co -treatment 
with dexamethasone.
Implants and levonorgestrel -releasing intrauterine systems are associated with an increased risk of 
infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics should be 
considered particularly in patients with neutropenia. 
Pregnancy testing
Medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/mL must be performed for 
females of childbearing potential, including females of childbearing potential who commit to complete 
abstinence, as outlined below.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
130
Approved , Date: 12 June 2019Before starting study drug
Female Patients:
FCBP must have two negative pregnancy tests (sensitivity of at least 25 mIU/mL) prior to starting study 
drug. The first pregnancy test must be performed within 10 to 14 days prior to the start of study drug and 
the second pregnancy test must be performed within 24 hours prior to the start of study d rug. The patient 
may not receive study drug until the study doctor has verified that the results of these pregnancy tests are 
negative.
Male Patients :
Must practice complete abstinence or agree to use a condom during sexual contact with a pregnant female 
or a female of childbearing potential while participating in the study, during dose interruptions and for at 
least 28 days following study drug discontinuation, even if he has undergone a successful vasectomy.  
During study participation and for 28 days fo llowing study drug discontinuation 
Female Patients:
FCBP with regular or no menstrual cycles must agree to have pregnancy tests weekly for the 
first 28 days of study participation and then every 28 days while on study, at study 
discontinuation, and at day 28 following study drug discontinuation. If menstrual cycles are 
irregular, the pregnancy testing must occur weekly for the first 28 days and then every 14 
days while on study, at study discontinuation, and at days 14 and 28 following study drug 
discontin uation.  
At each visit, the Investigator must confirm with the FCBP that she is continuing to use two 
reliable methods of birth control.  
Counseling about pregnancy precautions and the potential risks of fetal exposure must be 
conducted at a minimum of e very 28 days. 
If pregnancy or a positive pregnancy test does occur in a study patient, study drug must be 
immediately discontinued.
Pregnancy testing and counseling must be performed if a patient misses her period or if her 
pregnancy test or her menstrual bleeding is abnormal. Study drug treatment must be 
discontinued during this evaluation.
Females must agree to abstain from breastfeeding during study participation and for at least 
28 days after study drug discontinuation.
Male Patients:
Counseling about the requirement for complete abstinence or condom use during sexual 
contact with a pregnant female or a female of childbearing potential and the potential risks of 
fetal exposure to lenalidomide must be conducted at a minimum of every 28 days.  
If pregnan cy or a positive pregnancy test does occur in the partner of a male study patient 
during study participation, the investigator must be notified immediately.
Additional precautions
Patients should be instructed never to give this medicinal product to anothe r person and to 
return any unused capsules to the study doctor at the end of treatment.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
131
Approved , Date: 12 June 2019Female patients should not donate blood during therapy and for at least 28 days following 
discontinuation of study drug.
Male patients should not donate blood, semen or sperm during therapy or for at least 28 days 
following discontinuation of study drug.
Only enough study drug for one cycle of therapy may be dispensed with each cycle of 
therapy. 
1.1.1.3 Lenalidomide Education and Counseling Guidance Document 
To be comp leted prior to each dispensing of study drug.
Protocol Number: ____________________________________________
Patient Name (Print): __________________ DOB: _____/_____/_____ (mm/dd/yyyy)
(Check the appropriate box to indicate risk category)
Female: □
If female, check one:
□FCBP (Female of childbearing potential): sexually mature female who: 1) has not 
undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy 
(the surgical removal of both ovaries) or 2) has not been natur ally postmenopausal 
(amenorrhea following cancer therapy does not rule out childbearing potential) for at least 
24 consecutive months (i.e., has had menses at any time during the preceding 24 
consecutive months)
□NOT FCBP
Male: □
Do Not Dispense study drug if:
The patient is pregnant.
No pregnancy tests were conducted for a FCBP.
The patient states she did not use TWO reliable methods of birth control (unless 
practicing complete abstinence of heterosexual contact) [at least 28 days prior to 
therapy, dur ing therapy and during dose interruption].
FCBP:
1.I verified that the required pregnancy tests performed are negative.
2.I counseled FCBP regarding the following:
Potential risk of fetal exposure to lenalidomide: If lenalidomide is taken during pregnancy, it 
may cause birth defects or death to any unborn baby. Females are advised to avoid pregnancy 
while taking lenalidomide. The teratogenic potential of lenalidomide in humans cannot be 
ruled out. FCBP must agree not to become pregnant while taking lenalidomide . 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
132
Approved , Date: 12 June 2019Using TWO reliable methods of birth control at the same time or complete abstinence from 
heterosexual contact [at least 28 days prior to therapy, during therapy, during dose 
interruption and 28 days after discontinuation of study drug].
That even if she has amenorrhea she must comply with advice on contraception  
Use of one highly effective method and one additional method of birth control AT THE 
SAME TIME. The following are examples of highly effective and additional effective 
methods of contraception:   
Highly effective methods:
oIntrauterine device (IUD)
oHormonal (birth control pills, injections, implants)
oTubal ligation
oPartner’s vasectomy
Additional effective methods:
oMale condom
oDiaphragm
oCervical Cap
Pregnancy tests before and during treatment, even if the patient agrees not to have 
reproductive heterosexual contact. Two pregnancy tests will be performed prior to receiving 
study drug, one within 10 to 14 days and the second within 24 hours of the start of study 
drug.
Frequency of pregnancy tests to be done:
Every week during the first 28 days of this study and a pregnancy test every 28 days
during the patient’s participation in this study if menstrual cycles are regular or every 14 
days if cycles are irregular.
If the patient missed a period or has unusual menstrual bleeding.  
When the patient is discontinued from the study and at day 28 after study drug 
discontinuation if menstrual cycles are regular. If menstrual cycles are irregular, 
pregnancy tests will be done at discontinuation from the st udy and at days 14 and 28 after 
study drug discontinuation.
Stop taking study drug immediately in the event of becoming pregnant and to call their study 
doctor as soon as possible. 
NEVER share study drug with anyone else.
Do not donate blood while taking study drug and for 28 days after stopping study drug.
Do not breastfeed a baby while participating in this study and for at least 28 days after study 
drug discontinuation.
Do not break, chew, or open study drug capsules.
Return unused study drug to the stu dy doctor.
3.Provide Lenalidomide Information Sheet to the patient.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
133
Approved , Date: 12 June 2019FEMALE NOT OF CHILDBEARING POTENTIAL (NATURAL MENOPAUSE FOR AT LEAST 
24 CONSECUTIVE MONTHS, A HYSTERECTOMY, OR BILATERAL OOPHORECTOMY):
1.I counseled the female NOT of child bearing potential regarding the following:
Potential risks of fetal exposure to lenalidomide (Refer to item #2 in FCBP)
NEVER share study drug with anyone else.
Do not donate blood while taking study drug and for 28 days after stopping study drug.
Do not break, chew, or ope n study drug capsules
Return unused study drug capsules to the study doctor.
2.Provide Lenalidomide Information Sheet to the patient.
MALE:
1.I counseled the Male patient regarding the following:
Potential risks of fetal exposure to lenalidomide (Refer to item #2 in FCBP).
To engage in complete abstinence or use a condom when engaging in sexual contact 
(including those who have had a vasectomy) with a pregnant female or a female of 
childbearing potential, while taking study drug, during dose interruptions and f or 28 days 
after stopping study drug.
Males should notify their study doctor when their female partner becomes pregnant and 
female partners of males taking study drug should be advised to call their healthcare provider 
immediately if they get pregnant.
NEV ER share study drug with anyone else.
Do not donate blood, semen or sperm while taking study drug and for 28 days after stopping 
study drug.
Do not break, chew, or open study drug capsules.
Return unused study drug capsules to the study doctor.
2.Provide Len alidomide Information Sheet to the patient.
Investigator/Counselor Name (Print): ____________________
(circle applicable)
Investigator/Counselor Signature: _______________________ Date: _____/_____/_____
(circle applicable)
**Maintain a copy of the Education and Counseling Guidance Document in the patient records.**
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
134
Approved , Date: 12 June 20191.1.1.4 Lenalidomide Information Sheet 
FOR PATIENTS ENROLLED IN CLINICAL RESEARCH STUDIES 
Please read this Lenalidomide Information Sheet before you start taking study drug and each time y ou get 
a new supply. This Lenalidomide Information Sheet does not take the place of an informed consent to 
participate in clinical research or talking to your study doctor or healthcare provider about your medical 
condition or your treatment.   
What is the most important information I should know about lenalidomide?
1.Lenalidomide may cause birth defects (deformed babies) or death of an unborn baby.
Lenalidomide is similar to the medicine thalidomide. It is known that thalidomide causes life -
threatening birth defects. Lenalidomide has not been tested in pregnant women but may also 
cause birth defects. Findings from a monkey study indicate that lenalidomide caused birth defects 
in the offspring of female monkeys who received the drug during pregnancy .
If you are a female who is able to become pregnant:
Do not take study drug if you are pregnant or plan to become pregnant
You must practice complete abstinence or use two reliable, separate forms of effective 
birth control at the same time: 
for 28 days before st arting study drug
while taking study drug 
during dose interruptions of study drug 
for 28 days after stopping study drug 
You must have pregnancy testing done at the following times:
within 10 to 14 days and again 24 hours prior to the first dose of study drug 
weekly for the first 28 days
every 28 days after the first month or every 14 days if you have irregular menstrual 
periods
if you miss your period or have unusual menstrual bleeding
28 days after the last dose of study drug (14 and 28 days after the last dose if menstrual 
periods are irregular)
Stop taking study drug if you become pregnant during treatment
If you suspect you are pregnant at any time during the study, you must stop study drug 
immediately and immediately inform your study doctor. Your s tudy doctor will report all 
cases of pregnancy to Celgene Corporation 
Do not breastfeed while taking study drug
The study doctor will be able to advise you where to get additional advice on contraception.
If you are a female not of childbearing potential:
In order to ensure that an unborn baby is not exposed to lenalidomide, your study doctor will 
confirm that you are not able to become pregnant.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
135
Approved , Date: 12 June 2019If you are a male:
Lenalidomide is detected in trace quantities in human semen. The risk to the foetus in females of 
child bearing potential whose male partner is receiving lenalidomide is unknown at this time.  
Male patients (including those who have had a vasectomy) must practice complete abstinence 
or must use a condom during sexual contact with a pregnant female or a female that can 
become pregnant:
While you are taking study drug 
During dose interruptions of study drug 
For 28 days after you stop taking study drug  
Male patients should not donate sperm or semen while taking study drug and for 28 days 
after stopping study drug. 
If you suspect that your partner is pregnant any time during the study, you must 
immediately inform your study doctor. The study doctor will re port all cases of 
pregnancy to Celgene Corporation. Your partner should call their healthcare provider 
immediately if they get pregnant.
2.Restrictions in sharing study drug and donating blood:
Do not share study drug with other people. It must be kept out o f the reach of children 
and should never be given to any other person.
Do not donate blood while you take study drug and for 28 days after stopping study drug. 
Do not break, chew, or open study drug capsules.
You will get no more than a 28 -day supply of s tudy drug at one time.
Return unused study drug capsules to your study doctor.
Additional information is provided in the informed consent form and you can ask your study 
doctor for more information.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
136
Approved , Date: 12 June 2019Attachment 6:Conversion Table for Glucocorticosteroid Dose
Generic Name Oral or Intravenous
Dose (mg)
Dexamethasone 0.75
Methylprednisolone 4
Prednisolone 5
Prednisone 5
Betamethasone 0.6
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
137
Approved , Date: 12 June 2019Attachment 7:Asthma Guidelines
Componen ts of
SeverityClassification ofAsthma Severity
IntermittentPersist ent
Mild Moderate Severe
0-4yrs 5-11 yrs 12+yrs 0-4yrs 5-11 yrs 12+yrs 0-4yrs 5-11 yrs 12+yrs 0-4yrs 5-11 yrs 12+yrs
Impairment
Normal FEV 1/FVC :
8-19 yr 85%
20-39 y r80%
40-59 y r75%
60-80 y r70%Symptoms≤2days/w eek > 2days/w eek but not daily Daily Throughout theday
Nighttime 
awakenings0 ≤2x/month1-2x/
month3-4x/month3-4x/
month>1x/week butnot nightly >1x/
monthOften 7x/week
SABA use for 
symptom control 
(not prevention
of EIB)≤ 2days/w eek≤ 2days/w eekbut not daily>2days / 
week but not 
daily, and
notmore 
than 1x on
any dayDaily Several time per day
Interference with 
normal activity None Minor limitation Some limitation Extremely limited
Lung function
FEV1
FEV1/FVCN/ANormal FEV1 
between 
exac erbations
>80%
>85%Normal FEV1 
between 
exac erbations
>80%
NormalN/A>80%
>80%>80% NormalN/A60-80%
75-80%60-80% 
Reduced 5%N/A<60%
<75%<60% 
Reduced 5%
RiskExacerbatio ns 
requi ring oral 
system ic 
corticosteroids0-1/year≥2 
exacerbation s 
in 6months 
requi ringoral 
steroid s or>4 
wheezing 
episodes/1 year
lastin g>1 day
andrisk factors
for persistent 
asthma≥ 2/year
Relati ve annual
risk may be 
related to 
FEV1.≥ 2/year
Relati ve annual
risk may be 
related to 
FEV1.≥ 2 
exacerbations 
in6months 
requiring oral 
steroids or >4 
wheezing 
episo des/1 year 
lasting >1 day
andrisk factors
for persistent 
asthma≥ 2/year
Relati ve 
annual risk 
may be related
to FEV1.≥ 2/year
Relati ve 
annual risk 
may be 
related to 
FEV1.≥ 2 
exacerbations in
6months 
requiring oral 
steroids or >4 
wheezing 
episo des/1 year 
lasting >1 day 
and risk factor s 
for persist ent 
asthma≥ 2/year
Relati ve 
annual risk 
may be related
to FEV1.≥ 2/year
Relati ve annual
risk
may berelated
toFEV1.
Consider severity andintervalsincelastexacerba tion.Frequ ency a ndseveri ty may f luctuate over time forpatients inanyseveri tycategory.
Recommended Step for
Initiating TreatmentStep 1 Step 2Step 3 and 
consider 
short cou rse 
oforal 
steroidsStep 3: 
medium do se 
ICSand 
consider
short cou rse of
oral steroidsStep 3 and 
consider sho rt 
course of oral 
steroidsStep 3 and 
consider sho rt 
course of oral 
steroidsStep 3: medium
dose ICS OR
Step4 and
consider short
course of oral
steroi dsStep 4 or5 and
consider sho rt 
course
oforalsteroi ds
In2-6 w eeks, evaluate levelofasthmacontrol that isachieved.
0-4 y ears: Ifnoclearbenefit is observed in4-6 w eeks, stop treatme nt and consider alternate di agnos is oradjusti ng th erapy.  5-11and12+years: adjust therapy accord ingly.
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
138
Approved , Date: 12 June 2019Components of 
ControlClassification of Asthma Control
Well Controlled Not Well Controlled Very Poorly Controlled
0-4 yrs 5-11 yrs 12 + yrs 0-4 yrs 5-11 yrs 12 + yrs 0-4 yrs 5-11 yrs 12+yrs
Symptoms≤ 2 day s/week but not 
morethan once on
each day≤ 2 day s/
week> 2 day s/week or 
multiple times on 
≤2 day s/week> 2 day s/
weekThroughout the day
Impairme ntNighttime 
awakenings≤ 1x/month ≤ 2x/month > 1x/month ≥ 2x/month 1-3x/w eek > 1x/we ek ≥ 2x/we ek ≥ 4x/we ek
Interference with 
normal activity None Some lim itation Extremely limited
SABA use for symptom 
control (not prevention of
EIB)≤2 days/week >2 days/week Several times per day
Lung function
FEV1orpeakflow
FEV1/FVCN/A>80%
>80%>80%N/A60-80%
75-80%60-80%N/A<60%
<75%<60%
Validated q uestionnaires
ATAQ
ACQ
ACT0
≤ 0.75
≥ 201-2
≥ 1.5
16-193-4
N/A
≤ 15
RiskExacerbatio ns requiring oral 
system ic cort icosteroids0-1/year ≥2/year
Consider severity and interval since last exacerbation
Reduction in lung growth/ 
Progressive loss of lung 
functionEvaluation requires long-term follow -up
•Maintain current step
•Regular foll ow-u p every Step up 1 
stepStep up at 
least 1 st ep• Step up
1 step
• • Consider short course
of oral steroids
• Step up1-2steps• Consider 
short cou rse 
oforal 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
139
Approved , Date: 12 June 2019Recommended A ction for
Treatment1-6 months
•Consider step down if well 
controlled for at least 3 
months•Before step u p:
Review adherence to me dicat ion,
inhaler techni que, and en vironmental 
control. If alternati ve treatment was 
used, disco ntinue it and u se prefe rred
treatment for that step.
•Reevaluate the levelof asthma
contr ol in 2-6 w eeks to achieve 
contr ol.
0-4 years: Ifno clear be nefit isobser ved 
in
4-6 weeks, consider alternative 
diagnoses or ad justin g therapy.
5-11 years: Adj ust thera pyaccordin gly.
•For side effects, consi der
alternative treatment opt ions.Reevalua te
in2-6 
week
s
• Forside 
effects, 
consider 
altern ativ
e 
treatment 
options•Before step u p:
Review adherence to me dicat ion,inhaler 
techni que, and en vironmental co ntrol. If 
alternati ve treatment was used, 
disco ntinue it and u se prefe rred
treatment for that step.
•Reevaluate the levelof asthma
contr ol in 2-6 w eeks to achieve 
contr ol.
0-4 years: Ifno clear be nefit isobser ved 
in
4-6 weeks, consider alternative dia gnoses
or ad justin g therapy.
5-11 years: Adj ust thera pyaccordin gly.
•Forsideeffects, consi der
alternative treatment opt ions.steroids
• Step up1-2 
steps
• Reevaluate 
in2 weeks
• Forside
effects, 
consider 
altern ative 
treatment 
optio ns
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
140
Approved , Date: 12 June 2019Attachment 8:International Staging system
International Staging System
Stage Criteria Median Survival (months)
I Serum ß 2microglobulin <3.5 mg/L , serum 
albumin ≥3.5 g/dL62
II Not I or IIIa44
III Serum ß 2microglobulin ≥5.5 mg/L 29
a There are 2 possibilities for Stage II: 
  1) Serum ß 2microglobulin <3.5 mg/mL but serum albumin <3.5 g/dL ,or 
  2) Serum ß 2microglobulin 3.5 –5.4mg/L irrespective of the serum albumin
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
141
Approved , Date: 12 June 2019Attachment 9: The Family of antihistamine medications
The following antihistamines may be used for daratumumab preinfusion medication (including, but not 
limited to):
Diphenhydramine
Cetirizine
Fexofenadine
Loratadine
Clemastine
Dexchlorpheniramine
Promethazine*
* The IV use of promethazine should be avoided . 
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
142
Approved , Date: 12 June 2019Attachment 10: A nticipated A dverse Events
Anticipated Event
An anticipated event is an adverse event (serious or non -serious) that commonly occurs as a consequence 
of the underlying disease or condition under investigation (disease related) or background regimen.
For the purposes of this study the following events will be conside red anticipated events:
Anaemia
Bleeding
Bone diseases
Hypercalcaemia
Hyperuricemia
Hyperviscosity syndrome
Infection
Neutropenia
Renal failure or insufficiency
Thrombocytopenia
Reporting of Anticipated Events
All adverse events will be recorded in the CRF regardless of whether considered to be anticipated events 
and will be reported to the sponsor as described in Section 12.3.1 , All Adverse Events. Any anticipated 
event that meets serious adverse event criteria will be reported to the sponsor as described in 
Section 12.3.2 , Serious Adverse Events. These anticipated events are exempt from expedited reporting as 
individual single cases to Health Authorities. However ,if based on an aggregate review, it is determined 
that an anticipated event is possibly related to study drug, the sponsor will report these events in an 
expedited manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be established to perform reviews of pre-specified 
anticipated events at an aggregate level. T he ARC is a safety committee within the sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to 
the study drug.
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP).
[STUDY_ID_REMOVED]
JNJ-54767414 Daratumumab
Clinical Protoc ol54767414MMY3008 Amendment 6
143
Approved , Date: 12 June 2019
[STUDY_ID_REMOVED]
